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SUMMARY
This thesis describes some of the physical, chemical and 
biopharmaceutical properties of a poorly soluble salicylate, 
salicylsalicylic acid (SSA). In the introduction influences on drug 
absorption from the gastro-intestinal tract are described. These 
influences are of physical, chemical, physiological and pharmaceutical 
origin and are discussed with respect to drugs that are known to 
exhibit a poor or variable absorption that is limited by their 
solubility and dissolution behaviour. Methods for improving 
gastro-intestinal absorption of such drugs are introduced and the 
advantages of their coprecipitate formation with polyvinylpyrrolidone 
(PVP) and various bile acids, cholic (CA) and deoxycholic (DOCA) are 
reviewed^. Salicylsalicylic acid is presented as a drug suggested to 
show dissolution rate-limited absorption and was considered as a 
suitable model for investigating the influences of various pharmaceutical 
and formulatory manoeuvres on its absorption.
The experimental sections are divided according to in vitro and 
in vivo disciplines.
The in vitro studies describe the characterization of SSA with respect 
to purity, particle size distribution and surface area, crystallinity, 
melting point, solubility, pKa, partition coefficient, stability, 
dissolution rate and the influence of different media on its 
recrystallisation. These studies showed the drug to exhibit poor 
solubility and high stability in acidic media and established a 
relationship between particle size and dissolution rate. Parameters 
relevant to the pH-partition hypothesis indicated that, provided SSA
was in solution, then its absorption would occur throughout the 
entire gastro-intestinal tract. The preparation of SSA coprecipitates 
and admixtures with PVP, CA and DOCA are described together with 
their subsequent characterisation for purity, crystallinity and, in 
the case of the SSAzCA systems, their in vitro dissolution.
In vivo studies are preceded by an introduction to some basic 
pharmacokinetic concepts and the methods of pharmacokinetic analyses 
used in this thesis. Investigations were performed in man to establish 
a correlation between plasma and saliva salicylate levels following 
oral doses of SSA. This correlation was not shown and, following a 
report of the limited studies carried out in man, the majority of 
this section deals with studies in the rat. Various pharmacokinetic 
criteria were established between the dose of SSA given by 
intravenous and oral routes. The drug was formulated as a suspension 
and the influences of suspending agent and particle size were 
ascertained. A relationship between in vitro dissolution rate and 
in vivo absorption for material of varying particle sizes was 
established and, in an attempt to improve bioavailability, the 
absorption of SSA from coprecipitates and admixtures with PVP, CA and 
DOCA was determined. These formulatory manoeuvres met with varied 
success; indeed, only the SSA:CA 1:1 systems significantly improved 
drug availability. These studies are discussed with respect to the 
literature and suggestions for further work are presented.
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In order to exert a pharmacological effect a drug has generally to 
attain a certain concentration at the receptor site. Above this 
minimum concentration the intensity of the pharmacological response 
is a function of that concentration at the receptor site, the precise 
measurement of which is generally impossible due to the unknown or 
diffuse location of the receptor or its inaccessability. The drug is 
rarely, if ever, administered directly to the receptors but, is made 
available to the body at a site remote from the site of action, 
reaching the receptor via the various fluids of distribution. The 
concentration of the drug in the blood or other body fluids (C.S.F., 
urine, synovial fluid, etc) is used inferentially to gain knowledge 
of the concentration at the receptor site and is correlated, wherever 
possible, with direct physical measurements, e.g. muscle contraction, 
heart rate, urine flow, or a pharmacological response. It is assumed 
that an equilibrium exists between the drug concentration in the 
blood and other body tissues and organs such that a change in blood 
concentration reflects a change at the receptor site. Frequently 
therefore, the therapeutic efficiency of a drug formulation, i.e. its 
onset, duration and intensity of action, is stated in terms of drug 
concentration in the blood. This concentration is a function of the 
absorption, distribution, metabolism and excretion characteristics of 
the drug which are in turn determined by the physical and chemical 
properties of the drug molecule and the nature of the biological 
systems involved.
Most drugs are administered by the oral route and in order to elicit 
any systemic effect they have to cross the gastrointestinal barrier 
to reach the blood. The rate at which this occurs varies widely in 
different portions of the gastrointestiLnal tract because of the
environmental differences encountered in the different regions in 
terms of pH, surface area, peristalsis, enzyme concentrations, fluid 
content, etc. These physiological influences on drug absorption 
following oral administration are well documented and are summarised 
in Table 1.1. Many extensive reviews on the subject have been 
published (Schanker, 1971; Prescott, 1975; Rowland, 1973;
Gibaldi, 1971; Bates and Gibaldi, 1970).
However, it is believed that the mechanism of absorption is the same 
in all parts of the gastrointestinal tract and, wherever a drug of 
structure alien to the body has to cross a biological membrane, it is 
believed to do so by a process of passive diffusion. Very simply, 
the membrane may be considered a§ a bimolecular lipid layer 
surrounded by protein, although localised variations in this structure 
are probable in order to account for specific functions. The drug, 
in order to cross the membrane, has therefore to partition from 
aqueous solution into the lipid layer and then move out again on the 
other side into solution in the aqueous medium. The driving force is 
the concentration gradient of the absorbable form of the drug in 
solution on either side of the membrane.
The rate of absorption is a complex function of many interrelated 
biological, physical and chemical characteristics, although much 
information regarding the absorptive process can be gained from a 
consideration of the kinetics of diffusion.
Table 1.1 Physiological Influences on Gastrointestinal Drug 
Absorption.
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Given certain limiting conditions, diffusion can be expressed by a 
modification of Pick's Laws as
I I  = - ^  (Cj-c^)    (1)
where is the diffusion coefficient of the drug in the membrane, 
of area (A) , and thickness {{, ) , and is the membrane : water
partition coefficient of the drug. and C2 are the drug
concentrations in the fluids on each side of the membrane. The 
overall rate of diffusion is also influenced by the relative 
volumes of the fluids, the maintenance of the integrity of the 
membrane and the ability of the drug to freely diffuse in either 
direction. Since under in vivo conditions the drug is distributed 
into a large blood volume and is still further distributed into the 
remaining intra- and inter-cellular fluids, the concentration of drug 
in the blood will be very low with respect to that in the gastro­
intestinal lumen, i.e. Cj]^C2 . Consequently the driving force for 
diffusion is large and is essentially proportional to the lumenal 
drug concentration. The removal of diffused drug molecules from the 
serosal side of the membrane via the blood (i.e. drug concentration 
C2 ) has been demonstrated to be affected by the rate of blood flow 
(Ochsenfahrt and Winne, 1968; Winne and Remischovsky, 1970; 
Crouthamel et al, 1975).
It is evident from equation (1) that the rate of diffusion is 
influenced by certain properties of the membrane itself. Regional 
differences in the rate and extent of gastrointestinal absorption can 
be explained in terms of the surface area of the membrane, and 
examination of the microstructure of the small intestine, in 
comparison to that of the stomach or large intestine, supports this.
The membrane; water partition coefficient of the drug is determined 
by its lipid solubility (hydrophobicity) and, if it is assumed that 
the unionised form of the drug is lipid soluble the ionisation 
constant of the drug and the environmental pH are determinants of 
that partitioning behaviour.
1.1 THE INFLUENCES OF DRUG DISSOLUTION ON GASTROINTESTINAL 
ABSORPTION
For drugs in solution absorption is the process limiting the 
onset of therapeutic activity. However, many drugs given orally 
are solids and have to dissolve prior to their absorption taking 
place. Until the 1950's and the advent of sustained-release 
dosage forms, disintegration testing was considered to be an 
adequate assessment of drug release from solid dosage forms.
The subsequent development of dissolution testing methods led to 
the realisation that disintegration was not able to discriminate 
between similar, albeit subtly/ different, formulations since 
any correlation between absorption and disintegration times 
was, at best, tenuous. In 1957 Nelson reported that differences 
in the intrinsic dissolution rates of theophylline salts could 
provide an explanation for observed variations in their 
systemic availability and, since then, dissolution rate-limited 
absorption of many classes of drugs has been described in the 
literature, together with the factors influential to such 
behaviour. The processes of dissolution from solid dosage 
forms are schematically represented in Fig. 1.1.1 and have been 
extensively reviewed elsewhere (Wagner, 1971 ; Swarbrick, 1971; 




















Fig. 1.1.1 Schematic Representation Of The Dissolution Processes 
Encountered With Various Drug Delivery Systems 
(from Wagner, 1971 ).
The relationship between the parameters controlling the 
dissolution process are described by progressive adaptations of 
the equation originally derived by Noyes and Whitney in 1897 for 
dissolution of solids in their own solutions
dc
dt = k (Cg-C) .......     (2)
Where Cg is the saturation solubility of the solute in the 
solvent, C is the concentration at time t, and k is a 
proportionality constant that is related to the model chosen to 
describe the possible mechanism of dissolution. Higuchi (1967) 
reviewed three mechanisms for dissolution which are depicted in 
Fig. 1.1.2. In the diffusion layer model (Fig. 1.1.2,A) the 
dissolution rate is controlled by the diffusion of dissolved 
material from the liquid-solid interface through the diffusion 
layer to the bulk solution and is, therefore, influenced by the 
thickness (h) of that layer. The interfacial barrier model 
(Fig. 1.1.2,B) describes dissolution where the non-instantaneous 
nature of the reaction at the solid-liquid interface is rate- 
limiting to the diffusion of dissolved substance into the bulk 
solution. Danckwerts' model (Fig. 1.1.2,0 assumes that solute 
transport away from the solid surface is achieved by means of 
macroscopic packets of solvent in contact with the surface that 
absorbs solute by normal diffusion and are then replaced by 
fresh packets of solvent.
Under well-defined experimental conditions the influences of 
surface area (S), diffusion coefficient (D) of the solute 
through the saturated diffusion layer of thickness (h) that
8
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Fig. 1.1.2 Possible Models Describing The Mechanisms Of Dissolution 
(From Higuchi, 1967).
For explanation of the symbols refer to text.
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surrounds the dissolving particle, the viscosity of the solvent 
( ) , and the volume of the solution (V) became identified and
quantifiable. These factors are incorporated into equation (2) 
to give:-
i  = ( f f    (3.
Although D, V and h are significant variables in vitro, under 
the conditions prevailing in the gut by far the greatest 
influence is exerted by changes in the saturation solubility and 
the surface area. (For discussion of the latter see 1.4.1).
1.1.1 INFLUENCE OF SOLUBILITY ON DISSOLUTION RATE
The total solubility of an ionisable acidic compound is given by 
equation (4)
Cs = c + [*‘3 (4)
where the total solubility (Cg) is the sum of the intrinsic 
solubility of the unionised acid ( [̂ HaJ ) , and the concentration 
of the ionised moiety ( ̂ A J ) . If ^HA^ = C^ and ^ A ^ is 
expressed in terms of the Henderson-Hasselbalch equation (8) 
then from equation (5) we get:-
C, = Co +     ,5)
It can be seen that the solubility of an acidic compound will 
therefore increase with pH. The converse can similarly be shown 
to be true for compounds basic in nature. By substitution of 
equation (5) into equation (2) we get:-
10
^  - k Tco + KgCg I .......................... (6)
Equation (6) only applies under sink conditions, where C is 
negligible with respect to Cg (i.e. C 0.2 Cg), and it is 
evident that the dissolution rate constant (k) will increase 
with pH. An analogous examination similarly indicates that a 
decrease in pH will facilitate the dissolution rate of basic 
drugs.
Equations (2), (3) and (6) show that an increase in the 
solubility (Cg) of a drug will cause a corresponding increase 
in the dissolution rate.
1.2 THE INFLUENCE OF DRUG CRYSTAL HABIT AND MORPHOLOGY ON 
GASTROINTESTINAL ABSORPTION
The habit of a crystal is its overt appearance and is a product 
of environmental change on the growing crystal that results in 
alterations of the external shape without inducing internal, 
polymorphic changes. The different habits are caused by inter­
ference with the uniform approach of crystallising molecules to 
the various faces of the growing crystal. Irregularly-shaped 
crystals are described as anhedral or allotriomorphic and can be 
produced under adverse or changing environmental conditions 
associated with the degree of supersaturation, the type and 
temperature of the solvent and the presence of cosolvents or 
cosolutes. These habits are characterised and classified 
according to the interfacial angles which are commonly measured 
by a reflecting goniometer. Changes in crystal habit have been
11
attributed to observed alterations in syringeability, 
tabletting behaviour (Shell, 1963) and dissolution (Piccolo 
and Tawashi, 1971).
The internal structure of solid materials can be described 
according to whether or not a definite repeating crystal 
pattern is present. Any element or molecule able to crystallise 
as more than one distinct crystalline species is said to exhibit 
polymorphism; e.g. carbon can crystallise as cubic diamond or 
hexagonal graphite. The polymorphic forms of a given compound 
are, in general, as different in structure and properties as 
the crystals of two totally unrelated compounds and can, as such, 
be distinguished not only by their crystalline structure but 
also by their solubility, melting point, density, and optical 
or electrical properties. Since the production of polymorphs 
can result from the same environmental changes known to modify 
the crystal habit, the stability, solubility and absorption 
behaviour could be controlled by refinement of the conditions of 
crystallisation designed to encourage the production of specific 
drug polymorphs. Polymorphism has been demonstrated in a large 
number of groups of pharmaceutical compounds including the 
sulphonamides, barbiturates and steroids (Kuhnert-Brandstatter,
1965). More recent reports have shown a relationship between 
the polymorphic behaviour and in vivo absorption of 
chlortetracycline hydrochloride (Miyazaki et al, 1974), 
tetracycline (Miyazaki et al, 1975) and sulphamethoxydiazine 
(Khalafallah et al, 1974). Polymorphic transition of digoxin, 
induced by ball-milling, has been shown to improve the 
solubility of this cardiac glycoside (Florence and Salole, 1976).
12
It should however be noted that enhancement of drug absorption 
is not always a consequence of the use of polymorphic analogues 
that show enhanced dissolution or solubility, since rapid 
conversion of a metastable polymorph to a more thermodynamically 
stable and less soluble crystal can often occur. Furthermore, 
two polymorphic forms of a drug maybe identifiable in terms of 
structure but show no differences on the basis of their 
dissolution or absorption behaviour (Gunning et al, 1976).
As well as being able to exist in more than one crystal form 
some solids can exist without any definite internal structure, 
and are described as amorphous. Amorphous solids can be 
considered as supercooled liquids in which the molecules are 
arranged in a random manner somewhat as in the liquid state.
The intrinsic solubility of an amorphous form of a compound is 
usually greater than that of the corresponding crystalline 
form. However, because the thermodynamic instability of 
amorphous drugs in aqueous suspensions promotes their 
reversion to a less soluble, albeit more stable, form they have 
found restricted therapeutic use. The slow reversion of 
amorphous novobiocin in aqueous suspension to a more stable, 
less soluble, crystalline form at first precluded its 
therapeutic potential. This was overcome when, in an examination 
of several agents likely to reduce this reversion, methyl- 
cellulose and polyvinylpyrrolidone were shown to be able to 
completely suppress the transition (Mullins and Macek, 1960).
In the same paper it was also demonstrated that amorphous 
novobiocin exhibited an absorption in man greater than that for 
an equivalent dose of the crystalline form. Similarly, the
13
oral absorption of the amorphous form of chloramphenicol- 
palmi tate (Aguiar et al, 1967) has been shown to be greater 
than that of the crystalline counterpart.
Crystallisation of substances from different solvents can 
result in changes in their crystalline structure due to 
incorporation of solvent molecules, leading to the production 
of solvates ; these are termed hydrates when water is the 
solvent. The solubility and rates of dissolution of solvates 
are usually lower than that for the non-solvated form. Using 
mean human serum levels Poole et al (1968) demonstrated that 
the oral absorption, from aqueous suspension, of the anhydrous 
form of ampicillin exhibited a more rapid onset, higher 
intensity of effect and longer duration of action than the 
corresponding trihydrate. However, these two forms of 
ampicillin showed bioequivalence (equal rate and extent of 
absorption) when given orally as tablets (Hill et al, 1975) . 
The differences in absorption of the suspended and tablet 
dosage forms for anhydrous and trihydrate ampicillin may be 
of little consequence since a large variability in the extent 
of ampicillin absorption, ranging from 30-70%, has been 
reported for any single dosage form (Loo et al, 1974;
Macleod et al, 1974; Jusko and Lewis, 1973).
Identification and standardisation of polymorphic, amorphous, 
anhydrous and solvated forms of compounds intended for 
therapeutic evaluation are essential requirements for reducing 
batch-to-batch and manufacturer-to-manufacturer variations in 
drug performance. If any pharmaceutical or formulatory
14
manoeuvres involve dissolution and subsequent precipitation or 
crystallisation from any solvent then changes in the crystalline 
nature of the product have to be investigated.
Whereas the overt habit of a microcrystal can be examined by 
light microscopy, the internal crystalline nature can be 
distinguished by the ability of crystals to diffract X-rays. 
X-ray diffraction can not only differentiate between crystalline 
and amorphous solids, but, since polymorphic and solvated 
forms also have differing crystal structure, they too can be 
separately identified by their diffraction patterns.
1.3 CHEMICAL INFLUENCES ON GASTROINTESTINAL DRUG ABSORPTION
1.3.1 PARTITION COEFFICIENT
If it is assumed that drug absorption proceeds across a lipid 
barrier by passive diffusion down a concentration gradient then 
the rate of transport across the membrane barrier is influenced 
by the degree of partitioning of the drug molecules into the 
membrane and subsequent removal via the circulatory and 
lymphatic systems. Drug partitioning into lipid from the 
aqueous intralumenal environment can be modelled by the ability 
of the drug to distribute itself between two immiscible 
solvents, and can be expressed as the partition coefficient (K) 
thus:-
K =   (7)
C2
where Cj and C2 are the equilibrium concentrations of the drug 
in solvents 1 and 2 respectively. The relationship expressed 
in equation (7) only applies to dilute solutions where
15
activity coefficients become negligible and where the same 
molecular species is found in both solvents. The relative 
concentrations in both solvent phases will obviously be subject 
to change by variations in temperature, the presence of cosolutes 
or cosolvents and the concentration of the molecular species 
common to both phases. Under in vivo conditions the 
partitioning of a drug in solution in the gastrointestinal 
fluids will be affected by its degree of ionisation, tissue and 
plasma binding, and drug-gastrointestinal tract interactions. 
However, low or negligible drug partitioning into organic 
solvents can be indicative of permeability-limited absorption.
The chloroform/water partition coefficient for a series of 
barbiturates has been correlated with the extent of their 
colonic absorption in the rat (Schanker, 1959). Since the 
barbiturates were essentially present as their unionised 
monomer, changes in ionisation did not influence their 
partitioning behaviour and absorption could therefore be 
related to lipid solubility. Similar rank order correlations 
have been established between lipid solubility and intestinal 
absorption for a number of basic and acidic drugs (Hogben et al, 
1958). These observations form the basis of the pH-partition 
hypothesis for drug absorption (Hogben et al, 1957; 1958;
Schanker et al, 1957; 1958; Shore et al, 1957).
Consideration of the in vitro use of ether, octanol, chloroform 
or heptane led Hogben (1971) to suggest that it may be more 
appropriate to use an organic phase that simulates the lipid 
nature of the cell membrane. However, Hansch and Dunn (1972)
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in a review of the large amount of published data relating to 
in vitro/in vivo partition correlations concluded that a wide 
variety of in vivo partitioning phenomena could be adequately 
described by partition coefficients determined in octanol/water 
systems.
1.3.2 IONISATION CONSTANT
Ionisation of acidic or basic drugs in aqueous solution will 
occur to a degree dictated by the ionisation constant (pK^) of 
the drug and the environmental pH. The relationship between 
these two parameters is expressed in the Henderson-Hasselbalch 
equation, which states that, for an acidic drug:-
ionised] 
unionise<^pH = pK^ + log   (8)
and for a basic drug:-
 ™
As lipid solubility is primarily a characteristic of the 
unionised moiety, the importance of environmental pH and drug 
pK_̂  in determining the extent of lipid partitioning of the drug, 
and ultimately its absorption, is clear. It follows therefore 
that weakly acidic drugs should be preferentially absorbed from 
the acidic gastric regions, whereas absorption of weakly basic 
drugs should benefit from the higher pH of the intestinal 
environment. However, other factors such as differences in the 
absorptive surface area of the various regions of the gut and 
the solubility of the drug in the unionised form must be taken 
into account. The results of perfused in situ rat intestine
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experiments (Schanker et al, 1958) suggest two pertinent........
conclusions. Firstly, that the mucosal barrier is preferentially 
permeable to the unionised drug species, and secondly, that the 
absorptive processes occurring in the stomach and the small 
intestine are essentially the same. Although, while absorption 
of bases does take place preferentially from the small intestine, 
where ionisation of the drug is retarded, absorption of acids 
from the intestine is often equivalent to or greater than their 
gastric absorption even though the drug is primarily present as 
the ionised species. That is not to say that the ionised species 
is absorbed, only that absorption of the small amount of 
unionised species present is rapid over the large membrane 
surface area, leading to re-establishment of the equilibrium 
between ionised and unionised forms and hence further absorption 
of the newly-created unionised species.
Transmembrane diffusion, however, has been demonstrated in the 
gastrointestinal tract for fully-ionised drug molecules e.g. 
tetracycline (Pindell et al, 1959). Furthermore, such ionic 
transport has been associated with drug complexation with 
endogenous membrane components and excipient counter ions for a 
number of fully ionised drugs and has been shown to both 
enhance (Irwin et al, 1969; Levine and Pelikan, 1961;
Tomlinson and Davis, 1976) and retard (Levine et al, 1955; 
Schanker, 1960; Plakogiannis et al, 1970) their absorption.
It should however be pointed out that, although the use of 
excipient counter ions increased the loss of drug from the 
lumenal side of the absorptive membrane (the situation reported 
by the work of Tomlinson and Davis), this is in no way a
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measure of absorption since the appearance of drug in the blood 
was not monitored and could therefore not be infecred. In this 
case the ion-pair complex could also be strongly bound within 
the membrane and unable to diffuse into the serosal fluids.
1.4 FORMULATORY INFLUENCES ON GASTROINTESTINAL DRUG ABSORPTION 
Barr (1973) intimated that drug products showing poor bio­
availability* generally have a greater variation in their 
observed therapeutic response. This variation is of both inter- 
and intra-subject origin and can be exacerbated by alterations 
in the physical and chemical characteristics resulting from 
separate batches or manufacturers of the drug. The specific 
example cited by Barr is that of the difficulties associated 
with the day-to-day management of convulsive disorders by the 
oral use of the poorly-soluble drug, phenytoin. The suggestion 
is that drugs exhibiting dissolution rate-limited absorption are 
more likely to show an erratic response than drugs that are 
rapidly dissolved and completely absorbed.
Improvement in the dissolution and absorption behaviour of 
poorly-soluble drugs can be effected by several means. These 
are primarily directed towards increasing the surface area or 
improving the solubility of the drug in the diffusion layer.
Footnote* Bioavailability is used here, and subsequently, to indicate 
measurement of both the rate and extent at which an 
administered drug reaches the general circulation from its 
site of absorption.
19
1.4.1 REDUCTION IN PARTICLE SIZE
A reduction in the particle size of a given weight of drug will 
increase the specific surface area and usually results in an 
increase in the dissolution rate. When absorption is dissolution 
rate-limited it will often be enhanced by the use of the drug 
of much smaller particle size. This has been demonstrated for 
many drugs including aspirin (Martin, 1971; Parrott, 1975), 
digoxin (Jounda and Sothmann, 1973), sulphisoxazole (Fincher 
et al, 1965), griseofulvin (Kabasakalian et al, 1970; Chiou 
and Riegelman, 1971), phenytoin (Neuvonen et al, 1977) and three 
sulphonamides (Kaneniwa and Watari, 1974). Conversely, a 
therapeutically more useful absorption could be the result of 
an increase in the size of the administered material. This is 
exemplified by the alleviation of the gastric intolerance of 
finely-divided nitrofurantoin by the oral administration of the 
drug in macrocrystalline form. The urinary excretion of the 
drug from both particle size preparations did not reflect any 
significant differences in the extent of their absorption 
(Conklin and Hailey, 1969).
1.4.2 INCREASE IN DRUG SOLUBILITY
Previous discussion (see 1.2.2) has implicated polymorphism, 
amorphism and solvation of a drug with changes in dissolution 
rate and absorption by alteration of the saturation solubility.
An increase in solubility can also be obtained by solubilisation 
of the drug into micelles, although, this may not be associated 
with increased absorption since the drug within the micelle is 
unavailable to the absorptive membranes. The use and mechanisms 
of surface active agents that alter gastro-intestinal absorption
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have been adequately reviewed by Gibaldi and Feldman (1970).
Increased dissolution rate associated with an increase in the 
saturation solubility of the drug in the microenvironment of the 
dissolving particle can be induced by changes in the ionic 
composition of the diffusion layer. This is illustrated by the 
formulation of aspirin into solid dosage forms containing 
various buffer salts. These and other aspirin formulations are 
reviewed by Martin (1971). Soluble salts of acidic and basic 
compounds generally exhibit a greater dissolution rate than 
their respective conjugate acid or base at an equal pH. The 
mechanism of this effect is due to an increase in the buffering 
capacity of the diffusion layer resulting from cation or anion 
release from the ionisation of dissolved acid or base respect­
ively. Although the use of the salt form of a drug usually 
increases its dissolution, studies with aluminium aspirin 
(Levy and Procknal , 1962), Warfarin sodium (O'Reilly et al,
1966) and benzphetamine pamoate (Higuchi and Hamlin, 1963) in 
tablet form showed that the salt form had a slower dissolution 
and subsequent absorption when compared to the corresponding 
free acid 'or base. These decreases in absorption and dissolution 
appeared to result from the precipitation of a less soluble film 
on the surface of the dissolving tablets preventing their 
deaggregation and reducing the effective surface area of the 
drug to the dissolving fluids. However, the successful 
therapeutic use of various salts is illustrated by absorption 
studies on phenoxymethylpenicillin (Colquhoun et al, 1957), 
barbiturates (Anderson, 1964; Nelson, 1958), sulphonamides 
(Nelson, 1958), novobiocin (Furez, 1958) and aminosalicylic acid 
(Pentikainen et al, 1974).
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The therapeutic potential and drawbacks associated with the 
use of drugs in their salt form has recently been reviewed 
(Berge et al, 1977) and the oral use of soluble salts of 
weakly acidic drugs has been questioned on the grounds that, 
under the acid conditions of the stomach, precipitation of the 
free acid would occur to an extent dependant on the ionisation 
constant and concentration of the drug and the volume and pH of 
the in vivo environment. This is illustrated by the unexpectedly 
erratic urine levels of reserpine, following its oral 
administration to rats as a solution of reserpine acetate 
(Stupak et al, 1974). The observed variation in urinary 
excretion was attributed to incomplete absorption resulting from 
its gastrointestinal precipitation.
The possible role of endogenous materials has been suggested in 
the prevention or retardation of in vivo precipitation and in 
the maintenance of a supersaturated solution of the unionised 
form of aspirin (Leonards, 1962; Martin, 1971) and pheno- 
barbitone (Finholt and Solvang, 1968). The occurrence of 
gastrointestinal precipitation, and its prevention, have received 
increasing attention particularly with reference to the 
prospective involvement of both endogenous (mucin, bile etc) and 
exogenous (polymers, surface active agents etc), substances 
(Finholt and Solvang, 1968; Solvang and Finholt, 1970; Stevens, 
1973; Stevens and Padfield, 1976).
1.4.3 COPRECIPITATION
Formulatory methods aimed at increasing the dissolution of 
poorly-soluble compounds have progressively improved over the
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last 15 years. The applicability of eutectic mixtures to 
pharmaceutical systems was postulated by Goldberg et al (1965) 
and increases in the rate of dissolution were demonstrated for 
eutectic mixtures of paracetamol and chloramphenicol with urea 
(Goldberg et al, 1966a; 1966b) and griseofulvin with succinic 
acid (Goldberg et al, 1966c).
The incorporation of poorly-soluble drugs on to a pharmacolog­
ically inert 'carrier' has been attempted in order to provide 
a greater surface area of the drug for dissolution. This 
technique was adopted by Monkhouse and Lach (1972a; 1972b) who 
reported an increased dissolution of hydrochlorothiazide, 
indomethacin, griseofulvin, chloramphenicol, reserpine, aspirin 
and sulphaethidole from their molecular dispersion on fumed 
silica dioxide.
Similarly the use of bile acids as 'carriers' was reported by 
Stoll et al (1969) for a reserpinercholanic acid system, where 
the method of preparation was to dissolve both components in a 
common solvent and to subsequently remove the solvent by 
evaporation. This, and similar techniques, have assumed the 
title of 'coprecipitation' and has been successfully applied to 
a number of drugs showing dissolution rate-limited absorption. 
The reserpine:cholanic acid study was based on previous 
observations by the same group of workers (Malone et al, 1966; 
Decato et al, 1969) that reserpine dissolution and absorption 
was enhanced after its coprecipitation with a series of 
unconjugated bile acids (cholanic, cholic, deoxycholic, 
lithocholic and trihydroxycholane). These studies suggested
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that the enhanced dissolution from bile acid coprecipitates was 
mediated through an increased surface area of the drug. This 
concept is supported by Stoll et al (1973) who prepared a 
nitrofurantoin:deoxycholic acid coprecipitate and concluded 
from dissolution and human urinary excretion data that the 
improved nitrofurantoin availability from the coprecipitate 
(over that of the pure drug or a drug:bile acid physical 
mixture) could be attributed to the dispersion of fine drug 
particles over a large surface area of bile acid. They further- 
suggested that the bile acid formed a matrix around the finely- 
divided drug and, upon dissolution in alkaline media, the bile 
acid dissolved rapidly leaving an even smaller nitrofurantoin 
particle to dissolve in what was then a solution of bile salt.
The presence of bile acids or salts in the gastrointestinal or 
in vitro environment can improve drug dissolution by mechanisms 
other than those resulting from coprecipitation. As previously 
suggested (See 1.1.1), drug dissolution and the increased wetting 
of powders can also be induced by the concomitant use of 
physiological surface active agents. Since duodeno-gastric 
reflux is a common occurrence (Kallner, 1975), especially under 
fasting conditions (Rhodes et al, 1969), it can be expected that 
bile will be present in the stomach and will influence the 
dissolution and wetting of drug preparations (Finholt and 
Solvang, 1968). Although drug solubilisation in bile salt 
solutions has been shown to enhance the absorption of sulpha- 
diazine (Nightingale et al, 1971), jS -carotene, retinol (El-gorab 
et al, 1975), griseofulvin, glutethamide and hexoestrol (Bates 
et al, 1966) this need not always be so. Decreased drug
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absorption resulting from complex formation with bile salts 
has been reported for imipramine, quinine (Kimura et al, 1972), 
nystatin, neomycin, kanêimycin, polymyxin and vancomycin 
(Mahfouz, 1944; Faloon et al, 1966; Schneierson and 
Amsterdam, 1958).
Bile acid or bile salt interactions with the drug are not the 
only methods by which these surface active agents can influence 
absorption. Studies on the membrane effects of bile salts have 
shown disruption of the membrane of the rat intestinal mucosae 
(Feldman et al, 1973) and goldfish gills (Harriot and Kellaway, 
1976) and an increased wetting of frog skin (Whitworth and Jun,
1973). Similarly the co-administration of conjugated bile 
acids (taurodeoxycholic acid and glycocholic) has been shown to 
potentiate the production of aspirin-induced lesioning of the 
rat gastric mucosa (Semple and Russell, 1975). Such effects 
were not, however, observed for the deconjugated bile acids 
(cholic, chenodeoxycholic and deoxycholic).
The method of drug coprecipitation with a water-soluble polymer 
has also been successfully employed to aid the dissolution of 
poorly-soluble compounds. In the mid-1960's colloidal 
dispersions of ^ -carotene in polyvinylpyrrolidone (PVP) were 
prepared by coprecipitation and found to increase dissolution 
of the vitamin (Tachibana and Nakamura, 1965). Other drugs 
showing improved dissolution following coprecipitation with PVP 
include griseofulvin (Mayersohn and Gibaldi, 1966), sulpha- 
thiazole (Simonelli et al, 1969; 1976), reserpine, digitoxin 
(Stupak and Bates ; 1973; Bates, 1969; Stupak et al, 1974),
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acronycine (Svoboda et al, 1971), nystatin (Dexter, 1975), 
hydroflumethiazide and hydrochlorothiazide (Corrigan and 
TI money, 1975; 1976). In all cases the coprecipitated systems 
were reported to be superior to the drug alone, or to an 
equivalent physical mixture of the components, when compared by 
dissolution and/or in vivo absorption studies. Particularly 
good correlations were obtained between the in vitro and in vivo 
behaviour of the reserpine; PVP systems (Stupak and Bates,
197^; Stupak et al, 1974). In all cases where the internal 
crystal structure of the drug:PVP coprecipitates was examined 
by X-ray diffraction techniques no evidence was found for 
crystallinity and the coprecipitates were considered to be 
amorphous. The mechanisms involved in the production of 
amorphous drug:PVP coprecipitates can be related to the ability 
of PVP to retard, and even prevent, the growth of drug crystals 
(Mullins and Macek, 1960; Simonelli et al, 1976; Corrigan and 
Timoney, 1974). However, by far the most definitive examination 
of drug release from PVP coprecipitates has been achieved for 
sulphathiazole by Simonelli et al (1969; 1976). These workers 
found a rank order relationship between the rate of dissolution 
and the molecular weight of PVP used and, by following the 
release of both drug and polymer from discs of constant surface 
area and from X-ray diffraction, solubility and cell diffusion 
studies, they proposed a model to describe the release of 
sulphathiazole and PVP from their coprecipitates. The model 
was based on the differential release of drug and polymer from 
coprecipitates of varying drug:polymer ratios and adequately 
described the observed dissolution behaviour throughout the 
range. The overriding conclusions were that the enhanced
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solubility and dissolution resulting from coprecipitation with 
PVP is primarily a property of the amorphous nature of the 
final product.
1.5 PURITY AND STABILITY
Errors in dosage and differences in in vitro and in vivo 
behaviour of many formulated products can often result from the 
presence of impurities. These can be a consequence of the use 
of impure components during the manufacturing processes or 
degradation and contamination of the final product during 
storage, transport etc. In this context, Bundgaard (1974a) 
showed that acetylsalicylic anhydride impurities in discs of 
aspirin decreased the rate of dissolution of the aspirin to an 
extent related to the amount of impurity present. The same 
author (Bundgaard, 1974b) has also suggested that the immuno­
genic action of aspirin preparations could be attributed to the 
aminolytic attachment of glycine to trace acetylsalicylsalicylic 
acid impurities. Purity determinations are therefore essential 
in product assurance and the control of untoward therapeutic, 
toxicological and pharmacological actions. This is especially 
true if the pharmaceutical and formulatory manoeuvres employed 
in preparation of suitable dosage forms are capable of promoting 
the degradation of the active principle.
An understanding of the susceptibility of drugs to degrade is 
of use in the design and interpretation of pharmaceutical and 
absorption studies. The correlation of in vitro with in vivo 
degradation for a series of penicillins (Schwartz and Buckwalter, 
1962) and more recently for digoxin (Gault,y^l977) illustrate 
this clearly.
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The most frequently occurring mechanisms of drug degradation
are those of hydrolysis and oxidation, the latter being capable
of photochemical initiation. Of greatest significance is
hydrolysis, especially when the drug is present in an aqueous
vehicle. The main factors that determine the rate of hydrolytic
^ —degradation are the concentrations of H and OH ions and 
temperature. Both the hydroxyl and hydronium ions (H exists 
predominantly as the hydrated H^O* ion) are catalytic in most 
instances resulting in a stability/pH profile showing a small 
pH range of maximum stability. The overall rate of hydrolysis 
can be written as:-
-  f  = ■'o M \ M  .........
where k^, k^ and k^ are the specific first order rate constants 
for the water, hydronium- and hydroxyl-ion-catalysed reactions 
respectively. As k^ is generally very small, under highly 
acidic conditions where |^H ̂  will be negligible equation (10) 
reduces to:-
- a# = ki [«3°"]   <“>
which, ignoring activity corrections, can be written as:-
log k , = log k - pH   (12)obs 1
where k , is the observed first order rate constant, obs
Similarly, in the presence of high hydroxyl ion concentrations:
log k ^ = log k_ - pk + pH .........................  (13)obs 2 ^ w
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therefore a plot of log against pH should show two linear
regions, one with a negative slope of 1 where hydronium ion 
catalysis is predominant and one with a positive slope of 1 
where hydroxyl ion catalysis is predominant. There will also 
be an intermediary region where all three terms in equation 
(10) make a contribution to the observed rate.
The ability of a drug to ionise will affect the overall rate 
constant as given by equation ( 14-) .
dc
dt k + k o
(14)’'6  ^ ^ ........................
where , jsH J and J are the concentrations of the
neutral, protonated and anionic forms of the parent drug. The 
concentrations of the different ionic species and hence their 
contribution to the overall rate of hydrolysis will be 
dependant upon the ionisation constant of the drug and the pH 
of the system. The change of substrate from one ionic species 
to another is responsible for the inflections and plateaus 
associated with the stability/pH profiles of aspirin (Kelly, 
1970), procaine (Higuchi et al, 1950) and atropine (Zvirblis 
et al, 1956).
1.6 DRUG MODEL USED IN THIS STUDY
At the beginning of this century many salicylate esters and 
other salicylate derivatives were synthesised in an attempt to 
alleviate the gastrointestinal toxicity associated with the 
oral use of salicylic acid or its sodium salt. The most
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outstanding of these was the acetyl ester, aspirin, a name first 
used by the Bayer Company in 1899. Aspirin has appeared in 
many dosage forms, as different salts, in soluble, effervescent, 
buffered and conventional tablets, in admixtures with glycine 
and as aluminium derivatives (Martin, 1971). Reduction in the 
gastrointestinal toxicity due to salicylate therapy has also 
been attempted by the formulation of sustained-release and 
enteric-coated tablets. Changes in the rationale behind the 
use of salicylate homologues has warranted reconsideration of 
salicylate acid precursors or prodrugs. This is based on the 
observations including those of Bayles and Tenckhoff (1959), 
that the exacerbation of rheumatic symptoms after the sleeping 
hours could be attributed to low plasma salicylate levels 
produced by the use of conventional salicylate therapy.
Examples of aspirin precursors are acetylsalicylsalicylic acid 
or Acesal ( Fig. 1.6.1,A) and more recently the paracetamol 
ester of aspirin Benorylate (Fig. 1.6.1,B). Other reported 
aspirin precursors include the alkylcarbonate anhydrides, and 
glyceryl, hydroxy..alkyl and acetomethyl esters (from Scheifer,
1974). Esters of salicylic acid, other than aspirin, have 
been synthesised subsequent to the association of salicylic 
acid with its antirheumatic, analgesic, anti-inflammatory and 
antipyretic actions. The use of the majority of these compounds 
has suffered from the dominance of aspirin with respect to their 
commercial and therapeutic potential. They are, however, 
receiving increased attention particularly with a view to 
providing a prolonged (12 hour) action without incurring the 
erratic performances shown by enteric-coated or sustained- 















Fig. 1.6.1 Chemical Structures Of Acesal (A), Benorylate (B) And 
Salicylsalicylic Acid (C).
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extensive review of the biochemical and pharmacological 
properties of anti-inflammatory drugs, states
" . . .  it is unlikely that any simple salicylate 
derivative will in fact displace salicylic acid as 
an anti-inflammatory drug, outside of commercial 
considerations. The only 'super-salicylate' which 
might be of value as an anti-rheumatic drug will 
probably be a drug combining within itself the 
structure of salicylic acid together with some other 
feature(s) which also carries potential anti­
rheumatic activity.".
One compound that fits the above description iS benorylate 
(Fig. 1.6.1,B) which has been developed by the Sterling- 
Winthrop Company. Another compound, which is available in 
Scandinavia and has recently (January 1977) been marketed in 
this country, is the double ester of salicylic acid, 
salicylsalicylic acid (SSA), (Fig. 1.6.1,0. Patented by the 
Boehringer Company of Germany in the early 1900's, SSA has 
enjoyed a limited use under such names as Diplosal, Persistin, 
Salysal (United States), Dinuclan (France), Nobacid (Scandinavia) 
and recently Disalcid (United Kingdom). The observed 
palatability of SSA over that of sodium salicylate has been 
attributed to its poor solubility (Hanzlik and Presho, 1925) and 
limited stability studies carried out by these authors led to 
the suggestion that
" . . .  the acidity of the gastric juice would not 
decompose SSA to any appreciable extent during its 
time of sojourn in the stomach.".
32
These authors further claimed that alkaline hydrolysis was 
negligible and suggested that intestinal absorption would be 
small unless other factors such as its lipid solubility or the 
increased solubility of the salt (ionised) form were significant. 
This suggestion is based on the assumption that SSA must 
degrade to salicylic acid prior to its absorption. Their 
excretion studies with man showed that salicylate could be 
detected in the urine up to 72 hours following oral 
administration of a 4-12 g. dose and could account for about 
60% of that dose. The gastrointestinal insolubility of SSA has 
been attributed as the cause of prolonged plasma salicylate 
levels (Steel et al, 1931; Bastide, 1955; Rubin, 1964;
Nordqvist et al, 1965) and, the absence of occult gastro­
intestinal blood loss and mucosal erosions in man (Leonards,
1969; Edmar, 1970) and the guinea-pig (Aberg and Larsson,
1970).
The indications, therefore, are that the gastrointestinal 
absorption of SSA is limited by its dissolution rate due to 
poor aqueous solubility. Moreover, since the physical and 
chemical characteristics of the drug are not reported, their 
determination would be a necessary prerequisite to an adequate 
description of its in vitro and in vivo behaviour. If 
dissolution is the rate-limiting step in SSA absorption 
following oral administration, then it should provide a useful 
model with which to investigate the possible benefits of novel 
pharmaceutical and formulatory manoeuvres.
CHAPTER TWO




Salicylsalicylic acid (SSA), mol.wt. 258.08, from a single 
batch, was used as supplied, (A. B. Bofors Nobel-Pharma,
Sweden)." It is a white to almost-white crystalline powder of 
'pharmaceutical grade' containing 98-101% w/w SSA, all of which 
should pass through a 40 mesh (400 pm) sieve (Bofors 1971).
Chemicals and reagents used throughout were of Analar grade, 
unless otherwise stated.
Distilled water was obtained from a double all-glass still.
For preparation of pH standard solutions freshly prepared double 
distilled water was boiled and cooled prior to use.
Glassware. Volumetric glassware was of grade B with the 
exception of a 10 ml grade A microburette employed for titri­
metric determinations. All glassware, when necessary, was 
cleaned by complete immersion in freshly prepared chromic acid, 
rinsed several times in tap water and five times with distilled 
water.
2.1.1 INSTRUMENTATION
Spectrophotometers. Ultraviolet and visible scanning spectro­
photometry employed for the identification of absorbance 
maxima and possible cosolvent or cosolute interference in mixed 
systems was achieved by use of a Unicam SP1800 recording 
spectrophotometer in conjunction with a Unicam AR25 linear 
recorder. Single point fixed-wavelength absorbance determinations 
were obtained by use of either the SP1800 or a Unicam SP500
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(series II) spectrophotometer. For ultraviolet and visible 
spectrophotometry 1 cm matched quartz and glass cuvettes were 
used respectively.
Infra-red spectrophotometry was carried out using a Unicam 
SP200 recording IR spectrophotometer.
Balances. An Oertling (model R20) single pan analytical 
balance was used for all weighings greater than 50 mg.
Temperature Control. For stability and solubility studies a 
waterbath fitted with a mercury contact thermostat capable of 
maintaining temperature - 0.05° was used (Type CT3. Laboratory 
Thermal Equipment, Oldham). Temperature control in other 
studies was achieved by the use of an insulated waterbath fitted 
with a thermostatically-controlled heating unit capable of 
maintaining temperature - 0.1° (TE4, Techne, Cambridge).
Measurement of pH. All pH measurements were made using a 
Radiometer type 27 pH meter fitted with a PHA925a type scale 
expander. The electrode used in all cases was of the combined 
type (Pye-Ingold E07 ref. 041). For each series of measurements 
within any one experimental procedure the pH meter was 
calibrated against two pH standards, prepared according to 
McGlashan (1971), that bracketed the experimental range.
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2.2 X-RAY DIFFRACTION ANALYSIS
Diffraction patterns are produced whenever light passes through
or is reflected by a periodic structure that has a regularly
repeating feature. In order for the diffraction pattern to be
prominent the repeat distance of the periodic structure should
be approximately equal to the wavelength of the light used.
Examination of the appropriate distances for most crystals and
-8X-ray light shows them to be of the same order, ie 10 cm.
If two electromagnetic waves are of the same frequency and are 
superimposed in phase there is a summation in amplitude, termed 
constructive interference. If, on the other hand, the maximum 
and minimum amplitudes of waves are superimposed, ie they are 
out of phase, they cancel each other, termed destructive 
interference. When the two waves are partially out of phase 
some destructive interference occurs and there is a diminished 
amplitude. If the diffracted waves are changed by an integral 
proportion, ie by an inte ger of m X , (where m = 0, 1, 2, 3 etc), 
then constructive interference results.
When X-rays of wavelength X  strike a single plane of atoms (or 
molecules) as in Fig. 2.2.1 and are reflected at an angle ^ ,
a summation of intensities resulting from constructive 
interference will ensue if the difference in the path of the 
adjacent rays is an integral number of wavelengths (m X ).
Under these conditions it is clear that the diffracted waves 
will arrive at the detector in phase.
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d.sine
Fig. 2.2.2 Diffraction From Successive Parallel Planes Of Atoms.
Fig. 2.2.1 Diffraction By A Row Of Equally Spaced Atoms,
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From Fig. 2.2.1 it is seen that adjacent rays follow different 
paths and this difference AD-BC must equal m "X . Thus
AD-BC = m X  ...................................... (15)
where m = 0, 1 , 2 , 3 . . .  etc
Furthermore where m = 0 and ^  = 0 it follows that:-
h = (cos ̂  - cos 0 ) =   (16)
therefore when the angles of the incident and diffracted beams 
are the same there is a maximum intensity at the detector.
Similarly for parallel planes of atoms (or molecules) the 
reflected (or diffracted) beams must reach the detector in phase 
in order for summation of intensities to occur. From Fig. 2.2.2 
the path difference for the two waves is given by the Bragg 
equation, 2dSin0 , where d is the spacing between planes. 
Therefore for parallel planes of atoms
n X = 2dSin 0     (17)
This equation has two important applications. Firstly, if the 
*d* spacings of the planes of the crystal lattice are known then 
the wavelength of the X-rays can be calculated from the measured 
angle of diffraction, 0 . This procedure has been used for the 
elements and subsequent determination of their atomic number. 
Secondly, if the wavelength of the incident light is known the 
characteristic interplanar spacings of a crystal ('d' spacings) 
can be computed from measurements of the diffraction angles, 0 .
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One basic assumption which enters the derivation of the Bragg 
equation is that the lattice planes are regularly spaced. If 
the arrangement of atoms (or molecules) in any one plane or 
between planes is irregular then sharp X-ray diffraction 
patterns are not observed.
Definitive descriptions of the internal structure of crystals is 
an extremely specialised science, usually centering on the 
study of single crystals. However for phase identification 
work powdered samples of material are studied by X-ray 
diffraction techniques. These do not require any chemical 
treatment of the sample and, apart from a reduction in particle 
size, samples can be examined as presented. Admixtures of 
differing crystallinity, which show no interaction, are revealed 
by a super-imposition of the X-ray patterns of the constituent 
materials. Solid solutions, polymorphic changes and amorphous 
substances all reveal characteristically different X-ray patterns 
from the parent crystal and can therefore be identified.
Apparatus. X-ray diffraction techniques have been used 
throughout these studies to examine for crystallinity and 
changes in crystallinity induced by recrystallisation in the 
presence of human and simulated gastric juice and PVP, and SSA 
coprecipitation with PVP, cholic acid and deoxycholic acid.
Two methods have been used, the choice of which was dictated by 
the size of the sample and the type of equipment available.
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2.2.1 POWDER CAMERA STUDIES
Material for examination was finely ground in a small onyx 
pestle and mortar and packed into the end of a 0.5 mm 
'Lindermann' glass capillary tube (Pantak Ltd, Berks) by gentle 
tapping. The capillary was then secured on a rotating spindle, 
centred in a powder film camera (Debye-Scherer, 114.8 mm 
diameter) loaded with X-ray sensitive photographic film 
(Kodirex) and the whole mounted on a Philips PWlO10/80 generator 
capable of producing Cobalt radiation (wavelength 1.79021 
X 10 ^ cm) . Exposure times for all samples were between 12 
and 16 hours. A diagrammatic representation of the type of 
powder film camera used is shown in Fig. 2.2.3. Resultant 
films were appropriately developed and examined for bands of 
diffraction. The relative intensities of the bands were 
subsequently obtained from densitometer scanning of the films.
2.2.2 POWDER PLATE STUDIES
Essentially the same principles apply to the powder plate 
diffraction techniques as for the Debye-Schedêr film camera 
except that detection of the diffracted rays is achieved by a 
direct measurement of their beam intensity, either by means of 
the ionisation produced- in a gas, or the fluorescence 
produced.in a solid. The monochromatic light source is focussed 
on a centrally-positioned flat sample holder and the X-ray 
detector (or counter) is placed on the circumference of a circle 
centred on the sample. The schematic features of the X-ray 
diffractometer are shown in Fig. 2.2.4. The supports for the 
detector and the specimen holder are mechanically coupled so 





















Fig. 2.2.3 Schematic Diagram Of A Debyè-Scherrer Powder X-Ray 
Diffraction Camera.
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by rotation of the specimen through x degrees, an arrangement 
necessary to maintain correct focussing conditions. The 
detector is usually linked to a flat-bed recorder synchronised 
to movement of the detector through increasing values of 26, 
producing a chart recording of X-ray diffraction intensities in 
a position proportional to 20. Consequently the 'd' spacings 
can be calculated by use of the Bragg equation (17) .
Larger amounts of material were required for X-ray diffractometer
analysis than for the film camera techniques and could therefore
be used for X-ray diffraction analysis where quantities in
excess of 2.0 g was available. 1-2.0 g of material was finely
ground in a glass mortar and placed in a flat metal holder in
such a manner as to avoid any preferred orientation of the
particles. The specimen, in its holder, was then fixed into
the diffractomer (Philips PW1050) and diffracted Copper
-8X-rays (wavelength 1.5418 x 10 cm) were detected by means of 
a Xenon probe counter with an appropriate pulse height 
discriminating facility to reduce background interference. A 
typical diffractometer recording is shown in Fig. 2.3.5.1.
2.3 DETERMINATION OF PURITY
2.3.1 INFRA-RED SPECTRUM
A potassium bromide/SSA disc was prepared from oven dried 
material and the IR spectrum obtained was qualitatively 
identical to th&t of the reference spectrum provided (Bofors,
1971). The wavelength of the peaks numbered in Fig. 2.3.1.1 
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2.3.2 THIN LAYER CHROMATOGRAPHY
TLC identification of SSA and other impurities in samples of 
salicylic acid has been previously reported (Bailey, 1964; 
Skelly, 1966). The method used by Bailey (1964) was adopted for 
the qualitative identification of salicylic acid as an impurity 
in SSA.
A silica gel Giwater (1:2) slurry was prepared and spread to a
depth of 0.25 mm on 20 cm x 20 cm glass plates. The plates
owere air dried, activated at 105 for one hour in a hot air oven
and stored over silica gel in desiccator until cool. Solutions
of a salicylic acid standard and SSA were prepared in ethanol to
-1give a final concentration of 10 mg.ml . Five 5 ̂ 1 aliquots of 
each were spotted 4 cm from the base of the plates using an Agla 
micrometer syringe (Burroughs Wellcome) fitted with a flat 
needle. Each spot therefore contained 250 ̂ g  of material.
The plates were developed using petroleum ether:ethyl acetate: 
glacial acetic acid (85:10:5) in circular glass tanks lined 
with Whatman No 1 chromatography paper. The tanks were allowed 
to stand for two hours before use to ensure equilibriation of 
the solvents with their vapours and to promote even development 
the tanks were placed in a dark cupboard. When the solvent 
front was within 3 cm of the top of the plate, the plates were 
removed, the solvent front marked, and air dried in a fume- 
cupboard. The spots were visualised either by examination of 
the plates under long wavelength ultraviolet light (Allen Co, 
London, Type A409) or by spraying with a solution of 1% w/v 
potassium permanganate in 1% w/v sodium hydroxide. Further
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differentiation between SSA and salicylic acid was achieved by 
spraying with ferric reagent (See 3.2.2) which produced a 
purple chromophore with salicylic acid only.
Result. From the TLC analysis no salicylic acid impurities in 
SSA were identifiable, and reproducible Rf values of 0.35 and 
0.52 were obtained for SSA and salicylic acid respectively.
2.3.3 TITRIMETRIC DETERMINATION
About 200 mg SSA was accurately weighed into a 250 ml conical 
flask and completely dissolved in 25 ml of absolute ethanol. 
This was titrated against standardised O.IN sodium hydroxide 
from a grade A microburette using bromothymol blue (0.1% w/v 
in 50% v/v ethanol) as an indicator. Before the endpoint 
25 ml of water was added and the titration continued until a 
constant blue colour was produced. The percent purity was 
calculated according to the relationship.
1 ml O.IN NaOH =  0.025808 g SSA
therefore
% purity = A.N.f. 0.025808 x 100   (18)
w
where A is the volume of NaOH of normality (N) , f is the 
correction factor and, w is the weight of SSA taken (in 
grammes) .
From the data tabulated overleaf (Table 2.3.3.1) the % purity 
was calculated to be 100.42 ~ 0.21%
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No. wt. SSA Vol. O.IN %(g) W NaOH (ml) Purity
A _____________
1 0.2302 8.99 100.79
2 0.2268 8.84 100.59
3 0.2045 7.98 100.71
4 0.2062 8.02 100.38




Table 2.3.3.1 Assessment of SSA Purity by Titration
2.3.4 MELTING POINT
An initial estimate of the melting point of SSA was obtained 
using the capillary tube method (Melting Point Apparatus, 
Gallenkamp). A more accurate determination on a hot bench 
(Type 7841, Shandon) using the initial estimate of 152° to give 
an indication of the range over which to calibrate the bench. 
Benzaldehyde and phenacetin with melting points of 163° and 
134° respectively were used as standards and repeated determina­
tions with SSA gave the melting point as 152-153°C. Values 
from the literature are given in Table 2.3.4.1 with their 
appropriate source.
47
Melting Literature SourcePoint C
135-139 Bofors (1971)
141-143 Patel et al (1972)
144-148 Kuhnert-Brandstatter (1971)
148-149 Dictionary of Organic
Compounds (1965)
147 Utermark and Schike (1963)
147 Hanzlik and Presho (1925)
141-143 Pharm. Helv. (1934)
Table 2.3.4.1 Literature Values for the Melting Point of SSA,
2.3.5 CRYSTALLINITY
X-ray diffraction patterns for SSA, as supplied, and after 
recrystallisation from chloroform, ethanol and methanol were 
obtained by the powder plate method as previously described 
(See 2.2.2) and are shown in Fig. 2.3.5.1. The 'd' spacings 
and relative peak intensities, calculated from the recording 
Fig. 2.3.5.1,A by use of the Bragg equation (17), are given in 
Table 2.3.5.1 and provide an X-ray diffraction standard for 
future reference.
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Fig. 2.3.5.1 X-Ray Diffraction Patterns For SSA As Supplied (A) And 




_ , .. 'd' spacing Peak height intensity
NO (ao, ( W  (% max)
1 9 8 5.23
2 6.7 153 100
3 5.9 120 78.4
4 4.85 43 28.11
5 4.7 7 4.58
6 4.55 29 18.95
7 4.1 152 99.35
8 3.8 86 56.21
9 3.55 4.5 2.94
,1 'd' Spacings and Relative Peak Intensities :
X-ray Diffraction of SSA (as supplied).
It is clear that recrystallisation from the three organic 
solvents did not result in any changes in the crystalline nature 
of the drug. The similar nature of the diffraction peaks is 
also indicative that products of solvation with the organic 
solvents were not formed.
2.4 PARTICLE SIZE DISTRIBUTION AND SURFACE AREA
A large number of methods are available for measurement of 
particle size, especially of powdered materials,which have been 
reviewed by Allen (1974) and Edmundson (1967) both of whom 
indicate that the classification of powders into size ranges is 
somewhat dictated by the method of measurement. The sieve range 
extends from approximately 45 jmm to a practical upper limit of 
approximately 1680 p.m and powders falling within this range are 
termed 'coarse' (B.P. 1973). Micromesh sieves, made by electro­
plating and photoengraving techniques, are available and can 
extend the sieve range down to 10 ^m. Methods other than
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sieving, based on microscopy, sedimentation, air permeability 
and the Coulter Counter have a useful sensitivity in the sub­
sieve (45 - 1/A.m) range. A third, submicron range, is 
receiving increased attention and analytical methodology for 
this submicron range includes electron microscopy. X-ray 
diffraction, gas adsorption and centrifugal sedimentation.
According to the standards provided for the particle size of 
SSA (Bofors, 1971) 100% should pass through a 40 mesh (400 ̂ m) 
sieve.
2.4.1 DETERMINATION BY SIEVING
Particle size determinations using sedimentation and the Coulter 
Counter techniques were discounted due to problems of inadequate 
wetting, a lack of a suitable electrolyte or suspending system, 
and, unknown SSA stability in aqueous environments.
Sieving was carried out in accordance with British Standard No 
1796 (B.S. 1952) using sieves of British Standard specifications 
(B.S. 1963). A nest of 6" sieves (Endecotts Ltd, London) was 
used on a mechanical sieve shaker fitted with an automatic time 
switch (Pascall Engineering Co, Crawley). The nest was composed 
of nine sieves that ranged from 40 mesh (400 ̂ m) down to 300 
mesh (53 jwm). These were individually weighed empty before the 
sieving procedure started. 100 g of SSA was placed on to the 
top sieve and the nest shaken for 15 minutes. The top sieve 
was removed, weighed with its contents, replaced and shaken for 
a further five minutes. The top sieve was then again removed 
and weighed. If the difference between the first and second
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weighings was greater than 0.2% of the total powder weight 
(100 g) the five minute shaking process was repeated. However 
if the difference was less than 0.2% the sieve was replaced and 
the five minute shaking and weighing cycle was repeated for the 
next sieve in the nest. This process was continued throughout 
the nest until complete. To prevent occlusion of the mesh each 
sieve was brushed with a brass sieve brush between each cycle. 
The final weight of material remaining on each sieve, ie amount 
oversize, was recorded. The subsieve fraction was transferred 
to a nest of micromesh sieves (Endecotts Ltd, London) and the 
shaking and weighing process repeated as before. The resultant 
sieve fractions were stored in clean dry glass containers in a 
desiccator.
The weight of material oversize for each sieve fraction is shown 
in Table 2.4.1 and the results are graphically represented in 
Fig. 2.4.1 as the cumulative % undersize vs sieve range. From 
this frequency ogive a median value of 78ywm is obtained. To 
establish whether the distribution of particles follows a normal 
or logarithmic pattern the cumulative % undersize as probability 
on the ordinate was plotted against the arithmetic mean or its 
logarithm on the abcissa as shown in Figs. 2.4.2 and 2.4.3.
From these graphs it is evident that the particle size 
distribution of SSA follows a logarithmic normal pattern. This 
type of particulate distribution is characteristic of material 
that has been subjected to particle size reduction by ball- 
milling and most other similar industrial procedures employed 
to reduce particle size (Herdan, 1960). Following sieving 
several of the particle size ranges were bulked to provide
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 ̂  ̂ , Arithmetic Geometric % Cumulative
Sieve interval Mean of In Range %
ange o ange Range Range By Wt. Undersize
<>*’"> (ym) (/im)
>  250 - - 0.2 99.99
180-250 70 215.0 212.1 3.19 99.79
150-180 30 165.0 164.3 8.39 96.58
125-150 25 137.5 136.9 8.21 88.15
105-125 20 115.0 114.6 21.34 79.91
90-105 15 97.5 97.2 19.32 58.46
75-90 15 82.5 82.2 15.41 39.05
64-75 11 69.5 69.3 10.15 23.56
53-64 11 58.5 58.2 5.97 13.36
38-53 15 45.5 44.9 5.59 7.36
30-38 8 34.0 33.8 1.73 1.75
< 30 - - - 0.01 0.01
£ 99.51
* Note. Cumulative % undersize calculated as a % of the
final weight of material (99.51 g).
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sufficient material for all of the proposed in vitro and 
in vivo studies requiring material of a specific particle size 
range, and approximately 50 g of subsieve material was 
"micronised” in a fluid energy mill. Therefore, from this stage 
onwards the SSA was of the following particle size ranges :- 
"Micronised"; 30-38; 38-53; 53-75; 75-105; 105-150; 150-180 and 
greater than 180^m.
2.4.2 BET SURFACE AREA
BET surface area determinations were carried out at Coulter 
Electronics Ltd, Luton, using a Digisorb 2500 Automatic Multigas 
Surface Area and Pore Volume Analyser. Each of the particle 
size ranges examined was degassed for 16 hours at 45-50° and at 
a pressure of 1 yum Hg. Krypton gas was used for the analysis.
Result. The relationship between particle size and BET surface












Micronised 10 (5) 0.7683
30 - 38 34 0.5111
38 - 53 45.5 0.5025
53 - 75 66.9 0.3606
75 - 105 91.7 0.2892
105 - 150 139 0.1156
150 - 180 165 0.1105
Note The average particle size given is calculated from
relative proportions of the bulked sieve fractions and not 
the arithmetic mean of the total range.






































2.5 ASSAY OF SSA IN AQUEOUS SOLUTION..................................
The presence of salicylates in solution can be quantitatively 
measured by many analytical techniques, the majority of which 
rely on the preliminary conversion of the salicylate to 
salicylic acid and its subsequent determination by either ultra­
violet spectrophotometry, ferric ion chelation followed by 
visible spectrophotometry, spectrophotofluorimetry, or gas 
liquid chromatography, (glc), (Kelly, 1970) ; the most commonly 
employed methods being the first two cited. A major disadvantage 
is that, in order to quantitatively measure the parent salicylate, 
such methods (except glc) rely on a differential assay that 
monitors salicylic acid concentrations before and after 
conversion of the parent salicylate to free salicylic acid. 
Associated with such methodology is the possibility of an 
increased error that would not occur with direct methods. For 
this reason a novel assay for SSA was developed, that was 
both specific and sensitive.
Ultraviolet absorption spectra for SSA and salicylic acid were 
obtained from their equimolar solutions in O.IN sodium hydroxide 
and 0.IN hydrochloric acid containing a final concentration of 
1% v/v ethanol. The spectra (Fig. 2.5.1) show a pronounced 
bathochromic shift for the wavelength of maximum absorption 
( A  max) of SSA from 310 nm in acid to 341 nm in alkali. The 
^ max for salicylic acid showed a slight hypochromic change 
from 307 nm in acid to 301 nm in alkali. The observed batho­
chromic shift in the A max for SSA affords a specific method 
for its measurement in the presence of salicylic acid and 

















380360260 320 340280 300
Wavelength (nm)
Fig. 2.5.1 Ultraviolet Absorption Spectra For SSA And Salicylic Acid 
(SA) In O.IN HCl (B) And O.lN NaOH (A).
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conditions utilising the A  max value at 341 nm.
Adherence to the Beer Lambert Law. A stock SSA solution was
prepared by dissolving 100 mg SSA in 1 ml of absolute ethanol
uocx4er
in a litre volumetric flask. Sufficient distilled^was rapidly
added (to prevent precipitation) and made up to the mark. From
-1this stock solution SSA standards (0.5 to 100 ml ) were
prepared by the appropriate dilution in distilled water. 5 ml
of each standard was diluted to 10 ml with 0.4N NaOH and the
absorbance immediately read at 341 nm against a suitably
prepared blank. Preliminary studies showed that the absorbance
values obtained in this manner did not change within a two
minute period, and the results shown in Table 2.5.1 and Fig.
2.5.2 for duplicate determinations verify that the Beer Lambert
Law is obeyed. Comparison of the duplicates by a Student 't'
test (Appendix I) shows them not to be significantly different
(t^bs ~ 0.̂ 62?; ^tab ~ 2.12; n = 20; p = 0.05), The duplicate
data was consequently pooled and submitted to linear least-
squares regression analysis to provide the equation for the
calibration line used in all subsequent SSA determinations in
1 %aqueous solution. The absorption coefficient, E , and the1cm
molar absorption coefficient, ^  were calculated to be 125.0 
and 3226.0 respectively.
2.6 SOLUBILITY OF SALICYLSALICYLIC ACID IN AQUEOUS SOLUTION
1
Experiments were performed to determine the saturation 
solubility of SSA in distilled water, O.IN HCl and their 1% 
ethanolic solutions.
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0.5 0.009 0.009 Analysis of 
Pooled Data
Slope 1.247 X 10~2 1.250 X lO'2 1.250 X 10“^
- SE Slope 8.413 X 10“^ 7.721 X lO"5 5.449 X lO"^
r 0.9998 0.9998 0.9998
Intercept 7.63 X lO"^ 7.498 X lO"3 7.563 X lO"^
+ SE Intercept 3.762 X lO"^ 3.453 X 10~3 2.437 X lO"^
Table 2.5.1 Verification of Beer Lambert Relationship for SSA In 
0.1% v/v Aqueous Ethanol at 341 nm








- 1,SSA Concentration (^g.ml )
Fig. 2.5.2 Duplicate Beer-Lambert Calibration Curves For SSA 
Absorbance At 341 nm.
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Apparatus. The apparatus (Fig. 2.6.1) consisted of a 250 ml 
two necked round-bottomed flask placed in a constant temperature 
(- 0.05°) waterbath. Through one neck was inserted a pH 
electrode, the other neck was used to remove samples for assay. 
The solution was rapidly stirred by means of a teflon-coated 
magnetic bar rotated by a submerged magnetic stirrer (Rank 
Bros., Bottisham, Cambridge) .
Initial solubility determinations were very irreproducible due 
to inadequate separation of the solid material from the liquid 
phase by the sintered-glass tubes originally employed for that 
purpose. Furthermore, difficulty was encountered in the use of 
sintered-glass filters ef smaller pore size. Removal of 
undissolved material was efficiently achieved by filtration 
through a 0.45y\m membrane filter (Millipore, London) held in 
a 25 mm Swinnex membrane filter holder (Millipore, London) that 
had been adapted to two-directional flow. This backwash 
facility was essential for mixing of the dead spaces in the 
sample tube and the membrane holder. Removal of filtrate into 
a 10 ml syringe allowed subsequent accurate pipetting of the 
sample prior to assay. This procedure for separation of 
undissolved particulate matter was used in all experiments 
requiring a similar type of filtration prior to assay (eg. SSA 
recrystallisation and dissolution studies).
Method. Excess material was added to 100 ml of solvent 
(previously equilibriated to the required temperature) and 
rapidly stirred. Approximately 6 ml samples were removed at 




















Fig. 2.6.1 Solubility Apparatus
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and assayed. The concentration was corrected for changes in 
volume due to temperature and monitored until no further increase 
was observed. Table 2.6.1 and Fig. 2.6.2 show the relationship 
between saturation solubility and temperature (expressed as a 
van't Hoff plot) for SSA in water, O.IN HCl and their 1% v/v 
ethanolic solutions.













+1% yV Ethanol 
± SE
19.85 3.415 88.82 93.34 37.47 42.86
i 0.27 ± 0.55 ± 0.26 ±0.94
29.60 3.305 119.96 128.61 56.07 67.65
± 0.74 ± 1.06 ± 0.54 ± 0.29
40.05 3.194 168.85 177.39 92.02 96.87
± 2.90 ± 1.99 ± 2.13 ± 0.95
50.00 3.096 240.99 257.49 144.24 155.77
± 1.30 ±1.38 ±1.10 ± 0.66
59.95 3.003 353.24 380.87 239.36 264.77
± 3.32 ± 7.01 ±2.42 ± 4.58
69.60 2.919 536.81 585.42 411.93 432.20
± 18.37 ± 8.37 ± 4.33 ± 3.43
Table 2.6.1 Influence of Temperature on the Equilibrium 
Solubility of SSA in Distilled Water, O.lN 
HCl and Their 1% Ethanolic Solutions.
The van't Hoff plot for SSA solubility exhibits a curvilinear 
profile that precludes the determination of heats of solution. 
What is evident is that 1% v/v ethanol increased the solubility 








3.0 3.1 3.2 3.4 3.53.3
®  Water 
O  1% ethanol
A  O.IN HCl
A  O.IN HCl + 1 %  ethanol
Fig. 2.6.2 Saturation Solubility Of SSA In Water O.IN HCl And Their 
1% Ethanolic Solutions With Respect To Temperature.
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the same order of magnitude (1.068 and 1.109 respectively).
A plot of solubility ratio (solubility in O.IN HCl/distilled 
water) vs temperature is shown in Fig. 2.6.3 and illustrates 
that SSA solubility increases to a greater extent in O.IN HCl 
than in distilled water. The data used to provide Fig. 2.6.3 









Table 2.6.2 Influence of Temperature on the 0. IN HCl/ 










SSA Solubility Ratio 
Between 
O.IN HCL-.Water
10 20 30 40 50 60 70
Temperature C C)
Fig. 2.6.3 Influence Of Temperature On O.IN HCl/Distilled Water 
Solubility Ratio Of SSA.
2.7 DETERMINATION OF IONISATION CONSTANTS OF SSA.
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Two methods were employed to determine the pK^ and pK^ values 
at 25°.
2.7.1 POTENTIOMETRIC TITRATION
Owing to the poor solubility of SSA a saturated solution was 
titrated against 0.02N NaOH. Mixing was achieved by a magnetic 
stirring bar and each titration was carried out in vessels 
immersed in a thermostatically controlled waterbath at 25 i 0.1*"
The titration curves produced are typified by the example shown 
in Fig, 2.7.1. In order to accurately interpolate the equiva­
lence point a plot of the rate of change of pH with respect to 
volume of titre is also given. It is clear from the
curve that it was not possible to exactly identify the 

















Volume 0.02m  NaOH Added
Fig. 2.7.1 Potentiometric Titration Curve (---) for SSA (Saturated
Solution) And Derived Rate Of Change Of pH vs Volume Of 
Titre (Solid Line) at 25°.
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2.7.2 ULTRAVIOLET SPECTROPHOTOMETRY
The bathochromic shift observed previously (see Fig. 2.5.1) 
indicated that ultraviolet spectrophotometry may be suitable to 
determine pKg, it was further anticipated that there might also 
be a spectral change suitable for pK^ determination. The 
theoretical basis for determination of ionisation constants by 
ultraviolet spectrophotometry is given in Appendix II.
Method. The ultraviolet absorption spectra of SSA with 
respect to pH were examined using drug solutions in the buffers 
set out in Table 2.7.1,
Buffer pH Range
Clark and Lubs 
KClzHCl 0.2N
1 . 0  -  2 . 2
2.2 - 5.5Mcllvaines
citrate :phosphate
Sdtensens phosphate 5.0 - 8.0
Gomoris tris : HCl 7.2 - 9.0
S/rfrensens glycine:NaOH 8.4 - 13.0
Table 2.7.1. Buffer Systems Employed In pK^ Determinations. 
(Documenta Geigy, 1962).
All buffer solutions were prepared double strength. A stock
-1SSA solution containing approximately 70 ̂ g.ml (accurately 
known) in 1% v/v ethanol was prepared and equilibr ated at 
25 t 0.1° with the buffer solutions. After equilibr ation each 
buffer solution was diluted with an equal volume of SSA stock 
solution and the absorbance spectra obtained with reference to
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the appropriately treated buffer using a constant temperature 
cuvette housing (Unicam SP874). For high pH values the SSA 
spectra did not show any significant changes within a five 
minute period after preparation, nevertheless spectra were 
always obtained immediately after preparation of SSA solutions 
and the pH was measured during the recording of the spectra.
To establish the potential of ultraviolet spectrophotometry in 
the determination of SSA ionisation constants spectra were 
recorded at 0.5 pH intervals throughout the range pH 1.0-13.0.
The extremes of this range were produced in O.IN HCl and NaOH 
respectively.
Examination of the resultant spectra, examples of the most 
important ones are given in Fig. 2.7.2 show the following changes 
with respect to pH.
pH 0.65 - 5.00 A shoulder to the main peak exists
at 285 nm which decreased with 
increasing pH.
pH 5.00 - 8.00 No change in spectra occurred.
pH 8.00 - 11.50 An increased absorbance associated
with a change in ̂  max from 310 nm 
to 341 nm (Bathochromic shift).
pH 11.50 - 13.00 No change in spectra occurred.
Superimposed plots of absorbance at 285, 310 and 341 nm against 







270 310290 330 370 390350
Wavelength (nm)
Fig. 2.7.2 Ultraviolet Absorption Spectra For SSA At pH 0.65 (A),
5.00 (B) And 12.25 (C)
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and approximate pK values obtained by interpolation from 
Fig. 2.7.3, are pK^ = 3.2 and pK^ 9.8.
Subsequent determinations, to define the pK^ values, were 
performed within the pH ranges 0.65 - 5.0 and pH 8.0 - 13.0 for 
pK^ and pK^ values respectively, using "analytical wavelengths" 
of 285 and 341 nm. Double strength buffer solutions were 
prepared at 0.2 pH unit intervals within those ranges, the final 
pH of the diluted test solution was again measured at 25° while 
the absorbance was measured.
Result. Using equation (63) in Appendix II, the pK^ and pK^ 
were calculated from a knowledge of the measured pH, the 
absorbance at that pH and the absorbance of the unionised and 
ionised species for that ionisation. From triplicate 
determinations of pK^ and pK^, the data for which is given in 
Table 2.7.2, the respective values are;-
pK^ = 3.450 - 0.008
pK^ = 9.825 ± 0,003 at 25°.
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pKj PK2
A B C A B C
3.4108 3.4775 3.4170 9.8080 9.8303 9.8173
3.3928 3.4509 3.4771 9.8370 9.8351 9.8185
3.3703 3.4558 3.4750 9.8311 9.8150 9.8374
3.4599 3.4380 3.4904 9.8331 9.8091 9.8068
3.4053 3.4778 3.4178 9.8420 9.8213 9.8019






X 3.4195 3.474 3.447 9.835 9.821 9.816
SD 0.034 0.034 0.035 0.010 0.010 0.016
SE 0.013 0.011 0.013 0.004 0.004 0.007
Grand
Mean 3.450 - 0.008 9 .825 - 0.003
Table 2.7.2 Triplicate Determinations of pK^ And pK^ For SSA 
at 25 - 0.1°C
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2.8 PARTITION COEFFICIENT
If a substance is added to a system composed of two immiscible 
solvents, in an amount insufficient to saturate either phase, it 
will become distributed between the two phases in a definite 
concentration ratio. This ratio (K) , also known as the 
distribution ratio, distribution coefficient or partition 
coefficient, can be expressed by the simple form of the 
Distribution Law:-
^   (19)
C2
where C^ and C^ are the equilibrium concentrations of the 
substance in solvents 1 and 2 respectively. There is no 
established convention as to whether the partition coefficient 
is expressed as C 1/C2 or vice versa; consequently the respective 
phases are stated, either generally (eg, oil/water), or 
specifically (eg, octanol/water) .
The simple form of the Distribution Law only applies to dilute 
solutions where a single molecular species is common to both 
phases. Hence when association occurs in either phase or 
ionisation occurs in the aqueous phase the overall distribution 
is more complex. In the latter case the total concentration of 
an acidic drug in the organic phase (C^), represents the 
unionised concentration ( jHA^ )̂ , since ionisation does not 
occur in that phase. The true partition coefficient
K f HAL . 0
f HAL . w
(20)
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where ^ and ^ are the concentrations of the unionised 
form in the oil and aqueous phases respectively. However, the 
total drug concentration in the aqueous phase,
C = r HÀ1 + M  ..........................  (21)w jw L J w
where is the aqueous concentration of the ionised species.
Further, if the total drug concentration in the aqueous phase is 
employed in the determination of the distribution between the 
two phases then the experimentally observed, or apparent, 
partition coefficient is given by:-
k! = c,o = [ ha]  o 
^  W w ” + M  w ..................
The true partition coefficient can be obtained by extrapolation 
from apparent partition coefficients determined over a range of 
hydrogen ion concentrations (See Martin et al, 1970) , or by 
analysis of the oil phase and of the water phase at a sufficiently 
low pH (ie pH = pK^-2) where 99% of the drug would exist in
the unionised form. The latter method was employed here since 
solutions of SSA prepared in O.IN HCl ensure that the drug is 
99.6% unionised.
Method. Prior to use 1-octanol was presaturated with O.IN HCl
o — 1at 25 . A solution of SSA (approximate concentration 50 ̂ g.ml )
was prepared in O.IN HCl. Six 20 ml volumes of solution were
shaken with an equal volume of presaturated 1-octanol in 50 ml
conical flasks (Quickfit) in a shaking waterbath (Type SS30
Grant Instruments, Cambridge) at 24.5 - 0.1°C for 16 hours; a
time that had been shown to be Sufficient for equilibrium to be
78
achieved. The shaking rate was approximately 120-150 min  ̂ and 
did not produce any émulsification within the system. After 
shaking the flasks were allowed to stand for one hour for the 
two phases to separate. Five ml of the aqueous layer was 
removed by pipette through the 1-octanol. Care was taken to 
prevent the organic solvent from entering the pipette, similarly, 
1-octanol was removed from the exterior of the pipette with a 
tissue. The initial and final SSA concentrations of the aqueous 
phase were assayed as described previously (See 2.5) and the 
drug concentration in the 1-octanol calculated by difference. 
1-octanol was shown not to interfere with the assay. The pH of 
the aqueous solution was checked before and after shaking and 
was found not to alter from pH 1.02. Table 2.8.1 shows the 
final concentrations of SSA for the O.IN HCl and 1-octanol 
phases.
Sample Absorbance at 341 nm
SSA 
O.IN HCl
^  g. ml
1-octanol
Initial 0.593 47.44 0
1 0.006 0.48 46.96
2 0.006 0.48 46.96
3 0.017 1.36 46.08
4 0.006 0.48 46.96
5 0.023 1.84 45.60
6 0.020 1.60 45.84
Mean 1.04 46.40
Table 2.8.1 Partitioning of SSA Between 1-octanol and 
O.IN HCl at 24.5°C.
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From Table 2.8.1 a 1-octanol/O.IN HCl partition coefficient of 
44.62 is obtained, and demonstrates that the unionised form of 
SSA is highly lipid soluble and suggests that the unionised 
species of SSA will be freely permeable across the gastrointestinal 
membranes.
2.9 DETERMINATION OF THE STABILITY OF SSA
SSA can be expected to hydrolyse in aqueous solution according 
to the following scheme.
c o o H
» 2 X
h c o oH
j - o H
In order to follow the time course of the hydrolytic reaction it 
was necessary to quantitatively differentiate between SSA and 
salicylic acid.
2.9.1 ASSAY FOR SSA IN THE PRESENCE OF SALICYLIC ACID
Examination of Fig. 2.5.1 shows that SSA and salicylic acid can 
be differentiated by examination of the ultraviolet absorption 
spectrum in solutions at high pH as previously demonstrated 
(See 2.5). However it was essential to ensure that the sodium 
hydroxide used to induce spectrum changes was of sufficient 
strength to cope with all the buffer systems (Table 2.9.1) used 
in these studies.
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-1A solution of SSA 37.S^g.ml ) was prepared in buffer 
systems throughout the range pH 1.0-13.0. The absorbance at 
341 nm and the pH of each SSA buffer system were measured before 
and after dilution with equal parts of 0.4N NaOH. Since hydroxyl 
and hydronium ions can catalyse hydrolytic degradation it was 
necessary that the absorbance values were obtained immediately 
after alkaline dilution. Table 2.9.1 shows that such alkaline 
dilution was sufficient to raise the pH of each buffer system 
to a value greater than pH 12.0.












1.0 12.80 0.035 0.477KClzHCl
Mcllvaines 2.94 12.60 0.036 0.475
5.00 12.60 0.034 0.478Citric Acid;
Phosphate 7.00 12.60 0.037 0.478
Sorensens 8.80 12.80 0.114 0.474
Glycine zNaOH 10.82 12.90 0.835 0.472
12.78 13.00 0.940 0.472
Table 2.9.1 Influence of 0.4 NNaOH on the pH and Absorbance
-1of SSA (37.5 ^g.ml ) in Different Buffer Systems
Salicylic acid influences on the absorbance spectrum of SSA are 
evident on examination of Fig. 2.5.1 which shows salicylic acid 
to have a low absorbance in alkaline media at 341 nm and should 
therefore be accounted for in the assay of SSA.
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For a two component system where both components absorb at a 
given wavelength the Beer-Lambert Law has to be modified from 
equation (5̂ 3 ) in Appendix II to (23) .
^ = 6  1 Cj + f  2 '= 2   (23)
where A is the absorbance at a given wavelength and ^  and C 
are the molar absorption coefficient and concentration 
respectively for components 1 and 2. The hydrolysis of 1 mole 
of SSA would result in the production of 2 moles of salicylic 
acid. If the fraction of SSA (initial molar concentration) 
remaining after time, t, is given by x, then the fraction of 
salicylic acid produced will be 2(l-x) and therefore from 
equation (23)
A = A^x + 2a  ̂ (1-x)   (24)
= A^x + 2A^ - 2AgX ..........................  (25)
where A is the absorbance of the two component mixture and A^ 
and Ag are the absorbances of SSA and salicylic acid respectively. 
It follows from equation (25) that
X - A  - 2Ag ........................................ (26)
A) - 2A^
The validity of this reasoning was established by measurement of
the absorbance (at 341 nm) of eight standard solutions of SSA
(in glycine buffer pH 12.5) before- and after complete hydrolysis.
Hydrolysis was achieved by autoclaiving the standards at a
- 2pressure of 15 lb in for three hours. The post-autoclaving
8 2
absorbances were compared to eight salicylic acid standards of
twice the equivalent SSA molar concentration, similarly prepared
in glycine buffer at pH 12.5. The results in Table 2.9.2 and
Fig. 2.9.1 indicate that complete SSA degradation to salicylic
acid had occurred, and that the Beer-Lambert plot obtained for
the hydrolytic products was superimposable and insignificantly
different (t , = 0.969; t = 2.18; n = 16; p' = 0.05)obs tab
from that for equivalent solutions of salicylic acid.
The % residual concentration for SSA can therefore be calculated 
using equation (27)
% residual concentration = A - Aoo
 ;—  X 100 ...........  (27)
where A^ is the absorbance at time, t, is the absorbance at
time, t = (ie after complete hydrolysis) , and A^ is the
absorbance at time, t = o.
2.9.2 GENERAL METHOD
-150 ml of SSA (approximately 75y^g.ml ) solution prepared in 
0.1% v/v ethanol and double strength buffer of the appropriate 
pH were equilibriated to the required temperature in separate 
vessels. At time, t = o, they were mixed and a zero hour 5 ml 
sample taken, further samples of 5 ml were removed and assayed 
for SSA according to the method described (See 2.5). Duplicate 
experiments were performed in all cases and the initial and 
final pH values for each experiment were determined. The 
apparent first order rate constants for the hydrolysis of SSA 

















100 12.64 0.087 12.67 1.250 107 12.63 0.096
80 12.68 0.075 12.77 1.020 85.6 12.65 0.078
60 12.61 0.058 12.76 0.750 64.2 12.62 0.062
40 12.58 0.038 12.78 0.532 42.8 12.60 0.042
20 12.60 0.022 12.76 0.255 21.4 12.60 0.024
10 12.62 0.014 12.76 0.127 10.7 12.68 0.012
5 12.69 0.009 12.76 0.073 5.35 12.59 0.006













Table 2.9.2 Comparison of the Absorbances at 341 nm of Standard 


























































































concentration against time. The values of slope and intercept, 
together with their respective standard errors, were calculated 
by submission of the data to linear least-squares regression 
analysis.
2.9.3 INFLUENCE OF BUFFER AND IONIC STRENGTH
The following buffer systems for the pH range 1.0- 13.0 were 
prepared double strength according to Documenta Geigy (1962).
Buffer System pH Range
Clark and Lubs 1.0 - 2.2
KClzHCl
Mcllvaines 
Citrate zphosphate 2.2 -  8.0
Gomoris tris :HCl 7.3 - 9.0
E^ensens glycine:NaOH 8.5 - 13.0
A comparison of the apparent first order rate constants for SSA 
hydrolysis in different buffer systems at the same pH was 
performed at a transition pH from one buffer system to another 
in single strength buffers at 50^\ Fine pH adjustments were 
made using minimal volumes (less than 0.5 ml) of Normal HCl or 
NaOH and final concentrations were corrected for temperature 
related changes in the sample volume.
Ionic strength effects were studied using single and half
strength buffers at a pH within the range covered by that system,
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The data presented in Table 2.9.3 indicates that no one buffer 
system significantly influenced the apparent first order rate 
constant for SSA hydrolysis at a given pH. The data for each pH 
was analysed for significant difference by use of the Bartlett 
test (Appendix I). Similarly, Table 2.9.4. shows the strength 
of buffer to have no significant effect on SSA hydrolysis when 
compared by Student 't' test.
First Order Rate 
pH Buffer System Strength Constant 't ' test *
- SE (sec-1)
+ —62.20 Clark and Lubs single 1.005 - 0.028 x 10 t , =
+ -6KClzHCl half 1.023 - 0.048 x 10 0.324
+ -56.05 Mcllvaines single 1.557 - 0.011 x 10 t , =
+ -5CitratezPhosphate half 1.709 - 0.089 x 10 1.700
+ -57.75 Gomoris triszHCl single 3.688 - 0.066 x 10 t
+ -5 °bshalf 3.613 - 0.036 x 10 0.998
+ -58.35 Sorensens single 8.482 - 0.026 x 10 t =
+ -5glycinezNaOH half 8.517 - 0.037 x 10 0.772
* In all cases t ^ = 2.306, N = 12, p' = 0.05 tab
Table 2.9.4. Effect of Buffer Strength on the Apparent First Order 
Rate Constant for SSA Hydrolysis at 50°C.
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......................... First Order Rate “V  2
pH Buffer System ^Constant Bartlett /\ value
- SE (sec )
+ —6Clark and Lubs 1.005 0.028 X 10
KClzHCl 1.050 + 0.037 X 10-G 27.12
2.20
+ . -6 X 2 = 35.71Mcllvaines 1.161 0.031 X 10 tab
Citrate zPhosphate 9.643 + 0.391 X 10-7 N = 24
p' = 0.05
+ -5Mcllvaines 1.904 - 0.039 x 10
CitraterPhosphate + Q Q33 x lO'^ 0.017
6.95
7.75
"^2 2 2 
Gomoris tris 1.859 - 0.043 x 10 tab
HCl 1.880 i 0.043 X 10-5 ” = ^4
p' = 0.05
+ -5Gomoris tris 3.688 - 0.066 x 10
3.465 - 0.156 X 10“  ̂ 1.004
Sorensens 3.446 - 0.066 x 10 "^tab
GlycinezNaOH 3.494 - 0.064 x ICT^ ^ = 24
J  -p' = 0.05
Table 2.9.3 Effect of Buffer Type on the Apparent First Order Rate 
Constant for SSA Hydrolysis at 50°C.
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2.9.4 INFLUENCE OF pH .................................................
The stability of SSA was studied as a function of pH at 50° 
utilising the buffer systems and methodology previously 
described (See 2.9.2), typical plots being shown in Fig. 2.9.2. 
The apparent first order rate constants calculated from such 
log % residual concentration time plots for pH 0.65-13.0 are 
shown in Fig. 2.9.3 ys pH. Since SSA is capable of ionising 
into one non-ionised and two ionic species, equation (14) can be 
rewritten to incorporate terms describing the contribution of 
these species to the overall rate constant, thus:-
-  f  M  "o  + + ’'3 H ^  "4 + + k g fo n jl
+ + kg ( o H ' j j   ..........................................  (28)
where j^S^ , ^ S A ^  and ^ S A ^  are the concentrations of the 
non-ionised, mono- and di-ionised species of SSA respectively. 
The different susceptabilities of the three ionic forms of SSA 
to hydronium ion-, hydroxyl ion- and water-catalysed hydrolysis 
is probably responsible for the plateaus and inflections of the 
pH-stability profile shown in Fig. 2.9.3.
Specific hydronium and hydroxyl ion-catalysed hydrolysis should, 
according to equations (12) and (13), be represented by linear 
plots of the observed first order hydrolysis rate constant v£ 
pH with negative and positive slopes respectively of 1. 
Examination of Fig. 2.4.3 shows that although sections (A - B;
B - c and D - E) of the pH-stability profile can be represented by 
straight lines, the slope of those lines are not 1, the values, 














Fig. 2.9.2 Influence Of pH On SSA Hydrolysis At 50
90
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Apparent First Order 







■ Sorensens Glycine:NaOH 
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Fig. 2.9.3 pH Profile For The Hydrolysis Of SSA At 50°
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- 0.244, + 0.635 and + 0.592 respectively. Other factors must 
therefore be operating over these pH ranges that determine the 
measured rates of reaction, but further investigations on this 
were not carried out.
2.9.5 INFLUENCE OF TEMPERATURE
The effect of temperature on the stability of SSA was studied at 
pH 3.12, 5.15 and 8.15 by the method previously described 
(See 2.9.2) , the pH of each solution being adjusted, at the 
appropriate temperature, to the required value by the addition 
of N HCl or NaOH where necessary. pH 3.12 and 8.15 were chosen 
since the pH stability profile (Fig. 2.9.3) showed hydroxyl-ion 
catalysis for the hydrolysis of the mono- and di-ionised species 
of SSA respectively, and pH 5.15 represented a stage of transition 
between the two.
The influence of temperature on reaction rate is given by the 
Arrhenius equation;-
k = Ae-2/*T
or log k = log A - E . J_
2.303R T .........................  ' '
where k is the specific reaction rate, A is a constant, the
frequency factor, E is the activation energy, R is the gas 
o -1 -1constant (8.3143 J K mole ) and T the absolute temperature.
It is evident from equation (29) that a plot of log k ys Vt 
will have a slope of - Ey^ 3Q3r intercept of log A.
The apparent first order rate constants obtained, shown in 
Table 2.9,5, are graphically expressed in Fig. 2.9.4 according
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-3 Apparent First Order 
Rate Constant (sec“ )̂
pH
★  8.15





Fig. 2.9.4 Arrhenius Plots For SSA Hydrolysis At pH 3.12, 5.15 
And 8.15.
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to equation (29) and the data at each pH was submitted to linear 
least-squares regression analysis to provide values from which 
E and A were calculated.
_ ^ Apparent First Order Rate ConstantTemperature (sec-1)
°c (xlO ■") pH 3. 12 pH 5. 15 pH 8. 15
19.85 3.415 1.45 X 10-7 3.48 X 10-7 1.45 X 10-6
29.60 3.305 4.05 X 10-7 1.18 X 10-8 4.21 X 10-6
40.05 3.194 1.15 X 10-8 4.23 X 10-8 1.60 X 10-6
50.00 3.096 3.84 X 10-8 1.51 X 10-5 5.40 X 10-6
59.95 3.003 1.02 X 10-5 4.36 X 10-5 1.47 X 10-4
Table 2.9.5 Influence of Temperature on SSA Hydrolysis at 
pH 3.12, 5.15 and 8.15
Activation energies for the influence of temperature on SSA 
hydrolysis at pH 3.12, 5.15 and 8.15 were calculated to be 
86.42 - 2.68, 98.22 - 1.47 and 94.83 - 2.24 KJ°K”^mole”  ̂
respectively. These values are within the range expected for 
ester hydrolysis. Departure from linearity for Arrhenius plots 
usually is indicative of a complex mechanism, or a change in the 
dominant mechanism, of degradation over the range studied. The 
linearity of the plots given in Fig. 2.9.4 suggest^ therefore 
that the overall mechanism of the hydrolytic degradation of SSA 
does not change with temperature. The differences in activation 
energies might reflect changes in the ratios of the ionic species 
undergoing hydrolysis since the pK^ of SSA can be expected to
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change with temperature also, thereby altering the proportions
of the ionised to non-ionised species. Where the ionic nature
of the molecule undergoing hydrolysis changes, then this will
modify the electrophi lie nature of the molecule. An ionic
species with a high affinity for the catalytic hydroxyl ion
would be expected to reflect itself in a significantly lower
activation energy, so that the value at pH 3.12 would be
expected to be lower than that at pH 8.15 as is found, the values
being 86.42 - 2.68 and 94.83 - 2.24 KJ°K ^mole  ̂ respectively.
Where the ionic nature of the molecule remains unchanged and the
^ *nature of the preponderant catalytic species, ie H^O or OH , 
varies then a more complex picture results where both the 
activation energy and the frequency factor would be expected to 
change. This may provide an explanation for the non-parallelism 
of the Arrhenius plots shown and the frequency factors of 
3.469 X 10®, 1.097 x 10^^ and 1.097 x 10^^ for pH 3.12, 5.15 and 
8.15 respectively.
2.10 RECRYSTALLISATION OF SSA FROM DIFFERENT MEDIA
The anticipated oral administration of SSA to man, in the form
of a solution of the sodium salt, required that the influence of
gastric juice on its in vivo precipitation should be investigated.
Precipitation can be expected since SSA is poorly soluble under
— 1 oacidic conditions (80 y^g.ml at 37 in O.lN HCl). If it is 
assumed that the volume of human gastric fluid is approximately 
100 ml, and of pH 1.0, then these conditions may be simulated 
in vitro to provide a model for the examination of the influence 
of gastric juice and other experimental media on the precipitation 
of SSA from solution.
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Method. The experimental design was essentially the same as
that used for the solubility studies previously reported
(See 2.6.1) except that the agitation intensity was controlled 
-1at 52 rev.min by use of a constant speed motor (Parvalux, 
Bournemouth) fitted with a flat-bladed stirring paddle. The 
apparatus is schematically shown in Fig. 2.10.1.
Approximately 60 mg SSA was accurately weighed and dissolved in
1 ml 2N NaOH. This solution was rapidly diluted with 200 ml of 
0.0015N HCl and immediately added to 100 ml of the test solvent 
system; both solutions were previously equilibriated at 37°.
2 ml samples were removed by millipore filtration at t = 0 and at 
appropriate time intervals and assayed for SSA as described
(See 2.5) . The pH was monitored throughout the time course of 
each experiment and was found not to change in any of the systems. 
Samples of material precipitated after 24 hours were removed by 
filtration through sintered glass and dried under vacuum 
overnight prior to photomicrographic and X-ray diffraction 
examination for differences in habit and morphology respectively.
The solvent systems used were:-
a) O.lN HCl,as a reference.
b) Simulated gastric juice (U.S.P. 1975), adjusted to pH 1.0 
with N HCl.
c) Half-diluted human gastric juice obtained by intubation from 
patients in a pre-operative situation. Samples from one 
subject, taken on one occasion, were pooled and diluted with an 







Filter A -152 rev.min
Fig. 2.10.1 Recrystallisation Apparatus
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d) Polyvinylpyrrolidone PVP (mol.wt. 44,000) of 0.1% and 
2% w/v in O.lN HCl.
Plots for the concentration of SSA remaining in solution vs time 
are given in Fig. 2.10.2 for each of the systems studied. It is 
evident that simulated and natural gastric juices and both PVP 
solutions considerably retarded the precipitation of SSA when 
compared to that shown for O.lN HCl alone. The initial fall in 
SSA concentration in both gastric juice systems was observed on 
each of three occasions this study was performed but was not 
present for either of the PVP solutions.
Photomicrographic analysis of precipitated material was achieved 
under the light microscope (Beck Kassel) fitted with a single 
lens reflex camera body (Praktica Super T.L.). Representative 
photomicrographs shown in Fig. 2.10.3 clearly demonstrate the 
gross differences in size, number and shape of the material 
precipitated from the various solvent systems. All the photo­
micrographs shown are of the same magnification and have been 
identically treated during printing.
X-ray diffraction patterns for the precipitates were obtained by 
use of the powder film camera technique previously described 
(See 2.2.1). This method of examination had to be used since 
the amount of precipitate produced in some of the solvent systems 
(PVP) was very small. Resultant densitometer tracings are given 
in Fig. 2.10.4 with SSA, as supplied, for reference. The 
coincidence of the diffraction peaks verifies that, although the 
precipitates differ greatly in siae and habit, they exhibit 























































Fig. 2.10.3 Photomicrographs of SSA Recrystallized from O.lN HCl (A) 
Simulated Gastric Juice (B), Human Gastric Juice (C) and 2% PVP (D) 











Fig. 2.10.4 X-Ray Diffraction Patterns For SSA Recrystallised From 
O.lN Hydrochloric Acid, Simulated and Natural Gastric 
Juice and 2% PVP At pH 1.0 and 37°.
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material. It may be cor.cluded, therefore, that PVP and some 
constituent of both gastric juice systems, while preventing and/ 
or delaying SSA recrystallisation, do not alter the morphological 
nature of the product.
The significance of these observations will be discussed later.
2.11 DETERMINATION OF THE DISSOLUTION RATE OF SSA IN O.lN HCL AS A 
FUNCTION OF PARTICLE SIZE.
2.11.1 APPARATUS AND METHOD
The apparatus used (Fig. 2.11.1) was based on the stirred-beaker 
method of Levy and Hayes (1960). The vessel, containing 1500 ml 
of O.lN HCl was partially inmiersed in a thermostatically- 
controlled waterbath at 37 - 0.1°C. Stirring was controlled by 
a constant speed motor at 52 rev.min  ̂ (Parvalux, Bournemouth).
At the commencement of each experiment the stirring rate was 
checked by a strcboscope (Flash Tac. Electronic Applications,
Hitchin) . Removal and separation of samples from undissolved 
material was achieved by the gnillipore membrane system previously 
described (See 2.6) . At each sampling time the 6 ml taken was 
replaced with an equal volume of solvent, introduced via the 
millipore filter. This ensured a constant volume and returned 
any undissolved particles from the surface of the membrane to the 
bulk solution. The apparatus was constructed such that the 
sampling assembly and the stirrer paddle were always at a fixed 
position in relation to the siLdes and bottom of the vessel.
Method. 200 mg of SSA was jpLaced on the surface of the dissolution
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medium equilibriated at 37° and at appropriate time intervals 
6 ml samples were removed, from which 5 ml was accurately pipetted 
and assayed according to the UV method described (See 2.5) for 
SSA content.
2.11.2 TREATMENT OF DATA
The appearance of drug, from dissolving particles, into solution 
can be expressed in several ways, the most common of which is to 
plot the amount dissolved ^  time to produce a dissolution-time 
profile. From such a plot a quantitative assessment of the rate 
can be made by measuring the time taken for a particular weight 
of material to dissolve, or alternatively, by measuring the 
amount dissolved after a specified time. These types of 
representation have been successfully employed in the correlation 
of in vitro dissolution with in vivo absorption for several drugs 
including aspirin (Levy, 1963; Wood, 1967), tetracycline 
(Macdonald et al, 1969) and salicylamide (Bates et al, 1969) .
For some compounds the rate of dissolution can be wholly 
described by first order kinetics and the apparent first order 
rate constants can therefore be used as a reference for 
comparison with other in vitro studies and/or with first order 
in vivo absorption processes for the same drug. Representation 
of dissolution data to yield apparent first order rate constants 
is based on the following rationale.
Under sink conditions, and where dissolution follows first order 
kinetics, it can be assumed that the surface area (S) decreases 
exponentially with time, ie.
S = S°e   (30)
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where S° is the surface area available for dissolution at the 
time when the apparent first order dissolution phase commences 
at time, t^, and ks is the rate constant that describes the 
change in surface area. Under sink conditions the concentration 
of the drug in solution, (C) , at time t is very much less than 
the saturation solubility (Cg) ie C 4^10% Cg, and can therefore 
be ignored. Under these conditions the Noyes Whitney equation 
(2) reduces to:-
dc
dt = k (Cg) ....................................... (31)
The amount of drug in solution (W) can be obtained by 
incorporation of a term relating to the volume (V) of the 
dissolution medium into equation (31) to give:-
f  = K'Cg ...............................  (32)
In this case = kV. Incorporation of a term for S (equation 
(30)) into equation (32) yields:-
f  = K'c3 S°e-’̂® for t >  t„   (33)
which integrates to give:-




-to) for t ^  t ^   (34)
where W^ is related to the change in weight associated with the
change in surface area (W = (K/, )CgS°) and W_ is the amountm 'ks o
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dissolved at time, t . Thereforeo
Wotf» =   (35)
where is the amount in solution at infinite time.
Rearrangement of equation (34) and substitution of Wo© for
W + W gives o m
Woo -W = ks(t to) t ^  to   (36)
Taking logarithms of both sides we get:-
log (Woo -W) = log Ŵ  ̂- ks (t-to) for t ^  t ^ .......  (37)
2.303
where Woo -W is the amount un dissolved at time t and W^ is the
amount finally dissolved. Examination of equation (37) shows
that a plot of log (Woo -W) vg time is linear, with an intercept
of log Wĝ  and a slope of - ks if dissolution can be
2.303'
adequately described by first order kinetics. Deviations of 
such plots from linearity, in the initial and final stages of 
dissolution of a solid dosage form, can be attributed to 
alterations in surface area associated with disintegration, 
deaggregation and complete dissolution of the smaller particles 
respectively. Wagner (1969) suggested a method for the 
determination of apparent first order dissolution rate constants 
for disintegrating tablets and capsules that was based on the 
change of surface area with time. His method accounted for 
the initial log time before which first order kinetics applies, 
and for the final phase associated with small particle dissolution,
Treatment of SSA dissolution data by the Wagner method was not
\  .
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valid since surface area changes for SSA dissolution could be 
attributed to wetting in the first place and the ultimate 
settling of undissolved material to the bottom of the vessel. 
Apparent first order dissolution rate constants for SSA could 
however be calculated from a linear section of the log % 
undissolved vŝ  time plot for each study.
The data for SSA dissolution studies can therefore be represented 
as both a dissolution profile and according to equation (37),
From the latter apparent first order dissolution rate constants 
can be calculated.
2.11.3 PRELIMINARY OBSERVATIONS
Initial observations indicated that SSA was only poorly wetted 
when placed on the surface of the dissolution medium. The 
technique was therefore considered unlikely to give reproducible 
results and the influence of wetting agent was therefore 
investigated. The non-ionic surface active agent, polysorbate 80 
(Honeywill-Atlas, Surrey) was chosen and preliminary studies
_3showed that a concentration of 5 x 10 % w/v was sufficient to
promote adequate wetting without significantly influencing the 
saturation solubility of the drug. Solubility studies carried 
out as previously described (See 2.6) gave a saturation
solubility of SSA in O.lN HCl containing 5 x 10 w/v
“f* “1 opolysorbate 80 of 80.4 - 0.3/wg.ml at 37 . Consequently O.lN
-3HCl containing 5 x 10 % w/v polysorbate 80 was used as the
dissolution medium for all future studies.
Apparent first order dissolution rate constants for SSA of
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180-250m particle size range were obtained using two similar
sets of apparatus, comparison of which revealed that, even
though the rate constants determined using either vessel were
reproducible, there was a significant difference between vessels.
This suggested that slight differences in vessel geometry would
influence the dissolution process by changing the hydrodynamic
characteristics of the vessel. In order to ensure consistency
the same set of apparatus was therefore used on all occasions,
and, in triplicate determinations of the apparent first order
dissolution rate constant for 180-250jMa material, determined in
+ -5the one apparatus, the values obtained were 1.101 - 0.069 x 10 
-1sec respectively. These values are not significantly different 
when compared by the Student 't' test, and illustrate the 
reproducibility of the system.
2.11.4 INFLUENCE OF PARTICLE SIZE ON SSA DISSOLUTION
The dissolution of different particle size ranges of SSA was
investigated, the dissolution vŝ  time profiles of which are
shown in Fig. 2.11.2. Apparent first order dissolution rate
constants are given in Table 2.11.1. The relationships between
BET surface area, particle size and dissolution is clearly
evident from examination of Figs. 2.11.3 and 2.11.4, which show
that, with the exception of the micronised material, there is a
good correlation between dissolution rate and BET surface area
(r = 0.984) . The studies on micronised material show an
anomalous result in that, although possessing the largest
- 2 -1surface area (0.7683 m g ) its dissolution rate is much slower 
than expected. This is probably because aggregates of incompletely, 
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BET Apparent First Order Dissolution
Surface Area Rate Constant
- SE (x lO'^sec” )̂(m^ g-1)
180-250 215 0.070* 0.118 - 0.006
150-180 165 0.1105 0.399 - 0.015
105-150 139 0.1156 1.350 - 0.034
75-105 91.7 0.2892 3.707 - 0.085
53-75 66.9 0.3606 4.132 - 0.052
38-53 45.5 0.5025 6.432 - 0.133
30-38 34 0.5111 7.910 - 0.105
Micronised 5 0.7683 2.319 - 0.041
* The mean particle size is calculated from a knowledge of the 
arithmetic mean of the sieve fractions previously bulked 
(See 2.4.1)
* Estimated by interpolation from Fig. 2.4.4.
Table 2.11.2 Relationship Between Particle Size, BET Surface Area































































and the low dissolution rate is probably a reflection of a 
reduced effective surface area, a phenomenon that is not 
uncommon for microcrystalline powders that have a high 
electrostatic charge.
2.12 PREPARATION OF SSA COPRECIPITATES AND ADMIXTURES WITH POLYVINYL­
PYRROLIDONE (PVP), CHOLIC ACID (CA) AND DEOXYCHOLIC ACID (DOCA).
2.12.1 SSA;PVP COPRECIPITATES
Coprecipitates of SSA:PVP in weight-to-weight ratios of 2:1,
1:1, 1:2, 1:5 and 1:10 were prepared by dissolving the appropriate 
amount of each in a common organic solvent, chloroform, the 
solvent was removed under vacuum, without heating above 40°, in 
a rotary evaporator (Rotavapor-R, Buchi, Switzerland). However, 
not all of the solvent could be removed this way and a glass-like 
gum was produced for each SSA:PVP ratio. The gum formation was 
attributed to polymer plasticisation by chloroform. The final 
traces of solvent were removed by physical manipulation of the 
gum, with a metal spatula, under petroleum ether (60-80° 
fraction) ; this promoted precipitation of a pale yellow/white 
solid. With the 1:5 and 1:10 coprecipitates a large degree of 
physical effort was required to induce precipitation from the 
'plasticised' gums which could only be achieved by grinding 
them, under petroleum ether, in a mortar. Final traces of 
solvent were removed by drying the coprecipitate to constant 
weight in a vacuum oven at 30°. After drying, each sample was 
sieved to obtain the 75-105yxm particle size fraction for 
subsequent in vivo studies and stored in glass jars in the 
desiccator.
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2.12.2 SSA: CHOLIC ACID AND SSA : DEOXYCHOLIC ACID COPRECIPITATES 
Cholic acid, CA, (mol.wt. 408.6) and deoxycholic acid, DOCA, 
(mol.wt. 392.6) were used as supplied (B.D.H.). Since the 
molecular weight of the bile acids was known the SSA:CA and 
SSA:DOCA coprecipitates (and admixtures) were prepared in molar 
ratios of 2:1, 1:1, 1:2, 1:5 and 1:10. The common solvent used 
for SSA:bile acid coprecipitate preparation was methanol since 
the bile acids were found to be insufficiently soluble in 
chloroform. The general method was the same as for SSA:PVP 
coprecipitates except that gums were not formed and the copre­
cipitates readily precipitated on solvent evaporation. A 
particle size fraction of 75-105y^m was again obtained by 
sieving and stored in glass jars in the desiccator for future 
use.
2.12.3 SSA:PVP, CA AND DOCA ADMIXTURES
These were prepared in the same ratios as their respective 
coprecipitates by physically mixing the appropriate amounts of 
each constituent in a closed jar. To enable direct comparisons 
between in vivo absorption data obtained from administration of 
the coprecipitate and admixture systems the latter were prepared 
from SSA, CA, DOCA and PVP of 75-105 ^ m  particle size.
2.13 CHARACTERISATION OF SSA COPRECIPITATES
Material outside the 75-105 m particle size range was retained 
to establish the SSA content of each ratio and for their X-ray 
diffraction analysis.
2.13.1 DETERMINATION OF SSA CONTENT
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2.13.1.1 SSA:PVP Systems
Weighed amot^ts of each ratio, equivalent to approximately 50 mg 
SSA^were dissolved in 1 litre of water and assayed for SSA by 
ultraviolet spectrophotometry as described previously (See 2.5). 
The influence of PVP on the UV absorption of SSA at 341 nm in 
alkaline medium was investigated and found not to be significant 
for the concentrations used. The results of duplicate 
determinations are given in Table 2.13.1.
The total acid content of each SSA:PVP : coprecipitate was also 
determined by titration of a weighed sample (approx 220 mg SSA) 
with O.lN NaOH as previously described (See 2.3.3). Blapk 
titrations were performed on the appropriate, theoretically 
expected, amounts of PVP, the titres of which were subtracted 
from their respective SSA:PVP titre. The values for the PVP 
titres and the calculated SSA content of each coprecipitate are 
given in Tables 2.13.2 and 2.13.3 respectively.
Weight PVP (mg)
100 200 400 1000 2000
Titre a 0.12 0.21 0.42 1.10 2.20
Volume b 0.12 0.22 0.41 1.10 2.20
O.lN
NaOH c 0.12 0.21 0.43 1.15 2.22
(ml) d 0.12 0.22 0.41 1.05 2.22
Mean 0.12 0.215 0.42 1.10 2.21












0 50.1 0.630 50.4 100.6
50.3 0.633 50.6 100.7
Mean 100.65
2:1 74.7 0.610 48.8 65.33
74.9 0.640 51.2 64.89
Mean 65.11
1:1 102.3 0.625 50.0 48.88
97.8 0.610 48.8 49.90
Mean 48.39
1:2 152.6 0.530 42.4 27.79
160.4 0.545 43.6 27.18
Mean 27.49
1:5 305.3 0.585 46.8 15.33
301.6 0.575 46.0 15.25
Mean 15.29
1:10 463.0 0.520 41.6 8.99
469.0 0.530 42.4 9.04
Mean 9.02
Table 2.13.1 Percentage Purity of SSA:PVP Coprecipitates as
















2:1 0.3064 7.82 7.70 64.86
0.2987 7.77 7.65 66.10
0.3080 7.92 7.80 65.36
0.3082 7.98 7.86 65.82
Mean 65.54
1:1 0.3975 7.66 7.44 48.30
0.4083 7.98 7.76 49.05
0.4133 8.07 7.85 49.02
0.4132 7.97 7.75 48.41
- Mean 48.70
1:2 0.6168 7.57 7.15 29.92
0.5945 7.34 6.92 30.04
0.7268 8.94 8.52 30.25
0.5839 7.17 6.75 29.84
Mean 30.01
1:5 1.2056 8.48 7.38 15.80
1.2201 8.50 7.40 15.65
1.2095 8.41 7.31 15.60
1.2015 8.33 7.23 15.53
Mean 15.65
1:10 2.2132 9.90 7.69 8.97
2.2323 9.92 7.71 8.91
2.2128 9.80 7.59 8.85
2.2025 9.88 7.67 8.99
Mean 8.93
* Blank values are those obtained from Table 2.13.2.
Table 2.13.3 Percentage SSA Content of SSArPVP Coprecipitates as 
Determined by Titration
116
A comparison of the experimentally determined % SSA purity with 




Mean % SSA Content 
Theor. UV Assay Titration
2:1 66.67 65.11 65.54
1:1 50.00 49.39 48.70
1:2 33.33 27.49 30.10
1:5 16.67 15.29 15.65
1:10 9.09 9.02 8.93
Table 2.13.4 Comparison of Experimentally Determined % SSA Content 
of SSA:PVP Coprecipitates.
2.13.1.2 SSA:CA and SSA:DOCA Systems
The poor aqueous solubility of the bile acids precluded the use
of the ultraviolet assay employed for the SSArPVP systems.
Assays were performed using ethanolic solutions of the
coprecipitates. Nine standard solutions of SSA (approx. 1.8 to 
-1118 yA g.ml , accurately known) were prepared in absolute ethanol. 
5 ml volumes of each standard and 0.4N NaOH were adequately 
mixed and the absorbance read at the previously determined 
A  max of 345 nm against an ethanol/NaOH blank. Even though 
aqueous dilution of ethanol resulted in a reduced combined 
volume similar treatment of each standard and test sample should 
be similarly affected and the volume change was therefore ignored. 
Fig. 2.13.1 shows a standard calibration plot that adheres to the 






































1 % ^to linear least-squares regression analysis gave a n d ^
values of 134.7 and 3476.1 respectively. Absorption spectra 
of identically-treated ethanol solutions of cholic and deoxy- 
cholic acids confirmed that neither absorbed at 345 nm nor 
induced changes in the absorbance spectrum for SSA under 
similar conditions.
Weighed amounts of each SSA;CA and SSA:DOCA coprecipitate 
( =  approximately 50 mg SSA) were dissolved in 50 ml of 
absolute ethanol. 5 ml aliquots of each were assayed as 
described following a further 1 in 25 dilution with absolute 
ethanol. The results in Table 2.13.5 for SSA:CA and Table 
2.13.6 for SSA:DOCA show good agreement with the theoretical 
% SSA content.
2.13.2 X-RAY DIFFRACTION EXAMINATION OF SSA;PVP COPRECIPITATES AND 
ADMIXTURES
Each of the SSA:PVP coprecipitates were examined by X-ray 
diffraction in order to establish whether or not the process of 
coprecipitation had altered the crystalline nature of the 
original constituents. The diffraction patterns were obtained 
using a Debye-Scherer film camera (See 2.2.1) and the resultant 
films used to give the densitometer tracings shown in Fig.
2.13.2. The tracings show that although SSA is highly 
crystalline, after its coprecipitation with PVP, in whatever 
ratio, the product showed no crystalline pattern and can be 
considered amorphous; PVP alone also showed amorphous behaviour.









% SSA Contentwt. SSA* 
determined Experi- Theoret- 
(mg) mental ical
2:1 74.3 0.433 25 40.18 54.08
0.434 25 40.28 54.21
Mean 54.15
1:1 90.8 0.388 25 36.01 39.66
0.386 25 35.82 39.45
Mean 39.56
1:2 140.5 0.370 25 34.36 24.46
0.371 25 34.43 24.51
Mean 24.49
1:5 292.3 0.362 25 33.59 11.49
0.363 25 33.69 11.53
Mean 11.51
1:10 529.6 0.310 25 28.77 5.43
0.309 25 28.68 5.42
Mean 5.425






Table 2.13.5 Percentage Purity of SSAzCA Coprecipitates Determined 
By UV Spectrophotometry
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SSA: W t  wt. SSA * % SSA Content
DOCA taken Absorbance Dilution determined Experi- Theoret-
Ratio (mg) at 345 nm (x) (mg) mental ical
2:1 92.3 0.568 25 52.71 57.19 56.79
1:1 124.7 0.532 25 49.37 39.59 39.66
1:2 200.1 0.520 25 48.26 24.12 24.74
1:5 437.1 0.566 25 52.53 12.02 11.62
1:10 826.9 0.478 25 44.36 5.36 5.17
* Corrected for 50 ml original volume.
Table 2.13.6 Percentage Purity of SSA:DOCA Coprecipitates 




1:5 (F) And 1:10 (G).
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indicated, as expected, that the crystalline structure of SSA 
could be detected over the amorphous nature of PVP as shown in 
Fig. 2.13.3. The progressive decrease in the SSA peak 
intensities could be related to increased proportion of the 
PVP present.
2.13.3 X-RAY DIFFRACTION EXAMINATION OF SSArCA COPRECIPITATES AND 
ADMIXTURES
X-ray diffraction studies using a powder plate diffractometer 
indicated that, with the exception of the 1:1 molar ratio, SSA,
CA and their coprecipitates were crystalline. The diffraction 
peaks of the coprecipitates were not coincident with those for 
SSA or cholic acid. Fig. 2.13.4 shows this for a representative 
coprecipitate. This indicates that the coprecipitates appear 
to have a different crystalline structure from either of the 
original components. Since the X-ray diffraction pattern of 
SSA has previously been shown not to be altered by its 
recrystallisation from methanol (See Fig. 2.3.5.1) it was 
concluded that changes in the X-ray diffraction patterns for 
the coprecipitates could be due to an alteration in the crystal 
structure of cholic acid following its recrystallisation from 
methanol. This possibility was examined by comparing the X-ray 
diffraction patterns for cholic acid, as supplied, to that after 
recrystallisation from methanol, and the resultant patterns 
shown in Fig. 2.13.5 indicate a change in the crystal structure. 
The possibility of different polymorphic forms 
of cholic acid cannot therefore be discounted. Comparison of 
the diffraction patterns for the SSA:CA coprecipitates, that 
exhibited a crystalline behaviour, with cholic acid recrystallised
123
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Fig. 2.13.3 X-Ray Diffraction Patterns For SSA (A) , PVP (B) , And 
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from methanol verifies that changes in their diffraction 
pattern are due to alteration of the crystal structure of 
cholic acid. Fig. 2.13.6 shows that all of the diffraction 
peaks for the SSArCA coprecipitates can therefore be attributed 
to either SSA or cholic acid and not to any other product of 
crystallisation. The strikingly anomalous amorphous pattern 
for the 1:1 ratio and the poorly crystalline nature of the 1:2 
ratio was checked by examination of the diffraction patterns of 
newly prepared samples. The original findings were confirmed 
and it was envisaged that the amorphous nature of the SSAzCA 1:1 
and 1:2 coprecipitates might be reflected in their absorption 
behaviour.
In light of the observed crystal changes for cholic acid 
resulting from its recrystallisation from methanol it was 
essential that the correct crystalline form be used in prepara­
tion of the corresponding admixtures. Therefore^ for reasons of 
comparison,the SSArCA admixtures were re-prepared using cholic 
acid recrystallised from methanol and sieved before use.
The X-ray diffraction patterns for the SSArCA admixtures show 
complete masking of the SSA peaks even for the 2r 1 ratio. All 
peaks are characteristic of those for the methanol recrystallised 
cholic acid. A representative pattern is given in Fig. 2.13.7 










Fig. 2.13.6 X-Ray Diffraction Patterns For SSArCA Coprecipitates, 








































































2.13.4 X-RAY DIFFRACTION EXAMINATION OF SSA:DOCA COPRECIPITATES AND 
ADMIXTURES
The powder plate X-ray diffraction technique was again used for 
the examination of the diffraction patterns of the SSA:DOCA 
coprecipitates and admixtures. Experience with the cholic acid 
systems suggested an examination for changes in the crystalline 
nature of deoxycholic acid following its recrystallisation from 
methanol prior to studies on the coprecipitates and preparation 
of the admixtures. Fig. 2.13.8 shows changes in the diffraction 
pattern of the methanol recrystallised deoxycholic acid. As 
for the SSA:CA admixtures, those for SSA:DOCA systems had to be 
prepared using deoxycholic acid recrystallised from methanol. 
Fig. 2.13.9 gives the diffraction patterns for the SSA:DOCA 
coprecipitates, and it is apparent, that changes in their 
crystalline nature can be attributed to alteration of the 
diffraction pattern of deoxycholic acid. Critical examination 
of Fig. 2.13.9 reveals that during progression through the 
series ( SSA : DOCA molar ratio) from 2:1 up to 1:10 the associated 
changes in X-ray diffraction behaviour reflect the progressive 
change in the ratio of constituents. This is illustrated by the 
2:1 and 1:10 SSA:DOCA ratios, where the former shows a 
diffraction pattern that is predominantly tfiat of SSA whereas 
in the latter the emphasis is on the diffraction peaks 
attributable to deoxycholic acid. It should be noted that 
although the 1:2 ratio coprecipitate showed a poorly-crystalline 
diffraction pattern the 1:1 ratio had a pattern indicative of a 
definite crystal structure. This is in contrast to the 
respective SSA:DOCA coprecipitates. Furthermore^ all SSA:DOCA 














Fig. 2.13.9 X-Ray Diffraction Patterns For SSArDOCA Coprecipitates, 
Deoxycholic Acid Recrystallised From Methanol (B) And 
SSA (A).
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~Z. in Fig. 2.13.9) that could not be accounted for.
The X-ray diffraction patterns of the SSA:DOCA admixtures were 
composed of the peaks of the two crystalline and non-interactive 
components and reflected the ratio of SSA to deoxycholic acid. 
Representative diffraction patterns for the 2:1 and 1:10 SSA; 
DOCA admixtures are given in Fig. 2.13.10 with those of SSA 
and methanol recrystallised deoxycholic acid for reference.
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Fig. 2.13.10 X-Ray Diffraction Patterns For Two Representative SSA: 
DOCA Admixtures (B 2:1, C 1:10) Deoxycholic Acid 
Recrystallised From Methanol CC) And SSA As Supplied (A)
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2.13.5 DISSOLUTION AND SOLUBILITY STUDIES ON SSArCA COPRECIPITATES 
AND ADMIXTURES
It has been suggested that the amorphous nature of the SSArCA 
1:1 and the poorly crystalline nature of the 1:2 coprecipitates 
may be reflected in an enhancement of SSA absorption. This 
was found to be the case for the 1:1 coprecipitate and 
admixture but for no other SSArCA system (See 3.3.II) . The 
respective areas under the plasma salicylate concentration vs 
time profiles for the 1:1 systems were significantly greater 
than the other SSArCA formulations and showed 100% 
bioavailability in comparison to the same dose given 
intravenously. The observed changes in bioavailability 
warranted explanation and, in an attempt to do this, the 
dissolution and solubility characteristics of the SSArCA 
systems were assessed in vitro.
Dissolution Studies. The dissolution apparatus has been 
described in Section 2.11.1 and the experimental protocol 
remained unaltered except that the volume of the dissolution 
medium was reduced to 750 ml, since for some of the SSArCA 
systems there was insufficient material to provide a saturated 
solution in the 1500 ml originally employed. As it was there 
was insufficient of the 1r 5 coprecipitate remaining after the 
in vivo absorption studies to be examined in vitro and is 
therefore not included.
100 mg (equivalent SSA) of each SSArCA system (75-105JUm
particle size range) was added to 750 ml O.lN HCl containing
-3 -15x10 % w/v polysorbate 80 stirred at 52 rev. min, and
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maintained at 37°. Each system was corrected for % SSA content, 
according to Table 2.13^5 for the coprecipitates, whereas the 
ratio of the components in the admixtures were assumed to be 
as prepared. 5 ml samples were removed by filtration through 
a 0.45yAm millipore as previously described (See 2.11.1) and 
assaydfor SSA accordingly.
The resultant dissolution profiles given in Fig. 2.13.11 show 
that dissolution for both the 1:1 coprecipitate and admixture 
is greater than that for the other SSAzCA systems and SSA 
alone (75-105^im). It is also evident that all CA-containing 
systems show a greater amount of SSA in solution after 60 
minutes than for SSA alone. For all systems studied, except 
the 2:1 coprecipitate, the material which settled during the 
experimental period formed a conical mound directly under the 
stirrer blade; the 2:1 coprecipitate was observed to form 
large aggregates that remained suspended. This 'caking' could 
therefore account for the anomalous profile that was produced 
by this material up to 45 minutes.
Solubility Studies. Saturation solubilities of the SSAzCA 
systems were determined using the experimental protocol 
previously described (See 2.6). Excess material was added 
to O.lN HCl containing 5x10 w/v polysorbate 80 and the 
equilibrium solubility determined after 24 hours. The results 
given in Table 2.13.6 show the presence of cholic acid to 
enhance the solubility of SSA by approximately 5% and that all 
CA-containing systems exhibited equivalent solubilities.
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Fig. 2.13.11 Dissolution Profiles For SSA:CA Coprecipitates And
Admixtures In O.lN HCl Containing 5x10 ^w/v Polysorbate 80
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On the basis of the solubility studies the enhanced 
dissolution of the 1:1 SSA:CA formulations cannot be 
attributed to changes in solubility and may therefore reflect 
the amorphous nature of the 1:1 ratio coprecipitate 
(Fig. 2.13.6). For the 1:1 ratio admixture another possible 
mechanism must be proposed and may include a molecular 
interaction within the diffusion layer of the dissolving 
particles and/or the solubilization of SSA within cholic acid 
micelles/aggregates.
„ _ Absorbance SSA concentrationSystem     -h  Mean(at 341 nm) (^g.ml.“ )̂
, 0.338 81.12 -,SSA alone 0.339 81.36 81.24











ADM 0.361 ' 86.64
1:5 0.368 88.32
COP 0.365 87.60










Table 2.13.6 Equilibrium Solubilities of SSA:CA Coprecipitates And
-3Admixtures In O.lN HCl Containing 5x10 % w/v




3.1 INTRODUCTION. SOME BASIC PHARMACOKINETIC CONCEPTS
The technical limitations associated with non-invasive method­
ology in biopharmaceutical and pharmacokinetic studies have 
meant that, for most drugs, assessment of their absorption and 
disposition relies on monitoring the drug concentration in body 
fluids and tissues. However, there are some drugs e.g. 
reserpine, that exert a clinical effect, the time course of 
which is not directly related to, and cannot be correlated with, 
blood or body fluid concentrations. Assessment of the absorp­
tion into and elimination from the body is employed, for the 
majority of drugs, to indicate the onset and duration of a 
clinically-useful or toxic response and to evaluate changes in 
that response resulting from pharmaceutical or formulatory 
variations.
Most absorption and disposition studies of drugs in the body 
depend on the measurement of unchanged drug and/or its 
metabolites in a body fluid (e.g. blood, urine etc) and are 
usually expressed graphically in the form of a concentration vs 
time profile. In recent years it has become possible to analyse 
these profiles by applying the principles of first order 
kinetics, an approach that has facilitated an understanding of 
the complex kinetic processes underlying the time course of a 
drug's presence in the body. The mathematical basis of this 
kinetic interpretation has been adequately reviewed by Notari 
(1975), Gibaldi and Perrier (1975) and Wagner (1971; 1975).
This type of analysis is termed 'pharmacokinetics' and has been 
defined as "the study of the kinetics of absorption, distribu­
tion, metabolism and elimination of drugs and their pharmacol-
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ogical, therapeutic or toxic response in animals and man" 
(Notari, 1975).
Implicit in any pharmacokinetic evaluation is the characterisation
\of a suitable model, or models, based on 'compartments' in the 
body exhibiting similar pharmacokinetic profiles. In this 
context a compartment may be defined as any ' kinetically- 
distinguishable pool'; it may represent a specific anatomical 
entity (e.g. liver or lung), a specific physiological entity 
(e.g. blood or urine) or a non-specific collection of entities 
(e.g. circulatory fluids, adipose or well-perfused tissues).
The advantage of such compartmental analysis is that knowledge 
of the pharmacokinetic profile for one readily-accessible 
compartment enables prediction of profiles for other non- 
accessible compartments.
The transfer of drug or its metabolites from one compartment to 
another is associated with specific rate constants which are 
generally first order and independent of dose. However, zero 
order transfer is being reported with increased frequency for 
capacity-limited processes that may be described by Michaelis- 
Menten kinetics. Compartmental analysis, therefore, provides 
quantification of these rate constants together with estimates 
of the volume of the compartment into which the drug is 
distributed.
Pharmacokinetic analyses have been utilised experimentally to 
determine the influence of formulation on absorption, disease 
or disposition and in comparisons of drug homologues in
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structure-activity relationships. The clinical use of pharmaco­
kinetics as a diagnostic tool has been proposed, particularly in 
cardiovascular, hepatic and renal disease, since there is a 
direct connection between these diseases and the disposition of 
both exogenous and endogenous substances.
The initial stage in a pharmacokinetic analysis therefore, is to 
define the compartmental model that adequately describes the 
data. Normally the simplest model is chosen but, in view of a 
comparison between the calculated and experimental data, this 
model may be modified, either to make it more complex or to 
simplify it further. In all compartmental analyses it must be 
remembered that the body is an 'open' system since it is 
continually disposing of administered drugs by excretion and/or 
metabolism.
Following an intravenous bolus injection the blood concentration 
vs time profiles for the majority of drugs are biphasic in nature 
(see Fig. 3.1) and may be described by a biexponential equation:-
P = A.e" + B.e "   (38)
where P is the plasma concentration of the drug at time t. This 
model is known as the 'two compartment open model' (Scheme 1 
Fig. 3,2) and c< and ^  are complex functions of the micro­
constants k^2 ' ^2' generally represent the distribution
and elimination phases respectively. A and B are the extrapolated 
intercepts derived from a plot of log P vs t and represent the 
hypothetical concentrations of drug in the central compartment 




Fig. 3.1 Characteristic Profiles For A Plot Of log^ Of Drug
Concentration In The Blood vs Time For Data Describable By 




^  Drug Eliminated
Bolus
Scheme II















Fig. 3.2 Diagrammatic Representation Of Drug Distribution For The 
Two (Scheme I) And One (Scheme II) Compartment Open Model 
Following Intravenous Injection, And The Two Compartment 
Open Model For Oral Administration (Scheme III) .
For explanation of the k values see text.
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respectively.
Equation (38) has been presented and discussed by several 
authors (Mayersohn and Gibaldi, 1971; Riegelman et al, 1968) 
and the parameters. A, B, OC and ^ can be determined by the 
method of residuals (feathering, stripping, peeling, back 
projection etc) as described by Notari (1975) and Wagner (1975). 
From a knowledge of these parameters the microconstants, k , can 
be calculated by use of equations given by the above authors. 
Although the method of residuals allows calculation of the 
microconstants, k, from oC and f}> the elimination phase ( ^  ) 
must be adequately defined by the experimental data; in practice 
this entails collection of blood and/or urine samples for a 
time equal to seven-ten times the elimination half-life.
For some drugs, distribution occurs very rapidly with respect to 
elimination such that an equilibrium between the concentrations 
of drug in the central and peripheral compartments occurs in a 
very short time. In this case ^  and, if the blood
concentration is not determined at sufficiently short periods 
following i.v. bolus injection, the pharmacokinetic profile may 
appear monophasic (See Fig. 3.1 line X) and may be described by 
the monoexponential equation (39).
P = B.e" ^ ^   (39)
which has the same designations as in equation (38) . This model, 
known as the 'one compartment open model', is shown in Scheme II 
Fig. 3.2. The simplicity of this model may, however, lead to 
misappropriation of the microconstants since the slope of the
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monoexponential plot is not equal to as it would appear from 
the scheme, but always represents the overall elimination rate 
from the body, designated by . Equation (39) does not imply 
that the distribution processes differ from those in the two 
compartment model, only that they occur very rapidly and there­
fore may not be detected experimentally.
The description of a drug's distribution according to the one- 
or two-compartment open model is therefore dependent upon the 
frequency of obtaining the initial blood samples and, under 
certain circumstances, it may be reduced from the two- to one- 
compartment model. This is illustrated by examination of 
Fig. 3.1 which shows that, if the first blood sample is taken at 
time tĵ following an intravenous bolus injection, then the data 
is described by a monoexponential equation (39), line X; whereas, 
if sufficient blood samples are taken between times tQ and t^, 
the initial distributive phase may be detected and the data may 
then be described by a bi-exponential equation (38) line Y.
Drug administration via the intravenous route ensures that all 
of the administered dose is available to the circulatory fluids 
and the area under the i.v. plasma level profile (AUC^^) is 
directly proportional to the dose. However, following oral 
administration the shape of the plasma concentration vs time 
profile described by Scheme III Fig. 3.2 will be influenced by 
the rate and extent of the drugs' availability, in addition to 
the influences of distribution and elimination discussed earlier. 
For Scheme III^Fig. 3.2^k^ is defined as an availability (rather 
than an absorption) rate constant since it combines not only
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the absorption process but also the rate of dissolution from a 
solid dosage form. Where only the rate of availability changes 
for a given drug in a single patient then the plasma concentration 
vs time profiles might appear as illustrated in Fig, 3.3.A. As 
increases the peak plasma concentration (Pp) will increase 
and the time taken to reach that peak (tp) will decrease 
although, if the drug is completely absorbed before it passes 
the sites of its absorption from the gastrointestinal tract, 
the area under the plasma level profile (AUCp^) will be constant. 
Therefore for a given dose contained in various formulations, a 
constant value for the AUC is indicative that the same amount 
of drug was released from each formulation and subsequently 
absorbed. Furthermore, when k^ is the only parameter undergoing 
change the AUC will be proportional to the total amount of drug 
released from the dosage form. Similarly if the size of the 
available dose is changed without any alteration to any of the 
pharmacokinetic microconstants then the AUC will be directly 
proportional to the dose. This would be true for oral as well 
as i.v. administration. This situation is illustrated for the 
case of oral administration in Fig. 3.3.B where peak concentra­
tion (Ppjof the drug occurs at the same time even though the 
concentration changes in a dose-related manner.
For drug disposition describable by the one compartment model 
the plasma concentration (P) is given by:-
■ T  ■ (îA) I--" .............
where fD is the fraction of the dose absorbed (assuming 













Fig. 3.3 Influence Of Alteration In The Absorption Rate Constant (A) 
And The Size Of The Dose Available For Absorption (B) From 
The Gastrointestinal Tract.
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the volume of distribution and is the apparent first order 
absorption rate constant. A plot of Ln P vs t will have a linear 
elimination phase ( /h ) and application of 'stripping' procedures 
(Notari, 1975) will enable elucidation of k^. Determination of 
ka for the two compartment model (Scheme III Fig. 3.2) involves 
the incorporation of a term for k^ into equation (38) to give:-
- (a  + b) e"   (41)
This is a complex situation where two exponential terms describe 
drug disappearance from the blood and one describes drug 
absorption. A usual assumption with this model is that 
ka^ or f* * hence C< is always greater
than ^ . Calculation of k^ is based on the further assumption
that all of the pharmacokinetic transfer and metabolic processes, 
excepting absorption, are first order.
The simplest approach to determination of ka would be the 
measurement of drug loss from the site of absorption. Unfortun­
ately in pharmacokinetic studies following oral or other 
extravascular routes of administration the amount of drug 
remaining unabsorbed is not usually available for direct 
measurement and values for k^ are derived from data describing 
the appearance of unchanged drug in the blood or urine. The 
most commonly employed methods for such inferential determina­
tions are those of Wagner and Nelson (1963) and Loo and 
Riegelman ( 1968), for the one- and two-compartment models 
respectively. The applications of these methods are further 
discussed by Notari (1975) and Wagner (1974; 1975a; 1975b). For 
a single compartment where elimination is wholly describable by
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capacity-limited, zero order, kinetics both of the above methods 
can be applied although this is not so where concomitant 
capacity-limited and first order elimination occur from either 
the one- or two-compartment open models.
Comparisons of blood level curves, for the same drug, may be 
summarised by two observations. A change in the time required 
to attain a peak plasma concentration, which reflects changes in 
k^/ and, a change in the area under the plasma level curve which 
indicates an alteration in the amount absorbed.
The early use of analogue computing techniques in pharmaco­
kinetic analyses (Garrett, 1964; Garrett and Alway, 1964) has 
largely been superceded by the widespread availability of 
powerful digital computer procedures which together with the 
subjective nature of fitting data by analogue methods, has led 
to the development of 'pharmacokinetic modelling packages' that 
utilise non-linear optimisation methods to determine the micro­
constants. The early SAAM package (Berman et al, 196%) was 
very cumbersome and has now been almost exclusively superceded 
by NONLIN (Metzler, 1969), a non-linear, least-squares regression 
program which has been rigorously tested and provides reliable 
least-squares estimates of the model parameters. The NONLIN 
programs have been incorporated into a package called AUTOAN 
(Sedman and Wagner, 1974) which has the provision for analysing 
zero-order transfer processes according to Mfchaelis-Menten 
kinetics. These programs require estimates of the parameters 
to be optimised, information that is normally provided by the 
method of residuals. However, the estimates of the parameters
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should be well chosen in order that the optimisation procedures 
converge to a global and not a local minimum.
The overall elimination rate constant ( ̂  ) of equations (38) 
and (39) is a composite function of terms that represent the 
loss of drug from the central compartment by excretion and 
metabolism. Excretion predominantly occurs via the kidneys into 
the urine but may also occur via the lungs, sweat, faeces 
(enterohepatic recycling) or saliva. Metabolic processes include 
chemical (hydrolysis, oxidation etc) or enzyme-catalysed degrad­
ation and transformation that may or may not be capacity-limited. 
If no capacity-limited (saturable) processes are involved in 
drug elimination then the apparent first order elimination rate 
constant ( jS or k^^) is a suiranation of all the concomitantly- 
occurring first order elimination processes. However, if 
capacity-limited transport or metabolism occurs then the 
elimination phase will exhibit deviation from linearity and 
cannot be wholly described by equations (38) and (39j unless the 
contribution of the non-linear processes is negligible with 
respect to those of apparent first order. If the blood concen­
tration is raised, by increasing the intravenous dose or the 
rate and extent of gastrointestinal absorption, then the 
contribution of the capacity-limited systems would be increased 
and kg2 (and the elimination half-life) will not be indepen­
dent of the blood concentration.
When the processes of transfer associated with absorption, 
distribution, metabolism or excretion are described by first 
order kinetics then the biological half-life (t̂ ) will be
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constant. In this context the biological half-life is the time 
required for the drug concentration in the central compartment 
to decrease to a half of the initial value, and as such should 
not be confused with the half-lives describing the absorptive or 
excretory processes. Since the determination of the biological 
half-life is dependent upon drug disposition obeying first order 
kinetics, any inconsistency in the half-lives calculated from 
data for different doses of a drug would be indicative that 
first order kinetics may not provide an adequate description of 
the blood drug concentration vs time profile. Therefore, 
changes in the biological half-life with respect to dose is one 
of the most discriminative methods of ascertaining the presence 
of capacity-limited transport or metabolic processes.
For drug transfer and metabolic processes that can be described 
by dose-dependent, zero order kinetics alone, the initial 
velocity of the process ("Vo) can be described by the Michaelis- 
Menten equation:-
V o  =   <42)
where is the maximum velocity of the process, C is the
concentration of drug substrate available to the metabolic 
enzymes or membrane carrier system, etc and is the Michaelis 
constant. A plot of"Vo vs C will be a rectangular hyperbola 
characteristic of saturable concentration-dependent processes. 
At low concentrations the initial velocity will be first order
ie "YT “ kC ................................ (43)
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but at high drug substrate concentrations the velocity will be
maximal, the reaction will be zero order, and V^ax will be
independent of drug substrate concentration. Furthermore,
according to Michaelis-Menten kinetics, it can be shown that at
half V the Michaelis constant (Km) is equal to the drug max
substrate concentration.
Rearrangement of equation (42) gives
- = — ^    (44)Vmax Vmax C
This equation forms the basis of the Lineweaver-Burk method for 
estimating Vmax and Km since a plot of 1/ ( w h e r e i s  the 
overall zero order elimination rate constant obtained from a plot 
of blood drug concentration vs time) against V c  (where C is the 
dose) will be linear, having a slope of and ordinate and
abcissa intercepts of “V K m  and Vvmax respectively. Zero order 
elimination from a two-compartment open model is illustrated in 
Scheme IV(Fig. 3.4^
A combination of two simultaneously-occurring modes of 
elimination, one of which is capacity-limited, and the other first 
order, is given in Scheme V^Fig. 3.4^for the two-compartment 
open model. In this example elimination occurs from the central 
compartment by urinary excretion and metabolism, where the 
capacity of the enzyme system involved in the metabolic process 
may be saturable, resulting in deviation of the pharmacokinetic 
profile from the biphasic curve associated with the two compart­
ment open model (See Fig. 3.5.Y). Under such conditions a plot
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Fig. 3.4 Diagrammatic Representation Of Drug Distribution For The 
Two Compartment Open Model For Zero Order Elimination 
Kinetics (Scheme IV) And Parallel First And Zero Order 
Elimination Kinetics (Scheme V) (k^ and k2 are zero and 




Fig. 3.5 Characteristic Profiles For A Plot Of log^ Of Drug
Concentration In The Blood vs Time For A Two Compartment 
Open Model Describable By First Order Elimination Kinetics 
Alone (Line Y) And By Parallel First And Zero Order 
Elimination Kinetics (Line ZÏ.
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p vs time would appear as in Fig. 3.5 Line Z.
Capacity-limited, non-linear pharmacokinetic processes associated 
with drug absorption, distribution, metabolism, renal and biliary 
excretion, and pharmacological action have been collated and 
reviewed by Wagner (1973b). The majority of non-linear 
processes occurring during absorption and distribution are 
associated with physiological functions such as changes in blood 
supply and saturable tissue binding. However, by far the most 
convincing evidence for non-linearities is that dealing with the 
saturable metabolism of ethanol, phenytoin and the salicylates. 
Furthermore it has been suggested (Wagner, 1973b) that the 
parameters and will provide a better description of the
saturable metabolism of these drugs, at all doses, than a series 
of zero order rate constants and elimination half-lives that 
vary with the amount of drug reaching the systemic circulation. 
Salicylate metabolism is of direct relevance to the work reported 
and will be discussed in greater detail.
Practically all of an administered dose of salicylic acid can be 
recovered from the urine as unchanged drug and as the four major 
metabolites, gentisic acid (GA), salicyluric acid (SUA), 
salicylacyl glucuronide (SAG) and salicylphenolic glucuronide 
(SPG). At low doses the major metabolite, salicyluric acid, 
has been shown to account for 0-91% of the salicylic acid dose 
administered (Schachter and Manis, 1958; Levy, 1965), the 
percentage decreasing as the dose was increased. The remainder 
of the dose is excreted in the approximate proportions :- 
GA, ^1%; SAG, 0-10%; SPG, 12-30%. The dose-dependent kinetics
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of salicylic acid metabolism have been attributed to the 
processes which lead to the production of SUA, SAG and SPG 
(Levy, 1965; Levy et al, 1972) and have been suggested to 
account for the non-linearity of salicylate pharmacokinetics in 
man. *
The precise site of formation of the various metabolites has 
not been identified although the indications are that the 
majority occurs in the liver. It has been suggested (von 
Lehmann et al, 1973) that the renal contribution of SUA formation 
could comprise 60-70% of the total metabolism of salicylic acid 
in man. This work was based on previous observations in the 
Rhesus monkey which clearly showed that the kidney was a major 
site for SUA formation (Wan and Riegelman, 1972) . However, these 
conclusions are not supported by Lowenthal et al (1974) who 
demonstrated that the overall elimination rate of salicylate in 
anephric patients was no different to that in normal healthy 
subjects. The saturable nature of SUA formation in both man and 
the rat has been shown (Nelson et al, 1966) to result from 
enzyme saturation rather than the rate of glycine availability. 
The degree of saturation in both species was such that the 
percentage of the dose metabolised to SUA decreased with 
increasing dose and could therefore be expressed according to 
Michaelis-Menten kinetics. Although SUA formation is capacity- 
limited, its elimination in man follows first order kinetics, 
and this has been demonstrated following both oral and 
intravenous administration of SUA (Levy et al, 1969).
The possible salicylate moieties appearing as various metabolites
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and unchanged drug in the urine, following oral administration 
Of SSA are given in Fig. 3.6 with the metabolic pathways that 
have been shown to be capacity-limited. SSA has been detected
in the urine following oral doses of 4-12 g (Hanzlik and Presho, 
1925) and in a private communication B. K. Martin has reported 
the presence of SSA conjugates with glycine in the urine. In a 
crossover design pharmacokinetic study in elderly patients, that 
compared the absorption and elimination profiles for oral doses 
of SSA, aspirin and sodium salicylate, Nordqvist et al (1965) 
reported SSA elimination to have a longer half-life than that 
for aspirin and quoted approximate values of 7.8 and 4.7 hours 
for SSA and aspirin respectively.
The increased incidence of reports of drug disposition showing 
capacity-limited kinetics has produced a number of mathematical 
and graphical methods for obtaining estimates of the various 
pharmacokinetic parameters involved. All of the methods reported 
have relied on the assumption that in the absence of zero order 
kinetic processes, the drug concentration-time profile can be 
described by first order kinetics according to a one-compartment 
open model (Wagner, 1973a; Martis and Levy, 1973; van Ginneken 
et al, 1974). Wagner (1975) has indicated that analysis of the 
two-compartment open model with capacity-limited elimination 
kinetics is complicated by the difficulties of obtaining initial 
estimates of the parameters and the expense (in terms of computer 
time). In all reported methods for the one-compartment model 
initial estimates of the kinetic parameters are obtained by 
graphical interpolation and provides the basis for subsequent 




























































made in any such analysis are that the values for K̂ j and V^ax 
are invariant and that only one capacity-limited process is 
involved.
The pharmacokinetic description of drug absorption, disposition 
and elimination has, until now, been associated with the 
measurement of drug in the blood or plasma. Certain experimental 
or ethical considerations may preclude the regular or repetitive 
withdrawal of blood by venupuncture and, under such circumstances, 
other body fluids have been used to supply pharmacokinetic 
information. Next to blood the urine is the most commonly 
sampled body fluid and urinary excretion data may be used to 
monitor the elimination and absorption of a drug and/or its 
metabolites. The provision of information from urinary 
excretion of unchanged drug and/or metabolites can be used to 
discriminate between rates of absorption although, it has been 
shown to be less definitive than corresponding plasma level data 
(Levy and Yacobi, 1975). The interpretation of urinary 
excretion data has been the subject of a paper by Martin (1967) 
who compared the advantages and disadvantages of the two 
standard methods of analysis, the 'rate method', and the 'Sigma- 
minus method'.
The 'rate method' necessitates obtaining urine samples at 
frequent, equally-spaced time intervals and when the log. of the 
excretion rate for a given time interval is plotted against the 
mid-point of that time interval the slope should be negative and 
linear. Linearity of the slope is indicative of an unchanging 
excretion rate and is therefore particularly applicable to studies
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where there is any progressive change in urinary excretion due 
to alterations in urine pH, volume, enterohepatic cycling or 
capacity-limited metabolism etc. The validity of this method 
does not depend on a knowledge of the total amount of drug 
excreted and, the loss of one urine sangle does not invalidate 
the analysis.
The 'Sigma-minus method' consists of plotting the logarithm of 
the amount unexcreted ^ log (Ue»o - vs time, where (U^o -U^)
is the sum (sigma) of the amounts of drug excreted until such 
time as excretion may be considered complete (U oo ), minus the 
cumulative amount of drug excreted to a time t (U^). When 
elimination is first order this is expressed as:-
log (Uoo -U^) = log Uo« - kt (45)
2.303
and a plot of log {\Joo - U^) vŝ  time will be linear with a
negative slope of - k , where k is the overall elimination
2.303
rate constant. Following oral administration there will be an 
initial time period over which such a plot will deviate from 
linearity due to absorption and can be used therefore to obtain 
information regarding the rate of drug absorption. The 
accuracy of the 'Sigma-minus' method depends entirely on the 
collection of urine until such time that excretion is complete 
and requires accurate determination of Ucx? . Slight errors in 
estimating U go will produce plots of log (U oo - U^) vs t that 
appear to be linear for an initial period and then exhibit 
curvature in the terminal segments. If curvature (either +ve 
or -ve) occurs it is difficult to establish the origin of the
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deviation and to ascertain whether it is a feature of the
drug's elimination of an artifact resulting from incomplete 
urine collection.
The various models proposed for drug disposition shown in Figs.
3.2 and 3.4 describe the distribution of non-protein bound 
material between the constituent compartments and subsequent 
urinary excretion and metabolism. Inference of drug concentra­
tion in the body has been achieved by studying the appearance of 
unchanged drug and/or metabolites in the urine by the methods 
of analysis outlined above. However, the measurement of drug 
concentrations in the saliva is currently receiving increased 
attention as a tool for reflecting free drug concentrations in 
the systemic circulation and may therefore, be of use in bio­
availability studies, monitoring of therapeutic drug concentra­
tions and diagnosis of drug overdose, etc.
Significant correlations between plasma and saliva concentrations 
have been established for digoxin (Joubert et al, 1976) , anti- 
pyrine (Brooks et al, 1976), salicylic acid (Graham and Rowland, 
1972), paracetamol (Glynn and Bastain, 1973), theophylline 
(Koysooko et al, 1974), lithium (Groth et al, 1974), tolbutamide 
(Matin et al, 1974) and phenytoin (Bochner et al, 1974). The 
clinical applicability of using salivary drug levels has been 
suggested by most of the above authors and utilised ^or para- 
aminosalicylic acid (Krakowka et al, 1966) theophylline (Levy 
et al, 1974; Eney and Goldstein, 1975) and isoniazid (Boxenbaum 
et al, 1975).
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The use of saliva drug concentrations in absorption studies 
could therefore provide a non-invasive method for following the 
time course of drug absorption and disposition that does not 
require medical supervision and allows the subjects to provide 
samples away from the laboratory. It is essential however, that 
a correlation between saliva and plasma concentrations of the 
drug should be established before the saliva can be routinely 
used as an inferential measure of blood concentration. This 
usually requires the measurement of free drug in the plasma 
since it is only that fraction of the total plasma concentration 
that is able to diffuse across the epithelia of the salivary 
glands. It has been shown that the diffusion of salicylate 
across the parotid epithelium of the dog was influenced by saliva 
pH but independent of saliva flow (Borzelleca and Putney, 1970) 
this study further related the change in saliva pH with plasma 
pH fluctuations associated with the intravenous infusion of 
hydrochloric acid and sodium bicarbonate. The contrasting 
experimental conditions .employed by Borzelleca and Putney (1970) • 
and Graham and Rowland (1972) have been tentatively suggested by 
the latter authors to account for the changing saliva/plasma 
salicylate ratio with time in the anaesthetised dog on the one 
hand, and the constant ratio observed in man on the other. 
Furthermore, since the saliva/plasma ratio is a function of the 
free drug concentration in the plasma it can be anticipated that 
an increase in the amount of free drug, resulting from higher 
blood levels and saturated binding, will be reflected by a 
corresponding decrease in the saliva/plasma ratio.
The evaluation of drug absorption using saliva can be further
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complicated by contamination of the saliva with foodstuffs that 
are known to interfere with the drug assay^ It should also be 
emphasised that several types of oral dosage forms, particularly 
solutions, suspensions, emulsions and uncoated tablets could 
lead to contamination of saliva resulting in erroneously high 
measured concentrations especially in the early samples of any 
study (Chiou et al, 1976; Joubert et al, 1976).
For estimation of drug bioavailability the extent of oral 
absorption is compared to that for an equivalent dose given by 
intravenous bolus injection, or if this is not feasible, to a 
standard reference oral dose which is usually a solution. The 
measured bioavailability for an orally-administered dose is an 
absolute term when compared to the corresponding intravenous 
dose, and a relative term when the reference is an oral solution, 
suspension, tablet or proprietary product. In the absence of 
urinary excretion data the extent of drug absorption by either 
route can be assessed from a knowledge of the area under the 
plasma level curve (AUC), which can be calculated by integration, 
to infinite time, of the equation that describes the drug 
concentration v£ time profile. If the relevant equation is not 
known then the area, or a parameter associated with it, can be 
calculated by three methods. The most commonly employed 
technique is that of dividing the plasma concentration vs time 
profile into a series of trapezoids and calculating the sum of 
the areas for each trapezoid; this is easily achieved by computer 
techniques and a program used for this purpose is given in 
Appendix . Less commonly employed methods are those of 
planimetry and the relationship between the weight of paper
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under the profile and the weight per unit area. The % bio­
availability for oral absorption can then be calculated from 
equation (46)
% Bioavailability = AUCn^
155% = ...
where AUCp^ and AUC^^ are the areas under the respective oral 
and intravenous plasma level profiles, for the same dose. This 
equation may be used as a means of determining the changes in 
bioavailability associated with variations in particle size and 
formulation etc following the oral administration of SSA to man 
and the rat. Similarly, if a correlation can be shown to exist 
between drug plasma and saliva concentrations then the corres­
ponding AUC values for saliva studies can be used, according to 
equation (47):-
% Bioavailability = AUC
X  100   (47)
AUC" sal-
where AUC' and AUC'' are the areas under saliva drug SAL SAL
concentration ys time profiles for an experimental and 
reference formulation respectively.
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3.2 HUMAN VOLUNTEER STUDIES
Physical and chemical studies on SSA have demonstrated that the 
drug is poorly soluble and exhibits dissolution behaviour that 
can be shown to be influenced by particle size. Also, formu- 
latory manoeuvres, designed to enhance solubility and dissolution, 
have been carried out by the coprecipitation of SSA with poly­
vinylpyrrolidone (PVP), cholic acid (CA) and deoxycholic acid 
(DOGA) and examination of the crystal morphology of these 
coprecipitates has suggested that the observed alteration of the 
crystalline nature of the SSAiPVP coprecipitates might be 
reflected in the gastrointestinal absorption of the drug following 
its oral administration. Similarly the SSArCA and SSA;DOCA 
coprecipitates may show in vivo behaviour exceeding that of the 
drug alone or drug:bile acid physical mixtures. This is 
especially true for the SSArCA 1:1 molar ratio coprecipitates.
To examine the above possibilities it was decided to monitor the
absorption of SSA from the gastrointestinal tract and to..........
investigate the possible influences of experimental formulations
on the bioavailability of the drug, in man, by measuring the
\
appearance of salicylate in the saliva and urine. The first 
objective was, therefore, to establish that urinary excretion 
and saliva concentration data could provide an adequately 
discriminative and sensitive means of quantifying SSA absorption 
in man.
3.2.1 EXPERIMENTAL PROTOCOL
Human volunteers taking part in these studies were male, aged 
between 25 and 38 years (mean 27.5) with body weights ranging
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from 64-^3 kg (mean 82) . All^subjects were instructed not to
consume alcohol for 48 hours before SSA administration and 
throughout the entire experimental period. Subjects receiving 
any drug therapy involving the use of salicylates, or any subject 
who manifested any untoward effect on taking salicylates were 
omitted from these studies. In an attempt to provide between- 
subject standardisation of the gastrointestinal environment 
volunteers were instructed not to consume food after the normal 
evening meal on the day preceding any study. On completion of 
each experiment subjects reverted to their normal dietary habits.
COLLECTION OF URINE. To promote an adequate flow of urine, water as 
customary beverages, was allowed ad libitum except that, on the 
day of each study, breakfast was to be no more than one cup of 
coffee or tea, and no further liquid was imbibed until four 
hours after dosing, excluding the volume of water required to 
facilitate swallowing of the dosage form (controlled at 200 ml) .
Urine was collected 30 minutes before drug administration, and 
at timed intervals thereafter, by direct micturition into a 
clean 250 ml measuring cylinder, 50 ml aliquots of the total 
measured volume collected at each time interval were retained 
for assay. Subjects were encouraged to void the bladder as 
completely as possible and to replace lost liquid by drinking an 
equal volume of water. All urine voided was collected for a 
total of 48 hours post-administration to ensure completion of 
salicylate excretion.
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COLLECTION OF SALIVA. On the days of study subjects were 
asked not to use fluoride toothpastes which could be expected to 
ihterfere with the fluorimetric assay techniques. Prior to 
saliva collection the mouth was thoroughly rinsed with at least 
three changes of distilled water and emptied by swallowing.
Mixed saliva was collected by free drainage from the lower lip 
into a clean McCartney bottle. Saliva flow was stimulated by 
applying varying degrees of pressure (not chewing) to a piece of 
Teflon (PTFE) held firmly between the premolar teeth. The 
saliva collected in this way was clear of cellular debris and 
entrapped air. In the studies designed to examine the 
correlation between plasma and saliva salicylate concentrations 
blood samples were removed at the midpoint of the saliva 
collection period, which was approximately 4-6 minutes. In all 
cases the volume of saliva produced was sufficient to allow 
removal of a 4 ml sample by pipette, this being stored at -15°C 
until assayed. In all studies the time at the midpoint of the 
collection period was used in analysis of the data. After taking 
any food or drink, collection of the next saliva sample was 
preceded by thorough rinsing of the buccal cavity with at least 
three changes of distilled water. Various drink substances 
expected to interfere with the salicylate fluorescence assay, eg 
tonic water, bitter lemon or other synthetic soft drinks and 
cordials, were avoided.
COLLECTION OF PLASMA. 2 ml samples of whole blood were removed 
by means of a syringe, via an indwelling cannula placed in the 
antecubital vein, and transferred to a heparinised centrifuge 
tube. The cannula was flushed with citrate anticoagulant after
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the removal of each sample in order to prevent blockage. Plasma 
was obtained from the blood sample by centrifugation immediately 
after its collection and 0.5 ml aliquots were placed in screw- 
capped tubes to be stored at -15°C prior to assay. Pooled plasma 
used in the preparation of salicylic acid standards was obtained 
by centrifugation of heparinised blood taken by venupuncture from 
the antecubital vein of normal healthy volunteers.
3.2.2 ASSAY METHODS
MATERIALS. Commonly available organic solvents, reagents, buffer
salts, etc, were used as supplied. Sorensen's phosphate buffer
was prepared at pH 7.0 according to Documenta Geigy (1962).
Hard gelatin capsules, size O, were obtained from Parke-Davis
3 -1and Co. , Pontypool and heparin (5 x 10 units ml ) from the 
Boots Co, Nottingham.
FERRIC REAGENT consisted of 1.5 g ferric nitrate, Fe(NO3 )3 .9 H2O, 
dissolved in 31 ml of a 1 in 100 dilution of concentrated nitric 
acid and made up to 100 ml with distilled water. This stock 
reagent was kept in an amber glass bottle and diluted 1 in 2 0  
prior to use.
GLASSWARE used in the fluorescence assays was cleaned by total 
immersion in a hot solution of Rapidex (Tool Importers Ltd,
London), then three tap water rinses and overnight immersion in 
a dilute nitric acid solution, followed by three distilled water 
rinses and drying in a hot air oven.
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INSTRUMENTATION. Visible spectrophotometric analysis of the 
salicylate-ferric ion purple chromophore was carried out using 
the Unicam SP1800 spectrophotometer and appropriate matched 
glass cuvettes.
Spectrophotofluorimetric analysis of the salicylate fluophore 
was achieved using the Aminco Bowman Spectrophotofluorimeter 
and the appropriate quartz cuvette.
AUTOCLAVING was carried out in a stainless steel autoclave 
(Taylor Rustless Fitting Co Ltd, Leeds).
3.2.2.1 Assay of Salicylate in Urine
Previous studies on the urinary excretion of salicylate after 
oral administration of SSA have shown that approximately 10% of 
the drug appears unchanged in the urine (Rubin, 1964; Hanzlik 
and Presho, 1925; MacDonald, 1973). Stability studies (See 2.9) 
and unpublished studies (MacDonald, 1973) have shown SSA to be 
readily hydrolysed under strongly alkaline conditions. This 
latter work demonstrated complete SSA breakdown to salicylic 
acid after autoclaving urine samples containing SSA with O.IN 
sodium hydroxide for three hours, whereas the similar use of 12N 
sulphuric acid only produced an average of 15% hydrolysis in the 
same time period.
The method employed in this work relied on the production of a 
purple chromophore, between ferric ions and salicylic acid, and 
its subsequent measurement of visible spectrophotometry. Details 
of the analytical procedure are given as a flow diagram in
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Fig. 3.2.1. Duplicate salicylic acid standard solutions (5-250 
jwg.ml S  prepared in pooled urine were analysed by the described 
method and the slopes of the lines (Fig. 3.2.2) were shown by a 
student ' t' test not to be significantly different. The data 
were therefore subsequently pooled, submitted to linear least- 
squares regression analysis and the resultant equation was used 
to calculate the salicylate concentration of the experimental 
samples. The duplicate and pooled slopes are given in 
Table 3.2.1 with their appropriate standard errors.
Slope - SE Intercept - SE Student
(x 10-3) (x 10-3 ^ 't' test
A 5.344 - 0.015 5.278 - 1.865 0.999 t^^^ = 0.376
4- _  + ...............  ^tab = 2.306B 5.337 - 0.011 0.844 - 1.311 0.999
Pooled 5.405 - 0.086 0.993 - 1.059 0.999
n = 10
d' = 0.05
Table 3.2.1 Student 't' Test Comparison Between Duplicate Standard 
Salicylic Acid Curves in Urine.
The total salicylate excreted for each study was calculated as 
the cumulative amount excreted, expressed as equivalents of SSA 
for each of the urine samples taken, and used to evaluate the 
% of the administered dose excreted.
3.2.2.2 Assay of Salicylate in Saliva
The method used was based on the production of a salicylate 
fluophore in phosphate buffer at pH 7.0 after ethereal extraction 
from acidified saliva and was an adaptation of that reported by 









+ 5 ml 5N NaOH
10.0 ml Urine Sample
10.0 ml Chloroform extract 
+ 10.0 ml Ferric reagent
Decant aqueous layer and read 
absorbance at 530 nm against 
a suitably prepared blank.
Remove aqueous layer by 
suction and discard.
Filter chloroform layer 
through Whatman No 1 
filter paper.
Autoclave at 15 lb in 
3 hours.
+ 20.0 ml Chloroform
+ 5.0 ml Cone. HCl
Cool
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are given as a flow diagram in Fig. 3.2.3. Plots of relative
fluorescence vs concentration are shown in Fig. 3.2.4 for
-1duplicate salicylic acid standards (0.05 - 3juig.ml ) prepared in 
pooled saliva and assayed according to the method described.
One of the standards was used to determine the activation and 
emission wavelength maxima used in subsequent analyses. These 
wavelength maxima were verified for each series of experimenta^l 
samples particularly where formulatory adjuvants had been 
administered. Comparison of the two standard curves by a Student 
't' test (Table 3.2.2) shows them not to be significantly 
different. The data were subsequently pooled and submitted to 
linear least-squares regression analysis, the equation from which 
was employed to calculate the salicylate content of the 
experimental samples.
Slope - SE Intercept - SE r 't' test
A 488.2 - 7.9 - 3.0 - 11.7 0.999 t^^^ = 0.319
+ + ^tab " 2.101
B . . .491.4 .6.4 . -.4.6. -- 9.4 - 0.999 - - - ' ^ ^ 2 2
Pooled 489.8 - 4.9 - 3.8 - 7.1 0.999
p' = 0.05
Table 3.2.2 Student 't' Test Comparison Between Duplicate Salicylic 
Acid Standard Curves in Saliva
3.2.2.3 Assay Of Salicylate In Human Plasma
The method employed was essentially the same as that for saliva
except that in Stage 1 (Fig. 3.2.3) 0.5 ml volumes of plasma
were acidified with equal volumes of 4N HCl prior to ether
- 1extraction. Salicylic acid standards (l-50^g.ml ) prepared in
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4.0 ml Saliva
Stage 1 + 0.5 ml ION HCl










Activation Wavelength 305 nm 
Emission Wavelength 410 nm
4.0 ml Ether extract 
+ 5.0 ml Ŝ zftensen's Phosphate 
Buffer pH 7.0
Remove ether by suction and
aeration and discard.
- 2Autoclave 15 lb.in 60 minutes
Cool












- 1 .Saliva Salicylate (jLvg.ml )
Fig. 3.2.4 Calibration Curve Of Fluorescence For Standard Solution 
Of Salicylic Acid In Human Saliva.
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duplicate gave identical fluorescence wavelength maxima to those 
obtained for saliva standards and plots of relative fluorescence 
vs concentration (Fig. 3.2.5) were found, by a Student 't' test, 
not to be significantly different (Table 3.2.3). The data was 
therefore pooled and submitted to linear least-squares regression 
analysis to give the equation of the line used in subsequent 
calculation of the salicylate content of experimental samples.
This equation accounted for the positive intercept of the standard 
curves, a value that was attributed to fluorescence derived from 
an unknown constituent of the plasma.
Slope - SE Intercept - SE r 't' test
A 64.14 - 1.03 53.35 - 28.87 0.999 ^obs = 0.765
B 63.24 - 0.58 58.79 - 16.14 0.999 N = 14
Pooled 63.69 - 0.57 56.67 - 15.92 0.999
p' = 0.05
Table 3.2.3 . Student '.t'. Test Comparison Between Duplicate Salicylic . -
Acid Standard Curves in Human Plasma.
Before proceeding with studies on SSA assurance of the validity 
of the experimental protocol was gained by investigating the 
saliva salicylate profile following oral administration of aspirin 
in solution (Solprin, Reckitt and Colman, Hull). Subjects 
received doses of either 300, 600 or 900 mg aspirin in solution 
in 2 0 0 ml of water, saliva samples were collected for a period 
of 28 hours and assayed for salicylate according to the method 
described. The resultant concentration-time profiles are given 
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Fig. 3.2.5 Calibration Curve Of Fluorescence For Duplicate Standard 
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Fig. 3.2.6 Saliva Salicylate (log scale) vs Time Profiles For Aspirin 
Following Oral Administration In Solution At Three Dosage 
Levels.
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indicated by the absence of an initial absorptive phase. One 
subject (CS) exhibited considerable scatter of salivary salicylate 
concentrations and the data could not be used in the calculation 
of an elimination rate constant from the terminal log-linear 
phase of the profile. For two other subjects (LS and TK) 
secondary and tertiary saliva peaks occurred at approximately 
four and nine hours after dosing which could be associated with 
the intake of food. Possible explanations for these mid-profile 
peaks will be discussed later. Subjective discrimination of the 
terminal data points and their subsequent linear least-squares 
regression analysis shows that the overall salicylate apparent 
first order elimination rate constants for each subject are 
comparable (Table 3.2.4). The data points used for these 
calculations were those visually distributed about a straight 
line that could be drawn through the terminal elimination phase 
of the profile. Further examination of the entire profile in 
this manner revealed a deviation from linearity for the 0 - 6  
hour samples, at .doses of. 600 . and .900 mg...........................
Dose (mg) 300 600 900
Subject NR NS TK JP LS
kgj(hr”S  0.3490 0.2585 0.2662
+ SE 0.0112 0.0230 0.0370
0.2536 0.1848
0.0217 0.0054
0.993 0.977 0.972 0.975 0.995
t^(mins) 119.2 160.8 156.2 164.0 225.0
Table 3.2.4 Apparent First Order Elimination Rate Constants and Half 
Life of Salicylate In Man After Oral Administration Of 
Aspirin In Solution.
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The elimination half-lives determined are of the same order as 
those reported by Graham and Rowland (1972) . The initial high 
salicylate concentrations are probably due to buccal contamina­
tion resulting from drug residing in the mouth following dosing 
with a solution, and would not, of course, be present had aspirin 
been given in capsules. However, the aim of the initial e:jq>eri- 
ment was fulfilled and the assay in saliva and the general 
experimental protocol provide a valid method for monitoring 
salicylate absorption and elimination following oral administra­
tion of aspirin. The areas under the saliva salicylate time 
profiles were calculated for each subject by use of the trapezoidal 








Table 3.2.5 Values For Area Under Saliva Level Curve Following Oral 
Administration Of Aspirin In Solution
The values from Table 3.2.5 are also plotted in Fig. 3.2.7 and
show a linear relationship between AUC and dose. The AUC value 
-1of 762.9yug.ml x min calculated for subject TK, who received 600 
mg aspirin, compares favourably with the values obtained for an 
oral dose of 650 mg aspirin obtained by Graham and Rowland (1972)
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Fig. 3.2.7 Relationship Between The Area Under The Saliva Level Curve 
(AUC) And Dose Following The, Oral Administration Of Aspirin 
In Solution.
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The proportionally higher figure quoted for TK is probably the 
result of a combination of both initial buccal contamination and 
greater aspirin bioavailability from solution, although no firm 
conclusions can be drawn. Similarly, the negative intercept of 
the AUC vs dose plot may be due to exaggerated AUC values 
resulting from buccal contamination the degree of which would be 
significantly influenced by the dose of aspirin given.
Preliminary urinary excretion studies were then performed to
establish the ability of urinary excretion data to differentiate
between the in vivo behaviour of SSA when given orally, as a
solution or as encapsulated material. The poor solubility of
o — 1SSA in O.lN HCl at 37 (80^ g.ml ) indicated that, if given in
solution as the soluble salt then, depending on the dose, 
precipitation may occur in the acidic environment of the stomach 
and any incurred unorthodox absorption may therefore be reflected 
by the urinary excretion of total salicylate.
3.2.3 URINARY EXCRETION OF SALICYLATE AFTER ORAL ADMINISTRATION OF SSA 
IN SOLUTION AND CAPSULES
Using a crossover design, with a week between studies, six 
subjects received 60 mg SSA either as a solution or as 150-180^ m  
particle size material in a single hard gelatin capsule. The 
solution was prepared as for the recrystallisation studies (See 
2.10) and both doses were taken with 200 ml of water. Urine 
samples, collected at zero time, and at appropriate time intervals 
for 48 hours, were assayed for total salicylate as described. 
Urinary salicylate excretion is represented in Fig. 3.2.8 as 









Fig. 3.2.8 Sigma-minus Plots Obtained Following Oral Administration Of 
SSA In Solution (closed symbols) And In Capsules, 150-180^m 
(open symbols). Dose 60 mg.
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minus' method described earlier (See 3.1 equation (45)). These 
plots show that the excretion for the two dosage forms follow 
different profiles and that the elimination for the solution 
exhibits less inter-subject variation than that for the capsule. 
This may be explained by possible variations in SSA absorption 
associated with erratic and prolonged dissolution of the poorly 
soluble particulate material under in Vivo conditions. It is 
also evident that if in vivo precipitation had occurred to any 
significant extent then the log % unexcreted vs time profiles 
for the solution would have shown a greater degree of inter­
subject variation than that observed. However, the lack of 
significant difference between the % dose excreted for either
formulation (t , = 0.825; t. _ = 2.228; N = 12, p' = 005) isobs tab
indicative of precipitation occurring since complete absorption 
from solution would have been anticipated. The apparent first 
order elimination rate constants and respective half-lives, 
calculated by regression analysis of the log-linear terminal 
section of the profiles are given in Table 3.2.6. It is evident 
from the values given that their variability is greater, 
following oral administration of encapsulated material, than that 
for solution. These observations will be further discussed with 
respect to the recrystallisation studies previously reported 
(See 2.10).
The ability of urinary excretion data to discriminate between 
the absorption of the above formulations is somewhat limited and 
it was considered unable to provide an adequate means of 
differentiating between particle size and the influences of 
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performed to establish the ability of salivary salicylate levels 
to provide a non-invasive method for the assessment of the
disposition of salicylate following oral administration of SSA.
3.2.4 CORRELATION OF SALIVA WITH PLASMA SALICYLATE CONCENTRATION
FOLLOWING ORAL ADMINISTRATION OF SSA IN AN AQUEOUS SUSPENSION.
Six volunteers received either 300, 600, 900 mg of 'micronised* 
SSA as an aqueous suspension in 100 ml distilled water; a further 
100 ml, used to rinse the mouth, was also swallowed. Plasma and 
saliva samples were taken at zero time and at time intervals 
until seven hours after dosing. Each plasma sample was obtained 
by centrifugation of heparinised blood removed at the mid-point 
of the saliva collection period. The resultant plasma and 
saliva salicylate concentration ys time profiles are shown in 
Figs. 3.2.9 and 3.2.10 respectively for each of the three dosage 
levels. From these profiles the approximate pesik salicylate 
times and concentrations were obtained and are given in Table 
3.2.7.
Plasma Peak Saliva Peak
Dose Subject time Concentration time Concentration
(mg) (hr) (^ g.ml"l) (hr) ( /Ag.ml-1)
300 BM 2 . 0 14.0 2.0-4.0 0.48
SM 2 . 0 1 2 . 0 ND* ND
600 CS 1 .0 -2 . 0 23.0-27.0 4.0 0.95
NR 2 . 0 36.0 2.0-4.0 1.13-1.50
900 JP 3.0 55.0 4.0 3.7
LS 1.5-3.0 50.0-55.0 1.5-3.0 2 .4-2.8
* ND Not Determinable
Table 3.2.7 Approximate Peak Plasma and Saliva Times and Concentrations 
of Salicylate Following Oral Administration of SSA In Aqueous Suspension
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Fig. 3.2.9 Plasma Salicylate (log scale) vs Time Profiles For SSA 

















Fig. 3.2.10 Saliva Salicylate (log scale) vŝ  Time Profiles For SSA 
Following Oral Administration In Suspension At Three 
Dosage Levels.
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The correlation of saliva with plasma salicylate concentration 
is shown in Fig. 3.2.11 as a plot of saliva vs plasma concentra­
tion for all samples taken after two hours post administration. 
Earlier samples are not included due to the high degree of con­
tamination of the saliva with residual drug in the buccal cavity. 
The amount of extraneous SSA in the mouth was sufficient in all 
cases to mask the majority of the absorptive phase of the saliva. 
Fig. 3.2.11 clearly shows that the saliva-plasma correlation 
changes with time and only stabilised after six hours when both 
plasma and saliva profiles entered the elimination phase. The 
mean ratio of salicylate concentration in the saliva to that in 
the plasma is given for each subject in Table 3.2.8. The values 
used in calculation of the mean exclude those exhibiting obvious 
salicylate contamination of the pre-two hour saliva samples.
The coefficients of variation associated with these saliva/plasma 
values vary from 16-37% even though the mean ratios for the 
individual subjects are of the same order of magnitude, ranging 
from 0.051-0.067.
Dose Mean Saliva standard Coefficient
SSA Subject Plasma _ . of Variation
(mg) Ratio Devxation
300 BM 0.0620 0.0103 16.61
SM 0.0516 0.0177 34.30
600 CS 0.0586 0.0148 25.30
NR 0.0510 0.0188 36.86
900 JP 0.0604 0.0161 26.66
LS 0.0667 0.0182 27.28
Table 3.2.8 Saliva/Plasma Salicylate Concentration Ratios Following 















Change in the saliva/plasma salicylate ratio with time is also 
shown in Fig. 3.2.12. Some of the early (pre-two hour) samples 
are included to illustrate the erroneously high ratio associated 
with buccal contamination.
The most significant observations of this study are the saliva 
contamination resulting from oral administration of suspended 
material and the change in the plasma-saliva salicylate ratio 
with time. In an attempt to overcome the first of these disad­
vantages a second study was performed where SSA was given by 
mouth in hard gelatin capsules. From such a study it was 
anticipated that a complete saliva-plasma correlation could be 
achieved which may aid in the elucidation of the causative factors 
of the time-related change in that ratio.
3.2.5 CORRELATION OF SALIVA WITH PLASMA SALICYLATE CONCENTRATION
FOLLOWING ORAL ADMINISTRATION OF SSA IN HARD GELATIN CAPSULES 
The experimental protocol was identical to that of the previous 
study except that two subjects received 600 mg micronised SSA in 
two hard gelatin capsules with 200 ml of water. To aid character­
isation of the respective peaks saliva and plasma samples were 
obtained at half-hourly intervals. The plasma and saliva 
salicylate profiles shown in Fig. 3.2.13 follow the same time 
course but the early saliva samples do not exhibit the contamination 
observed in the previous study. The peak plasma salicylate 
concentrations occurred at 1.5 and 3.0 hours for NS and LS 
respectively whereas both the corresponding peak saliva salicylate 
concentrations were approximately three hours post-administration. 
The delay in the occurrence of the saliva peak with respect to
191
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Fig. 3.12.13 Saliva (closed symbols) And Plasma (open symbols)
Salicylate (log scale) vs Time Profiles Following Oral 
Administration In Hard Gelatin Capsules. Dose 600 mg.
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that for plasma would explain the changes in the salicylate
saliva-plasma ratio with time depicted in Fig. 3.2.14. This
loto
change in ratio is also represented by the^correlation 
coefficients for the plot of salicylate concentration in the 
saliva vs that in the plasma shown in Fig. 3.2.15. The data 
for the two subjects and the pooled data was submitted to linear 
least-squares regression analysis and the resultant correlation 
coefficients are given in Table 3.2.9.
Individual





0.0423 - 0.009 0.809
0.0501 - 0.009 0.833
0.0423 - 0.005 0.834
Table 3.2.9 Correlation Between Saliva and Plasma Salicylate
Concentration Following Oral Administration of SSA in 
Capsules.
Apparent first order elimination rate constants were obtained 
from least-squares regression analysis of the appropriate log- 
linear sections of each of the plasma and saliva profiles and 
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NS SALIVA 0.2278 - 0.022 0.969
PLASMA 0.1399 - 0.004 0.996
LS SALIVA 0.2474 - 0.017 0.982
PLASMA 0.1201 - 0.025 0.828





tab 2.132 t^ ^ = 2.080tab . . . .
Table 3.2.10 Comparison of Overall Elimination Rate Constants
Obtained From Salivary and Plasma Concentration Time 
Profiles Following Oral Administration of SSA in Capsules,
For both subjects the apparent first order elimination rate
constants calculated from either plasma or saliva data are
comparable since the Student 't ' test shows them not to be
significantly different. However, comparison of the elimination
rate constants calculated from plasma and saliva data for each
subject show, in both cases, that there is a significant
different between the two. For NS, t = 3.931; N = 21;obs
p^ = 0.05; t^ . = 2.132: For LS, t , = 4.211; N = 23;tab obs
p' = 0.05; t ^ ^  =2.093 . It can therefore be concluded that
although saliva and plasma salicylate profiles can be used in 
their own right, to describe the time course of SSA absorption 
and salicylate elimination, it has been demonstrated that there 
is no direct relationship between the two in the subjects used. 
Saliva levels cannot therefore be used to describe the sequence 
of pharmacokinetic events occurring in the plasma.
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Since drug elimination can be studied by the rate and extent of 
the appearance of unchanged drug and/or drug metabolites in the 
urine it was of interest to establish any degree of similarlity 
between elimination rate constants calculated from urinary 
excretion data with those derived from saliva data.
3.2.6 SALIVA CONCENTRATION VS TIME PROFILE AND URINARY EXCRETION OF
SALICYLATE FOLLOWING ORAL ADMINISTRATION OF SSA IN HARD GELATIN 
CAPSULES
Five subjects received 600 mg micronised SSA in two hard gelatin
capsules with 200 ml water. Saliva and urine samples were taken
at zero time and at appropriate times thereafter, the resultant
saliva salicylate concentration vs time profiles and 'Sigma-
minus' plots are shown, for each subject, in Figs. 3.2.16 and
3.2.17 respectively. The corresponding apparent first order
elimination rate constants are given in Table 3.2.11. Comparison
of these rate constants by a Bartlett Test (See Appendix % )
shows them to come from the same distribution ( , =1.671;obs
p^ = 0.05; N = 70; . = 90.53) and not to be significantlytab
different.
Comparison between the apparent first order urinary elimination 
rate constants for this study with those where the SSA dose was 
60 mg shows them to be significantly different ^obs ~ 2.682;
N = 9; p =0.05; t ^ ^  = 2.365 . A possible explanation for
this is derived by examination of the accompanying salicylate 
saliva vs time profiles obtained at the higher 600 mg dose 
(Fig. 3.2.17). From these profiles a second absorptive phase is 
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Fig. 3.2.16 Saliva Salicylate (log scale) vs Time Profiles For SSA 
Following Oral Administration In Hard Gelatin Capsules. 
Dose 600 mg.
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Fig. 3.2.17 Sigma-minus Plots Obtained From Five Subjects Following 
Oral Administration Of SSA (micronised) In Hard Gelatin 
Capsules. Dose 600 mg.
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Subject
NR NS LS JP TK
kgj - SE (hr"S 0.1916 0.1831 0.1940 0.1951 0.2523
+0 . 0 1 0 -0 . 0 1 1 io.oo4 ^0.013 -0.005
r 0.992 0.984 0.998 0.991 0.998
g Half-life(mins) 217.0 227.1 214.3 213.1 164.8
% Dose 
Excreted 23.7 23.3 30.8 34.7 47.3
kgi-SE (hr'S 0.2308 0.1281 0.2151 0.2040 0.1752
^0.050 -0 . 0 1 2 -0.007 ^0.017 -0.023
g r 0.937 0.979 0.996 0.980 0.968
Half-life
(mins) 180.2 324.6 193.3 203.8 237.6
Table 3.2.11 Apparent First Order Elimination Rate Constants (kgj), 
Associated Half Lives and % Dose Excreted Determined 
From Urinary Excretion and Saliva Concentration Data 
Following Oral Administration of SSA in Capsules.
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tion over the sleeping hours (16-24 hours post-administration). 
Closer examination of the corresj^nding sections of the 'Sigma- 
minus' plots reveals a decrease in the apparent first order 
elimination rate constant 12-16 hours after dosing. The 
suggestion therefore, is that the discrepancy between the 
values for the two studies could be due to a much prolonged 
absorption or a secondary (somnambulant) absorptive phase of 
salicylate from the larger dose.
A further explanation for the observed differences in the 
elimination rate constants is the concentration range over which 
they were calculated. In the former study (60 mg SSA) elimination 
rate constants were derived from linear terminal portions of the 
'Sigma-minus' plots over the 10-1 mg range for SSA unexcreted.
In the later study (600 mg SSA) the corresponding range of the 
'Sigma-minus' plots were from 100-10 mg SSA unexcreted. It has 
previously been suggested (Section 3.1), and shown for aspirin 
(Fig. 3.2.6 and accompanying discussion), that deviations from 
true first order elimination kinetics is a characteristic of 
salicylate disposition a function which is capacity-limited. In 
view of this it can be postulated that the slower elimination 
observed for the higher dose could be a manifestation of 
capacity-limited kinetics; a situation that could be exacerbated 
by the prolonged time-course of SSA absorption.
3.2.7 GENERAL CONCLUSIONS FROM HUMAN STUDIES
The similarity in the parameters of salicylate elimination 
derived from salivary and urinary excretion data, but not from 
plasma, indicates the possibility of differences between salicylate
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analysis in saliva and urine with that for plasma. Since 
only non-protein-bound salicylate is able to be transferred 
from the blood into the salivary gland the respective assays 
must therefore also measure non-bound material. The discrepancy 
between saliva cind plasma elimination data and possibly the time- 
related change in the salicylate concentration ratio between the 
two body fluids could be attributed to the likelihood that the 
salicylate measured in plasma was an over-estimation resulting 
from displacement of protein-bound material during the acidifica­
tion and ether extraction procedures. However, the elucidation 
of analytical problems and subsequent absorption studies in man 
were not pursued for a number of reasons. Complete character­
isation of the plasma and saliva salicylate profile designed to 
provide a comprehensive saliva/plasma correlation was not 
feasible owing to the extended length of time over which subjects 
would be required to give blood samples. Furthermore, most 
volunteers were available for only a limited number of studies; 
this was due to their reluctance to be subjected to the experi­
mental conditions for a series of routine and extended studies.
It was extremely unlikely that volunteers would collaborate in 
intravenous administration studies that would be essential for 
the elucidation of some basic pharmacokinetic parameters. It 
was therefore necessary to employ an alternative experimental 
animal model that could be routinely used for biopharmaceutical 
investigations. All future studies were therefore performed 
using the rat since various limitations precluded the use of any 
other species.
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3.3 BIOAVAILABILITY STUDIES IN THE RAT
The limitations associated with the long-term use of a group of 
human volunteers necessitated that an alternative in vivo model 
was found that would allow routine evaluation of physical, 
chemical and formulatory influences on the gastrointestinal 
absorption of SSA, Barr (1972) has reviewed the use of several 
in situ perfused and closed intestinal preparations that have been 
successfully employed to study drug absorption from the gut in 
the anaesthetised animal and has concluded that, the greatest 
potential for differentiating between formulatory changes in vivo 
was offered by measuring the appearcuice of drug in the blood, as 
opposed to following its loss from the intestinal lumen. While 
the in situ approach would have been useful for studies on drug 
absorption from solution, investigations where the drug is 
introduced in a suspended or solid dosage form can be complicated 
by sedimentation throughout the perfusing system or in stagnant' 
sections of the perfused intestinal segment. Further 
complications arising from such anaesthetised preparations can
be anticipated from changes in mesenteric blood flow due to the
I
depth and type of anaesthesia. In view of these considerations 
bioavailability studies on suspended SSA systems were performed 
in the conscious animal by monitoring plasma or urine salicylate 
concentrations following oral administration.
3.3.1 ANIMALS
White albino male rats of the Wistar CFY strain (Anglia Labora­
tory Animals, Huntingdon) were housed in groups of six and 
allowed free access to water and food (Oxoid diet 41B) between 
experiments.
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3.3.2 GENERAL EXPERIMENTAL PROTOCOL
To allow the collection of sufficient samples of blood over a 
time period adequate to describe salicylate absorption and 
elimination (16-24 hours) it was necessary to use rats of the 
450-550 g weight range. Each absorption study was performed on 
a group of six animals and, where possible (e.g. for coprecipitate/ 
admixture comparisons), a cross-over design was implemented. 
However, due to the large number of studies envisaged for any 
single objective it was not possible to employ a complete cross­
over since, throughout an extended period animal weight gain 
would be excessive. For each stu^, animals were fasted over 
night (approx. 16 hours) prior to dosing and the fast continued 
for a further four hours; water was allowed ad libitum.
3.3.3 DOSAGE
For all experiments dosing was on a mg (equivalent SSA) kg  ̂
body weight basis. The SSA:PVP, CA and DOCA coprecipitates and 
admixtures were dosed according to their SSA content (See 
Sections 2.13.1.1 and 2.13.1.2).
3.3.3.1 ORAL ADMINISTRATION was achieved by direct oesophageal intubation 
of the manually-restrained animal, using an adapted, blunt, 
stainless steel, serum needle fitted to the appropriate size 
syringe.
3.3.3.2 INTRAVENOUS ADMINISTRATION of drug solutions was carried out, 
under light ether anaesthesia, by bolus injection via the dorsal 
vein of the penis. Anatomical examination of the cardiovascular 
system of the rat (Greene, 1935) and the studies of Nightingale
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and Mouravieff (1973) show that injection by this route avoids 
the enterohepatic circulation and that administered drug enters 
the systemic cardiovascular system via the inferior vena cava. 
This method was found particularly suited to large rats since 
injection via the more commonly used tail route is difficult to 
perform in animals over 300 g. Intravenous injection via the 
penis was quick, efficient, reliable and produced negligible, 
overt discomfort to the animals upon recovery from anaesthesia.
3.3.4.COLLECTION OF RAT URINE
Following dosing, animals were singly housed in a round (10" 
diameter) cage, fitted with a mesh floor, placed over a 
1 2 " diameter polyethylene funnel equipped with a glass 
urino-faecal separator. Urine and faeces were therefore 
collected separately, the latter being discarded. Urine was 
allowed to drain into a 50 ml measuring cylinder and at 4, 24 
and 48 hours after dosing each funnel was thoroughly rinsed, 
the washings being retained and added to the collected urine.
An aliquot of the measured volume of urine (+ washings) was 
stored at -15° prior to assay for total salicylate.
3.3.5.COLLECTION OF RAT PLASMA
Plasma used in the preparation of salicylic acid standards was 
obtained by cardiac puncture from animals, under light ether 
anaesthesia. Blood, withdrawn into a heparinised syringe, was 
centrifuged at 3000 rev.min  ̂in glass centrifuge tubes for 15 
minutes and the plasma removed by pasteur pipette prior to 
storage at -15°.
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Throughout the absorption studies 0.6-0.7 ml samples of whole
blood were taken from the tip of the tail of each animal at
specified times. For this collection animals were placed in all-
metal restraining cages that allowed minimal movement of the
animal and free access to the tail. The tip of the tail
(approximately 2 mm) was removed with a scalpel blade and blood
collected into a 0.75 ml polyethylene micro-centrifuge tube
(Sarstedt, Leicester) containing approximately 10ÿ<l heparin 
-1(5000 units ml ). Blood flow through the tail was facilitated 
by maintaining the animals at a room temperature of 25-29° and, 
drainage of blood into the collecting vessel was aided by gentle 
stroking of the tail with the fingers in a base-to-tip direction. 
Plasma was obtained by centrifugation, 0.2 ml aliquots of which 
were removed by automatic pipette (Oxford Laboratories) and 
stored at -15° prior to assay.
This method of obtaining plasma sanples imposed little discomfort 
on the animals and allowed repeated sampling over a 24 hour 
period. To ensure complete salicylate excretion and adequate 
healing of the tail, etc, a one week period was allowed between 
any consecutive studies on the same animal.
Familiarity with the time required to obtain a plasma sample from 
each of six animals enabled dosing to be staggered such that the 
times of sampling, following either oral or intravenous adminis­
tration, were similar (- 3 minutes) for each of the animals 
within a single group.
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3.3.6 ASSAY OF SALICYLATE IN RAT URINE
The method employed was the same as that described previously
(See 3.2.2.1). Values of slope and intercept for duplicate
-1salicylic acid standard (4-200y+g.ml ) calibration plots
(Fig. 3.3.1) are given in Table 3.3.1 with their respective 
standard errors and correlation coefficients. Comparison of the 
duplicates by the Student 't' test shows them not to be signifi­
cantly different; therefore, the data was pooled and submitted 
to linear least-squares regression analysis to provide the 
equation used in all future determinations of the salicylate 
content of the experimental samples.
Slope - SE Intercept - SE .
(xlO-3) (xlO-3)
A 5.248 i 0.035 3.964 - 0.046 0.999 t = 0.294
n = 1 4
B 5.235 - 0.027 2.141 - 2.339 0.999 p' = 0.05
____________________  :_______  t ^ = 2.281' tab
Pooled 5.241 - 0.021 3.052 - 1.830 0.999
Table 3.3.1 Comparison of Duplicate Salicylic Acid Calibration 
Curves in Rat Urine.
1%From Table 3.3.1 the slope of the Beer-Lambert plot gave an E ^ ^
of 52.41 and a molar absorbance coefficient of 723.8 for salicylic 
acid. As for the human studies the total salicylate detected in 











ml, the dilution (if any) and the volume voided. Total 
salicylate excreted was expressed as SSA equivalents to calculate 
the percentage of the dose excreted for each collection period.
To demonstrate the efficiency of the degradation of SSA and
salicylate metabolites by autoclaving under alkaline conditions,
- 1SSA was intravenously administered at a 20 mg.kg dose to a group 
of six rats, the urine collected as a single batch for 48 hours 
and assayed as described. The mean % dose excreted was calcu­
lated to be 95.25 - 1.41. This percentage of the dose excreted 
following intravenous administration provides a bioavailability 
standard for future urinary excretion studies where the same 
dose of SSA is administered.
3.3.7 ASSAY OF SALICYLATE IN RAT PLASMA
/
The total salicylate content of plasma samples was assayed
according to the flow diagram in Fig. 3.3.2. Standard salicylic
- 1acid samples (1-125 yi g.ml ) were prepared in plasma in tripli­
cate and assayed by the above procedure. Plots of relative 
fluorescence vs concentration are shown in Fig. 3.3.3 and the 
three calibration curves were compared by a Student 't* test 
using the data given in Table 3.3.2. These triplicate curves 
were shown not to be significantly different (Table 3.3.3), there­
fore the data was pooled and submitted to linear least-squares 
regression to provide the.equation used to calculate the salicylate 
content of experimental samples.
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stage 1 0 . 2  ml plasma 
+ 0.2 ml N NaOH










Remove ether by suction and aeration 
and discard
4.0 ml Ether extract 
+ 5.0 ml Phosphate buffer pH 7.0
+ 0.5 ml 2N Perchloric acid 
+ 5.0 ml Diethyl ether
Read fluorescence of aqueous layer 
Activation wavelength 305 nm 
Emission wavelength 410 nm
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Fig. 3.3.3 Triplicate Standard Fluorescence Calibration Plots For 
Salicylic Acid In Rat Plasma.
-1 -1 Slope + SE (xlO ) Intercept + SE (xlO ) r
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A 1 . 1 2 0  + 0 . 0 1 2 0.978 + 0.610 0.999
B 1.106 + 0.126 4.935 + 6.389 0.963
C 1.082 + 0.050 0.956 + 0.275 0.999
Pooled 1.103 + 0.040 2.290 + 2.019 0.986
Table 3.3.2 Data for Triplicate and Pooled Salicylic Acid 
Standard Curves in Rat Plasma
Comparison ^calc \ a b  " P'
A vs B 0 . 1 1 1 2.179 16 0.05
A vs C 0.739 2.179 16 0.05
B vs C 0.177 2.179 16 0.05
Table 3.3.3 Student 't* Test Comparison Between Triplicate 
Salicylic Acid Standard Curves in Rat Plasma
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3.3.8 REPRESENTATION OF DATA
3.3.8.1 URINARY STUDIES
All data is given as a percentage of the dose (equivalent SSA) 
excreted 4, 24 or 48 hours after drug administration.
3.3.8.2 PLASMA STUDIES
Data is presented graphically as plots of mean (- SE) salicylate
concentration on a linear or a logarithmic scale vs time. From
these plots it was possible to identify sections where either
first or zero order kinetics could be applied and thereby
isolate the appropriate data points for each animal that could
be submitted to regression analysis to obtain the respective
apparent first or zero order rate constants. Zero order rate
constants obtained from intravenous experiments were used to
construct a Lineweaver-Burk type of plot according to equation
(44) from which values of V and K , for concomitantly-max m
occurring capacity-limited metabolic processes, were interpolated. 
Apparent first order elimination rate constants and corresponding 
half-lives were calculated and used throughout for comparing the 
influence of formulation, etc on salicylate elimination.
Further comparison between studies was achieved by the use of the 
area under the curve (AUC) of the plasma salicylate concentration 
vs time profile, calculated according to the trapezoidal rule by 
use of the program given as Appendix III. Estimates of bio­
availability were calculated by comparison of AUC data for each 
of the experimental formulations with that for the corresponding 
f(\XC derived from intravenous or oral data according to equation 
(46) .
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Examination of the AUC and kgj data for variance attributable 
to formulatory changes, as opposed to those of animal origin, 
was achieved by a variance ratio test and, where any significant 
effect was evident a Student *t' test between each of the 
treatments was carried out.
3.3.9 INTRAVENOUS ADMINISTRATION OF SSA
The first studies performed in the rat were. investigations of the 
influence of dose on the plasma level vs time profiles following 
intravenous administration. The aims were to gain information 
regarding the disposition of total salicylate, to identify and 
possibly characterise any capacity-limited metabolic processes 
and to provide a bioavailability standard that could be employed 
as a reference for equivalent oral doses of SSA.
It should be made clear at this stage that all plasma and urine 
studies in the rat were based on the measurement of total 
salicylate which, by definition, includes SSA, salicylic acid 
and their respective metabolites (See Fig. 3.6). Although 
inferences regarding the specific pharmacokinetic behaviour of 
SSA, salicylic acid or any of the metabolites alone should not 
be made from such data, it does however, provide the means for 
assessing the efficiency of absorption and subsequent comparison 
between routes of administration, and between dosage forms of 
various formulations, particle size range, etc.
The poor aqueous solubility of SSA presented difficulties in the 
preparation of a suitable vehicle for its intravenous Civ) 
injection. Aqueous solutions incorporating propylene glycol as
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a cosolvent were immediately discounted due to the haemoglobin-
urea observed in a series of preliminary experiments. This type
of haemolytic response could have been expected to have severe
adverse effects, not only on the well-being of the animal, but
also on drug disposition and assay. A suitable aqueous vehicle
was obtained by the complete dissolution of SSA in 5 ml of 95%
ethanol and subsequent dilution to 25 ml with S^Tensen's phosphate
buffer, pH 7.4. The pH of the final solution was determined to
be 7.4 and thus unchanged upon dilution. This vehicle allowed
- 1i.v. bolus injection of SSA in doses of 50 mg.kg and below.
For each dose level only the initial weight of SSA was adjusted
so that animals received identical amounts of ethanol and buffer 
-1salts (on a mg.kg basis). Other experimental conditions were 
as previously described in Section 3.3.2.
3.3.9.1 INFLUENCE OF DOSE
-1I.v. doses of 50, 30, 20, 10 and 2.5 mg.kg were given by 
single bolus injection via the dorsal vein of the penis. Blood 
samples, taken at zero time and at appropriate intervals after 
dosing were assayed for total salicylate. The linearity of the 
mid-profile sections of plots of mean (- SE) plasma salicylate 
concentration vs time (Fig. 3.3.4) for the five dosage levels is 
indicative that zero order processes predominate. This is 
particularly evident for the higher doses.
Wagner (1975) has suggested that if the pharmacokinetic processes 
obey first order kinetics then the ratios between the plasma 
concentration (C) and the initial concentration (Ĉ ) should be 













Time (mins x 10%)
Fig. 3.3.4 Plasma Salicylate Profiles For SSA Following Intravenous 
Administration - Influence Of Dose.
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Q/C^ vs t should be superimposable. For the intravenous data
presented in Fig. 3.3.4, the Cq values were calculated as the
t = o intercept of a line defined by the first two data points.
CThe lack of superimposition of the plots of /G^ vs t (Fig. 3.3.5) 
is indicative of non-linearity in the pharmacokinetic processes 
occurring during salicylate disposition following i.v. injection 
of SSA at these five dosage levels. It is appropriate therefore, 
to propose that the overall disposition of SSA, as measured by 
total salicylate concentration in the plasma, exhibits capacity- 
limited kinetics that are probably metabolic in origin.
Consequently apparent zero order rate constants were calculated 
by subjective examination of the individual profiles at each 
dose level and submission of appropriate data points to linear 
least-squares regression analysis. The apparent zero order rate 
constants (k^) for each dose are given in Table 3.3.4 with their 
respective reciprocals. Since it is valid to pool concomitantly- 
occurring first order rate constants to produce an "overall rate 
constant" and it has further been suggested that parallel zero 
order kinetic processes can similarly be pooled (Sedman and 
Wagner, 1972), it therefore seemed justifiable to construct a 
Lineweaver-Burk type plot (V^ q vs ^/Dose) from the data given in 
Taüale 3.3.4. From such a plot it would be possible to provide 
information regarding the "overall zero order rate constant" of 
salicylate metabolism following i.v. administration of SSA. The 
plot is shown in Fig. 3.3.6.
The reported method of constructing such doublé reciprocal plots 
(Wagner, 1973a) and other mathematical treatments of data that
218
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Fig. 3.3.5 Relationship Between Percentage Of Initial Concentration 
(t = 0) And Time Following Intravenous Administration Of 



























































































































































































































































































obey Michaelis-Menten kinetics (Martis and Levy, 1973; van 
Ginneken et al, 1974; Wagner, 1975) all depend on the dispositon 
of the drug complying with the one-compartment model. In view 
of the fact that the observed data for SSA, even at low doses, 
cannot be described by this model, the Lineweaver-Burk plot was 
constructed using reciprocal dose rather than reciprocal Cq
- 1values. From Fig. 3.3.6 values for Kĵ  and of 6.94 mg.kg
-1 -1and 0.151.5 yxg.ml min respectively were calculated from the
slope and intercepts of the line obtained by least-squares
regression analysis. These values suggest that above i.v. doses
-1of SSA greater than 7 mg.kg the metabolism of the salicylate
in the rat will occur at an apparently constant rate. This
- 1value is in close agreement with that of 7 mg.kg quoted for
salicylurate formation in the rat following intraperitoneal
injection of sodium salicylate (Nelson et al, 1966) and suggests
that the major capacity-limited route for SSA elimination maybe
AroMthat of salicylurate formation free salicylic acid.
When the dose ^  K the rate of metabolite formation will bem
maximal, whereas when dose this rate will be minimal and
the Michaelis-Menten equation (44) reduces to:-
= kC ...................     (48) ̂o
which shows 'V'q / the initial rate of salicylate elimination, to 
have a first order dependence on C, the dose, where k is the 
apparent first order elimination rate constant. When the plasma 
salicylate concentration has declined to such an extent that the 
influence of the capacity-limited processes are negligible, then
2 2 2
the overall elimination of salicylate should be described by 
first order kinetics. An examination of the experimental data 
for sections of the profile where first order kinetics can be 
applied was achieved by plotting the mean (- SE) plasma 
salicylate concentration (log scale) vs time (Fig. 3.3.7). It 
is evident that the terminal elimination phase for each set of 
mean data exhibits first order linearity and apparent first order 
elimination rate constants (k^j) were calculated for each animal 
within each dose range. These are given in Table 3.3.5 with the 
corresponding half-lives and correlation coefficients. Examina­
tion of these rate constants by a variance ratio test (Table 
3.3.5a) shows that the size of the intravenous dose has no 
significant influence on the overall first order salicylate 
elimination rate constant.
Source of Sum Degrees of Mean F F F
Variation Sq. Freedom Sq. Value Ratio Tabulated
4Dose 31.26 4 7.814 2.097 F^ = 5.19
1.489
Animal 26.23 5 5.246 1.408 p' = 0.05
Residual 63.36 17 3.727
Total 120.8 26
Table 3.3.5a Variance Ratio Test for SSA Following Intravenous
Administration At Five Dosage Levels - Elimination.
Area under the plasma salicylate concentration vs time profile 
(AUC) was calculated for each animal at each dose level (Table 
3.3.6) and Fig. 3.3.8 shows that AUC and dose are linearly related
223
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Time (mins x 10%)
Fig. 3.3.7 Plasma Salicylate (log scale) vs Time Profiles For SSA
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Fig. 3.3.8 Relationship Between Area Under The Plasma Level Curve
(AUC) And Dose For SSA Following Intravenous Administration,
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(r = 0.981). Such a linear relationship is not unexpected for 
measurements of total drug (unchanged drug and all metabolites, 
both free and protein-bound) even when capacity-limited processes 
are occurring. If AUC ^  dose plots for unchanged drug, or any 
one of the metabolites, were made then the relationship would 
be altered and should show dose dependency. Such a plot for 
AUC of unchanged drug would, however, be linear provided capacity- 
limited processes played an insignificant role in drug clearance. 
Conversely, the AUC ys dose relationship for any metabolite 
formed by a capacity-limited system would manifest an asymptomatic 
value, above which, increases in dose would not result in a 
corresponding increase in the AUC for that metabolite.
Intravenous Dose (mg.kg ) SSA
2.5 10 2 0 30 50
4391.3 16160.7 37407.2 52300.0 108393.3
4828.7 12025.3 40857.2 71131.1 90837.1
4605.6 11772.6 38754.5 69884.0 90524.1
4085.0 17151.5 54439.4 64036.6 101662.3
5252.2 20976.6 55455.1 69202.4 103187.6
4254.6 18406.3 - 63137.0 -
4569 16082 45383 64948 98921
1 +' - 173 - 1478 - 3947 - 2857 - 35450)s+i
Table 3.3.6 Area Under the Plasma Salicylate-Time Profile (yug.ml xmin) 
Following Intravenous Administration of SSA at Five Doses.
Although intravenous data provides the ideal standard for 
comparing drug bioavailability of other dosage forms or routes
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of administration it has been stated that relative measurements 
of bioavailability can be achieved with reference to an oral 
dosage form, ie solution or proprietary product, etc. To examine 
the two approaches the gastrointestinal absorption of SSA from a 
solution was studied.
3.3.10 ABSORPTION OF SSA FROM SOLUTION
SSA was dissolved in Sorensen's phosphate buffer, pH 7.4, to give
a concentration of 2 mg.ml ^, this was administered by oral
intubation at a dose of 1 ml . 1 0 0 g  ̂body weight, giving 
-1
^ 0  mg.kg .
The resultant mean plasma salicylate (- SE) profiles are given 
in Figs. 3.3.9 and 3.3.10 for plots of salicylate concentration 
and salicylate concentration (log scale) ys time respectively. 
Elimination half-lives and apparent first order elimination 
rate constants (kgj) are given in Table 3.3.7 with AUC data.
Elimination Data AUC
kei - SE (xlO“^min“ )̂ th (mins) r (^g.ml x min)
5.678 - 0.24 122 0.996 24162.2
6.504 - 0.23 107 0.999 24718.0
6.704 - 0.29 103 0.998 26947.5
6.630 - 0.34 105 0.997 23249.0
7.451 - 0.69 93 0.996 23472.7
7.040 - 1.21 99 0.986 22995.3
§ OT 6 . 6 6 8  - 0.242 1 0 5 - 4  - 24257.5 - 596.8
S-H
Table 3.3.7 Apparent First Order Elimination Rate Constant (k^^), Half 
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Fig. 3.3.10 Plasma Salicylate (log scale) vs Time Profile For SSA
Following Oral Administration In Solution. Dose 20 mg.kg-1
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Dissolution studies (Section 2.11) had demonstrated the 
necessity for a surface active agent to aid wetting and facili­
tate the exposure of the maximal effective surface area to the 
dissolution medium. Similarly, initial attempts at preparing 
SSA suspensions in distilled water, suitable for oral adminis­
tration to the rat, were abandoned due to incomplete wetting and 
rapid settling of the material. This was particularly important 
to avoid in order to ensure that each aliquot of suspended 
material contained the same percentage of suspended SSA. It was 
considered that SSA suspensions should, therefore, incorporate 
a suspending agent that adequately wetted powders of varying 
particle size producing homogeneous suspensions. Of several 
potential agents investigated polyvinyl alcohol, (PVA), prepared 
as a 4% w/v solution, was found to satisfy the above criteria 
and was therefore used as a vehicle for the oral administration 
of SSA suspensions. It was of interest then, to examine the 
possible difference in the absorption of SSA from this vehicle 
in comparison with that from a simple aqueous suspension.
3.3.11 INFLUENCE OF PVA AS A SUSPENDING AGENT ON SSA ABSORPTION 
FOLLOWING ORAL ADMINISTRATION
Using a cross-over design with one week between studies, six
rats were administered SSA (75-105jmm particle size range;
- 1
2 0 mg.kg ) prepared as a simple aqueous suspension or suspended 
in 4% w/VPVA. Other experimental conditions were as before 
(See 3.3.2).
The mean (- SE) plasma salicylate vs time profiles for both 















from the PVA system than from distilled water. AUC analysis for 
individual animals is given in Table 3.3.8 with the elimination 
data for both studies.
The elimination rate constants were calculated from the linear 
terminal phase of the respective logarithmic profiles given in 
Fig. 3.3.12 and when compared by the Student 't' test, are shown
hot to be significantly different " 1.984; N = 12, p' =
0.05; t = 2.228). Similar comparisons between the respective 
tab
AUC values shows them not to be significantly different either
(t , = 0.982; N = 12; p* = 0.05, t. ^ = 2.228). The AUCODS tab
-1values for animals receiving 20 mg.kg SSA as solution (Section 
3.3.10) were unexpectedly lower than those for the suspended 
formulations and will be commented on in later discussion.
Subjective examination of the profiles given in Fig. 3.3.11 
shows them both to have a second peak concentration. This is 
more pronounced in the profile for the water vehicle than that 
for the PVA vehicle and probably reflects a greater SSA 
solubility in the PVA solution.
Further discussion regarding secondary peaks will be given later.
3.3.12 INFLUENCE OF DOSE ON PLASMA SALICYLATE LEVELS FOLLOWING ORAL 
ADMINISTRATION OF SSA SUSPENSIONS IN 4% W/V PVA 
The linearity in the relationship between i.v. dose and the area 
under the curve (AUC) of the resultant plasma salicylate profiles 
(See Fig. 3.3.8) is indicative that a similar linear dependency 
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Fig. 3.3.12 Plasma Salicylate (log scale! vs Time Profiles For SSA 
(75 - lOS^m) - Influence Of Vehicle Following Oral 
Administration. Dose 20 ing.kgm ^.
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is based on the assumption that the assay is a determination of 
total drug plus metabolites. If this relationship does exist it 
would support the assessment of absorption efficiency by AUC 
analaysis even in the presence of concomitantly-occurring 
concentration-dependant and -independant kinetic processes.
SSA (75-105yum particle size range) prepared as 0.2, 0.4, 1.0
and 2.0% w/v suspensions in 4% w/v PVA, was orally administered
- 1by intubation, 0.5 ml 100 g body weight, to give doses of 10, 
20, 50 and 100 mg.kg respectively. Other experimental 
conditions were as previously described (Section 3.3.2).
The plasma salicylate vs time profiles for mean (- SE) data, 
given in Fig. 3.3.13 show a dose-dependant change. Corresponding 
AUC values for individual animals at each dose level are given 
in Table 3.3.9 and represented graphically vs dose in Fig. 3.3.14, 
where there is a linear relationship (r = 0.959) between dose 
and AUC for the doses studied.
Apparent first order elimination rate constants (k@i), respective 
half-lives (t%) and correlation coefficients (r) are given in 
Table 3,3.11. The k@i values were calculated following subjective 
examination of plasma concentration (log scale) vs time profiles 
for individual animals and least-square regression analysis of
the appropriate terminal data points. A plot of mean (- SE)
\
plasma salicylate concentration (log scale) vs time for each dose 
is given in Fig. 3.3.15. Comparison of the k^j values for each 
dose is given in Table 3.3.10 where a variance ratio test does 
not demonstrate any significant difference between the overall
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180) Plasma Salicylate 
( ylg.ml-1 )
160’







2Time (mins x 10 )
Fig. 3.3.13 Plasma Salicylate Profiles For SSA (75 - 105^4 m) - 
Influence Of Dose Following Oral Administration.
- 1Dose (mg.kg. )
Animal
100 50 2 0 10
1 , .166141........  48525.........50667......... 16750
165899 48510 36003 14144
146081 54792 37880 14416
156040 37711 41036 13791
129965 54370 41220 12635
167122 64133 36388 13992
Mean 155208 51340 40532 14288
+ SE 6047 3589 2222 553
-1Table 3.3.9 Influence Of Dose On AUC (yug. ml. x min) 
Following Oral Administration of SSA, 
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Fig. 3.3.14 Relationship Between Area Under The Plasma Level Curve 
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Fig. 3.3.15. Plasma Salicylate (log scale) vs Time Profiles For SSA 
(75 - lOSyUm) - Influence Of Dose Following Oral 
Administration.
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rate constants for salicylate elimination.
Source of Sum Degrees of Mean F F F
Variation Sq. Freedom Sq. Value Ratio Tabulated
5.462 3 1.821 0.758 1.831 F^=54|
Animal 4.973 5 0.995 0.414 p'=0.05
Residual 3.122 13 2.402
Total 4.166 21
Table 3.3.10 Variance Ratio Test for SSA Following Oral Administration 
at Four Dosage Levels - Elimination.
It can therefore be expected that changes in the extent of SSA 
absorption from suspended experimental dosage forms would be 
reflected by changes in the AUC even though capacity-limited 
processes are known to occur.
3.3.13 INFLUENCE OF SSA PARTICLE SIZE ON PLASMA SALICYLATE LEVELS 
FOLLOWING ORAL ADMINISTRATION
The correlation between BET surface area and dissolution rate 
for various particle size ranges of SSA has already been 
demonstrated (Section 2.11, Fig. 2.11.4). This in vitro 
relationship may not necessarily be reflected by the in vivo 
absorption of SSA from suspension unless absorption is 
dissolution rate-limited. To establish whether or not SSA 
absorption is a function of dissolution rate various particle 
size fractions of the drug were administered per os and the
842
resultant plasma salicylate concentration ys time profiles 
examined.
Various particle size ranges were formulated as 0.4% w/v
suspensions in 4% w/v PVA and orally administered by intubation,
-1 -10.5 ml 100 g body weight, to give a dose of 20 mg.kg
The mean (- SE) plasma salicylate profiles for the six ranges of 
particle size are shown in Figs. 3.3.16 and 3.3.17. Parameters 
such as peak times and the occurrence of a secondary peak will be 
discussed later in an attempt to correlate them with drug 
availability and the in vitro dissolution data previously 
presented. Respective AUC data is given in Table 3.3.12 and 
compared by a variance ratio test in Table 3.3.17.
Apparent first order elimination rate constants, calculated 
from the terminal linear phase of a first order plot for each 
animal, are given in Tables 3.3.13 and 3.3.14. First order plots 
for mean (- SE) plasma salicylate concentration vs time 
profiles are shown in Figs. 3.3.18 and 3.3.19. A variance ratio 
test for possible particle size effects on salicylate elimination 
was carried out and although the result (Table 3.3.17) does not 
show any significant effect the variance due to formulation was 
greater than that due to biological variation. The k©l values 
for each particle size were subsequently compared by a Student 
't* test (Table 3.3.15) which shows that elimination following 
oral dosing with the 150-180/Am particle size material was 

































-1AUC (^g. ml. x min) For Particle Size Ranges ^m)
Micron 38-53 53-75 75-105 105-150 150-180
29456 22952 44278 50667 29842 39558
40848 30307 28258 36003 24320 56864
27375 22220 27336 37880 30808 37716
34917 31649 32841 41036 29371 41564
29277 36708 41220 24920 34928
27745 25518 30463 36388 23363 46765
Mean 31603 26529 33314 40532 27104 42859
+ SE 2154 1909 2590 2222 1328 3232
Table 3.3.12 Area Under Plasma Salicylate Profile Following 
Oral Administration of SSA Of Varying Particle 
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' Plasma Salicylate 
( g.ml"^)
100
Particle Size {jlA m)
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2 a 12 144 6 10
Time (mins x 10^)
Fig. 3.3.18 Plasma Salicylate (log scale) vs Time Profiles For SSA -
Influence Of Particle Size. Dosé 20 mg.kg-1
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'plasma Salicylate 
( ug.mi-1) Particle Size (y^m) 
O  150 - 180 
A  105-150 
□ 75 - 105
2 4 6 8 10 12 14
Time (mins x 10 )
Fig. 3.3.19 Plasma Salicylate (log scale) vs Time Profiles For SSA -
-1Influence Of Particle Size. Dose 20 mg.kg .
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Particle 









2.523 6.2092.386 3.209 4.293
150-180
For N = 9 \ a b  ■ 2.365
N = 10 ^tab 2.306
N = 11 ^tab = 2.262
N = 12 ^tab 2.228
p' - 0.05
Table 3.3.15 Student 't ' Test Comparison Between
Apparent First Order Elimination Rate
Constants (K , ) for SSA of Various Particle el
Size Ranges Following Oral Administration 
-120 mg.kg.
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Since the variance ratio test for the AUC data has shown 
particle size to be an influential factor, a Student 't' test 
comparison between the values for each formulation was performed 
and is shown in Table 3.3.16. The results of this test are 
depicted below, where the particle size ranges are given in 
order of decreasing AUC, and the bars show where no significant 




150-180 75-105 53-75 Micron 105-150 38-53
Particle Size 
/A m
These results will be further discussed in Chapter 4.
The variance ratio analysis for both the elimination and AUC 
data given in Table 3.3.17 shows there to be a significant effect 
of particle size on the AUC in comparison to that of animal 
origin. While indicating particle size to be influential on the 
AUC it does not follow that the variances for AUC and are 
related even though a change in k©l will produce a corresponding 
change in AUC (assuming all other pharmacokinetic functions remain 
unchanged). Examination of the salicylate profiles of the mean 
data for each particle size range show obvious alterations in the 
attainment of peak levels and the concentrations themselves, 
factors which suggest a change in the rate and extent of 
absorption. Consequently the particle size related variation in
252
Particle 




































For N = 12 
For N = 11
‘tab = 2-228 ) 
‘tab = 2.262 i
p' = 0.05
Table 3.3.16 Student 't' Test Comparison Between
AUC Values for SSA of Various Particle































Animal 9.12 5 1.827 0.775





AUC 14.31 5 2.813 9.163
7.10 5.05
p'=0.05Animal 1.980 5 0.396 1.290
Residual 7.379 24 0.307
Total 23.69 34
Table 3.3.17 Variance Ratio Test For SSA Following Oral 
Administration Of Varying Particle Sizes - 
Elimination And AUC.
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AUC cannot be associated with the changes in kgl per se.
The significance and possible explanation for these findings 
will be discussed later.
Urinary excretion studies with SSA in man (Section 3.2.3) have 
shown urinary excretion data to be unable to adequately discrim­
inate between the influences of particle size on SSA absorption. 
To establish whether the same criticism can be levied for 
similar studies in the rat the following investigations were 
carried out.
3.3.14 INFLUENCE OF PARTICLE SIZE ON SSA ABSORPTION FROM SUSPENSION AS 
MEASURED BY URINARY EXCRETION OF TOTAL SALICYLATE 
1% w/v aqueous suspensions of various particle size ranges of
-1SSA were prepared in 4% w/v PVA. Animals received 1 ml 100 g
-1body weight (100 mg.kg ) and urine collected 4 and 24 hours 
after dosing. The mean (- SE) % dose excreted after these times 
are given for each particle size range in Table 3.3.18.
To examine for particle size related changes in % dose excreted 
a variance ratio test was performed and the results given in 




Mean % Dose Excreted (- SE) After:
4 hours 24 hours
150 - 180 21.09 + 0.82 48.20 + 5.23
105 - 150 13.40 + 2.36 59.62 + 3.10
75 - 105 16.09 + 2 . 6 6 68.99 + 1.39
53 - 75 12.87 + 2.51 57.97 + 2 . 2 1
38 - 53 18.16 + 1.43 64.07 + 4.59
30 - 38 17.38 + 2.51 56.62 + 1.77
Micronised 19.60 + 2.85 58.51 + 3.36
Vehicle Control 0.05 + 0 . 0 1 0.16 + 0 . 0 1
Table 3.3.18 Dose SSA Excreted After 4 and 24 Hours Following Oral 
Administration of SSA Suspensions of Various Particle 
Sizes.
It is evident that the variance in % dose excreted associated 
with particle size is not significantly greater than that 
associated with animal variation for either the 4 or 24 hour 
samples, however, although urinary excretion of total salicylate 
has shown no significant variation that could be attributed to 
particle size after 24 hours, there was a suggestion that after 
4 hours some influence was evident (ie higher F value. Table 
3.3.19). If coprecipitation of SSA with PVP or the bile acids 
had any significant influence of absorption then it may be 
reflected in the urinary excretion of total salicylate. To 
examine this possibility absorption of SSA from SSA:PVP 
coprecipitates was estimated by measurement of total salicylate
256
g Source Sum Degrees Mean F F FG•H of Sq of Sq value ratio tabulatedEh variation
Particle
Size 577.91 6 96.318 2.174
4.95
3.70 p'=0.05
Animal 130.09 5 26.017 0.587
tny
Residual 1329.14 30 44.305
Total 2037.14 41
Particle
Size 870.19 6 145.03 1.618
1.06 4.95
Animal 686.38 5 137.28 1.532 p'=0.05
5
Residual 2688.94 30 89.63
TTCN
Total 4245.30 41
Table 3.3.19. Variance Ratio Test For % Dose Excreted 4 And 
24 hours Following Oral Administration of SSA 
of Various Particle Sizes
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/
in the urine 4, 24 and 48 hours after oral dosing.
3.3.15 INFLUENCE OF COPRECIPITATION OF SSA WITH PVP ON SSA ABSORPTION 
FROM SUSPENSION BY MEASUREMENT OF URINARY EXCRETION OF TOTAL 
SALICYLATE
SSA:PVP coprecipitates were formulated as 1% w/v (equivalent
SSA) suspensions in 4% w/v PVA using 75-105yiAin material. Each
. . ratio was adjusted for SSA content according to their % SSA .
values reported previously (See 2.13.1.1). Groups of six
animals were orally-dosed with these suspensions at 1 0 0 mg 
_ 1(equivalent SSA)kg , urine was collected after 4, 24 and 48 
hours and assayed as described.
The total salicylate excreted, expressed as mean (- SE) % dose 
is given in Table 3.3.20 for the SSA:PVP (2:1, 1:1, 1:2 and 1:5) 
coprecipitates.
Coprecipitate _______ Mean - SE % Dose Excreted After:
SSA:PVP ratio 4 hours 24 hours 48 hours
2 : 1 11.90 + 4.40 70.53 + 8.31 74.99 + 8.32
1 : 1 15.63 + 2.36 71.38 + 2.82 76.14 + 2.18
1 : 2 14.37 + 2.87 63.90 + 4.20 73.79 + 5.89
1:5 7.10 + 1.61 34.16 + 2.79 47.27 + 2.83
Table 3.3.20 Urinary Excretion of Total Salicylate Following Oral 
Administration of SSA:PVP Coprecipitates.
Students 't' test comparison between the % dose excreted for the 
SSA : PVP coprecipitates with SSA alone (data taken from 75-105ŷ mr\
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particle size study given in Table 3.3.18) after 4 and 24 hours 
shows that the 1:5 ratio significantly retarded the efficiency 
of SSA absorption. ('t' values of 2.893 and 11.179 were 
calculated for the 4 and 24 hour samples respectively). The 
other ratios did not show any influence that was statistically 
distinguishable from SSA alone for either the 4 or 24 hour data. 
The data for all comparisons are given in Table 3.3.21.
Coprecipitate Students 't' value for 
SSA:PVP Ratio — 't' tabulated4 hours 24 hours
1:5 2.893 11.179 In all cases
1 : 2 0.440 1.152 ^tab " ^.228
1:1 0.136 0.759 ^
N = 1 2
2:1 0.861 0.194
Table 3.3.21 Student 't' Test Between % Dose Excreted After 4 and 24 
Hours Following Oral Administration of SSA:PVP 
Coprecipitates In Comparison To SSA Alone.
It is evident that the 't' values for the 24 hour data in Table 
3.3.21 above decrease with PVP content of the coprecipitate.
The significance of this will be discussed in due course. A 
Student 't' test comparison between the % dose excreted for all 
three time intervals is given in Table 3.3.22 for the SSA:PVP 
coprecipitates where it can be seen that the % dose excreted 
following administration of the 1:5 ratio is significantly 
different from the other SSA:PVP ratios at all times, with the 
exception of the four hour excretion for the 2 : 1 ratio. 







Ratio 1:5 1 : 2 1 : 1
2.215
1 : 2 N = 11 
2.983 0.336
4 hours 1 : 1 N = 12 N = 11
1.026 0.471 0.745
2 : 1 N = 11 N = 10 N = 11
5.903
1 : 2 N = 11 
9.391 1.479
24 hours 1: 1 N = 12 N = 11
4.160 0.723 0.085
2 : 1 N = 11 N = 10 N = 11
4.057
1 : 2 N = 11 
8.091 0.374
48 hours 1 : 1 N = 12 N = 11
3.154 0.118 0.134
2 : 1 N = 11 N = 10 N = 11
For N = 10 ^tab
N = 11 ^tab




p' = 0.05 dF = N - 2
Table 3.3.22 Students 't' Test Between % Dose Excreted After 4, 24 
and 48 Hours Following Oral Administration of SSA:PVP 
1:5, 1:2, 1:1 and 2:1 Coprecipitates.
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differences. These results indicate that the extent of SSA 
absorption from the 1:5 SSA:PVP coprecipitate is significantly 
retarded in comparison to the other coprecipitates and to SSA 
alone.
As suggested in the human studies, and in previous studies in 
the rat, the urinary excretion method of discriminating between 
SSA formulations was only able to differentiate between gross 
changes in bioavailability.
To follow the appearance of salicylate in the plasma would there­
fore provide a more precise and valid method of assessing the 
bioavailability of SSA from its coprecipitates and admixtures 
with PVP, cholic acid and deoxycholic acid.
3.3.16 ABSORPTION OF SALICYLATE FROM SSA:PVP COPRECIPITATES AND 
ADMIXTURES
The general experimental protocol has been described (See 3.3.2).
-1All animals received 20 mg (equivalent SSA) kg body weight by 
oral intubation, each dosage being corrected for % SSA content 
using the values given in Table 2.13.4. Dosage of the admixtures 
was corrected for % SSA content according to the ratio of the 
components in the physical mix. Blood samples, taken at zero 
time and at appropriate time intervals following dosing were 
assayed for salicylate as described (See 3.3.7).
The mean (- SE) plasma salicylate concentration vs time profiles 
are shown in Figs. 3.3.20 to 3.3.24 for the 2:1, 1:1, 1:2, 1:5 

























































salicylate concentrations and times were interpolated from each 
profile and are given in Table 3.3.23.
COPRECIPITATE ADMIXTURE
SSAiPVP







0 100 - 400 53 - 56 100 - 400 53 - 56
2 : 1 140 69 2 1 0 54
1 : 1 400 58 60 63
1 : 2 100 (290) 60 (58) 320 67
1:5 170 56 360 46
1 : 1 0 45 6 6 300 60
Table 3.3.23 Approximate Peak Salicylate Times and Concentrations
Following Oral Administration of SSA:PVP Coprecipitates 
and Admixtures and SSA Alone (numbers in parenthesis refer 
to a second peak).
The area under the plasma level profiles (AUC) for the individual 
animals receiving each SSA:PVP system (and SSA alone) are given 
in Tables 3.3.24 and 3.3.25 for the coprecipitates and admixtures 
respectively.
Variance ratio analysis for the influence of the SSA;PVP systems 
on the AUC for the animals used is given in Table 3.3.26. For 
both the SSA:PVP coprecipitates and admixtures the variance due 
to formulation is not significantly greater than that of 
biological origin.
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Area Under Curve For SSA:PVP Coprecipitates
-1(/xg.ml X min)
\Ratio
Animals. SSA 2 : 1 1 : 1 1 : 2 1:5 \ 1 : 1 0
1 50667 33595 28597 36693 - 36150
2 36003 37420 42259 ' ■ ■ 21800
3 37880 43230 48010 26865 25959 22322
4 41036 40766 41254 29490 31646 36346
5 41220 44239 52918 44589 - 32355
6 36389 34472 39794 31747 28472 27460
Mean 40532 38954 42139 33886 28692 29406
- SE 2 2 2 2 1832 7531 3127 1646 2672
Table 3.3.24 Area Under Plasma Level Curve Following Oral
Administration of SSA and SSA:PVP Coprecipitates
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AnimaTv. SSA 2 : 1 1 : 1 1 : 2 1:5 1 : 1 0
1 50667 35650 33519 44004 25031 45384
2 36003 30258 35331 39752 34477 31374
3 37880 28765 51160 38925 31459 32157
4 41036 33318 47124 38768 30224 31666
5 41220 39876 46271 44286 31815 43348
6 36389 - 29996 - 25560 46980
Mean 40532 33173 40567 41147 29761 38485
- SE 2 2 2 2 1912 3543 1236 1523 3058
Table 3.3.25 Area Under Plasma Level Curve Following Oral 


















AUC 7.419 4 1.855 5.456
2.36 5.19
p'=0.05Animal 3.932 5 0.786 2.312
&Pi
8W









p'=0,05Animal 1.539 5 0.308 0.800
Residual 6.920 18 0.385
Total 14.15 27 V
Table 3.3.26 Variance Ratio Test For SSA:PVP
Coprecipitates And Admixtures Following Their 
Oral Administration - AUC.
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The possible influence of PVP on the overall elimination rate 
of salicylate was studied by examination of the apparent first 
order elimination rate constants (kg^) and half-lives (t^), 
following subjective scrutiny of the first order plots for 
individual animals. Data points describing the linear elimina­
tion phase were submitted to linear least-squares regression 
analysis and the resultant kg^ and th values are given in Tables 
3.3.27 - 28 and 3.3.29 - 30 for the coprecipitate and admixture 
systems respectively. First order plots for the mean SE) 
data of both SSA:PVP systems are shown in Figs. 3.3.31 and 
3.3.32.
A variance ratio test (Table 3.3.31) was performed on the 
elimination rate constants given in Tables 3.3.27 - 30 and shows 
that for both the coprecipitated and admixed systems the variance 
associated with the experimental formulation was not significantly 
greater than that of biological origin.
These results for SSA:PVP systems will be discussed later.
3.3.17 ABSORPTION OF SALICYLATE FROM SSA:CHOLIC ACID (CA) COPRECIPITATES 
AND ADMIXTURES
The experimental protocol was similar to that for the SSArPVP 
systems. Dosage of the SSA:CA coprecipitates was corrected for 
SSA content according to the % purity data given in Table 2.13.5 
and the admixtures were corrected according to their SSA:CA molar 
ratio. Following oral administration of the SSA:CA 1:10 ratio 
systems the animals suffered severe gastrointestinal disturbance; 
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Fig. 3.3.31 Plasma Salicylate (log scale) vs Time Profiles For 
SSA:PVP Coprecipitates
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Animal 22.91 5 4.589 1.469
-
Residual 43.68 14 3.119
Total 73.49 23
’'el 5.187 4 1.297 1.046
2.06






Animal 13.36 5 2.672 2.155
Residual 21.07 17 1.240
Total 39.67 26 .




animals sacrificed. The significance of the effect of non- 
physiological concentrations of bile acids on the gastrointes­
tinal tract will be discussed later.
The mean (- SE) plasma salicylate concentration time profiles 
for the 2 :1 , 1 :1 , 1 : 2 and 1 :5 ratio coprecipitated and admixed 
systems are shown in Figs. 3.3.33 to 3.3.36.
Peak salicylate concentrations and times, obtained by interpola­
tion from the appropriate Figures are given in Table 3.3.32.
SSA:CA COPRECIPITATE ADMIXTURE








0 1 0 0 - 400 53 - 56 100 - 400 53 - 56
2 : 1 180 62 150 - 550 49 - 52
1 : 1 45 84 45 8 8
1 : 2 60 (330) 60 (58) 380 57
1:5 350 58 350 67
Table 3.3.32 Peak Salicylate Times and Concentrations for SSA and 
SSA:CA Coprecipitates and Admixtures Following Their 
Oral Administration to the Rat. (Numbers in parenthesis 
refer to a second peak).
The area under the plasma level curves (AUC) for the individual 
animals receiving each SSA:CA system (and SSA alone) are given in 
































































Area Under Curve For SSA:CA Coprecipitates
-1(jukg.ml xmin)
\Ratio
AnimaT\ SSA 2 : 1 1 : 1 1 : 2 . 1:5
1 50667 36941 49980 51518 30592
2 36003 41562 54259 37099 34999
3 37880 37526 47258 35548 36948
4 41036 45036 49633 32752 -
5 41220 46504 58552 31331 42486
6 36389 45231 56490 35866 38849
Mean 40532 42133 52695 37352 36775
- SE 2 2 2 2 1690 1803 2964 1979
Table 3.3.33 Area Under Plasma Level Curve Following Oral
Administration of SSA and SSAzCA Coprecipitates
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Area Under Curve for SSA:CA Admixtures
-1(jug.ml xmin)
\Ratio
Animal\ SSA 2 : 1 1 : 1 1 : 2 1:5
1 50667 46443 52903 36017 36058
2 36003 31527 49935 40881 43715
3 37880 47235 54916 32987 47837
4 41036 39534 - 42153 36265
5 41220 45679 51173 46120 43375
6 36389 40217 61507 44207 41457
Mean 40532 41773 54087 40394 41452
- SE 2 2 2 2 2445 2036 2039 1876
Table 3.3.34 Area Under Plasma Level Curve Following Oral 
Administration of SSA and SSA:CA Admixtures
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Variance ratio analysis for the influence of the SSA;CA systems 
on the AUC for the animals used is given in Table 3.3.35. For 
both the SSAzCA coprecipitated and admixed systems the variation 
in AUC associated with the formulation is significantly greater 
than that of animal origin, indicating that the coprecipitate 
and admixture prodd e d  ̂ ystems changes in bioavailability as 
determined by AUC analysis.
A Student 't' test comparison between the AUC data for the 
SSAzCA coprecipitates and admixtures is given in Table 3.3.36 
and shows that the 1 : 1 ratio coprecipitate and admixture has 
resulted in a significantly enhanced AUC in comparison to SSA 
alone and to all other SSAzCA systems. All systems apart from 
the 1 : 1 ratio showed no statistically distinguishable differences 
These results will be discussed later and possible explanations 
offered.
The influence of cholic acid on the overall elimination rate 
constant for salicylate was studied by examination of the rate 
constants (kgi) and corresponding half-lives (t%), following 
subjective scrutiny of the first order plots for individual 
animals. Data points describing the linear elimination phase 
were submitted to least-squares regression analysis; the result­
ant kgi and th values are given in Tables 3.3.37- 39 for both 
the coprecipitates and admixtures. First order plots of the 
mean (- SE) plasma salicylate levels for both SSAzCA systems 
are shown in Figs. 3.3.37 and 3.3.38.


















AUC 7.097 3 2.366 8.542
10.91
Fg = 5.41 
p' =0.05
Animal 1.084 5 0.217 0.783
H
s
§Residual 3.384 14 0.277




AUC 9.998 3 3.333 10.514
19.84
F^ = 5.41 
p' =0.05Animal 0.838 5 0.168 0.530
Residual 4.442 14 0.317
Total 15.29 2 2












For N = 11 ~ 2.262 p' =0.05
N = 12 t ^ = 2.228 p* = 0.05tab
Tablé 3.3.36 Student 't' Test Comparison Between AUC Data For 
SSAzCA Coprecipitates and Admixtures with SSA 
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Fig. 3.3.38 Plasma Salicylate (Log Scale) vs Time Profiles For 
SSA:CA Admixtures.
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constants for both SSA:CA systems, the results of which are 
given in Table 3.3.40, shows SSA coprecipitates and admixtures 
with cholic acid to have had no significant influence on the 
elimination of salicylate.
3.3.18 ABSORPTION OF SALICYLATE FROM SSA:DEOXYCHOLIC ACID (DOCA) 
COPRECIPITATES AND ADMIXTURES
The experimental protocol was similar to that for the SSA:PVP 
systems. Dosage of the SSA:DOCA coprecipitates was corrected 
for SSA content according to the % purity data given in Table 
2.13.6 and the admixtures were corrected according to their 
SSA:DOCA molar ratio. Administration of SSA:DOCA systems of 
a ratio greater than 1 : 2 were abandoned due to severe gastro­
intestinal disturbance of the animals which were subsequently 
sacrificed.
The mean (- SE) plasma salicylate vs time profiles for the 
SSA:DOCA 2:1 and 1:1 systems are shown in Figs. 3.3.39 and 
3.3.40 respectively. The truncated profiles for the 1:2 and 1:5 
admixtures are shown in Fig. 3.3.41. These profiles are not 
complete due to the sacrifice of the animals before completion 
of the experiment because of gastrointestinal disturbance.
Peak salicylate concentrations and times, interpolated from 





















^el 1 1 . 0 0 0 3 3.668 8.026
5.26 5.41
p'=0.05Animal 3.491 5 0.698 1.527





•'el 3.150 3 1.050 0.755
3.45 9.01
p'=0.05Animal 18.10 5 3.620 2.602
Residual 13.91 1 0 1.391
Total 35.16 18
Table 3.3.40 Variance Ratio Test For SSArCA Coprecipitates


















































0 100 - 400 53 - 56 100 - 400 53 - 56
2 : 1 300 71 300 53
1 : 1 50 - 150 47 - 49 150 - 400 38 - 41
1 : 2 - - 310 64
1:5 420 62
Table 3.3.41 Peak Salicylate Concentration and Time for SSA:DOCA 
Coprecipitates and Admixtures, and SSA Alone,
Following Their Oral Administration to the Rat.
The area under the plasma level curve (AUC) for the individual 
animals receiving each SSA:DOCA system and SSA alone are given 
in Table 3.3.42. A Student 't ' test comparison between these
AUC data is give in Table 3.3.43.
\
The Student 't' test analysis shows that apart from the 2:1 
coprecipitate the other systems (2 :1 , 1 : 1 admixtures and 1 : 1  
coprecipitate) exhibit a significantly reduced AUC in comparison 
to SSA alone, and, that these systems are not significantly 
different from each other. This reduced absorption will be 
discussed later.
The possible influence of deoxycholic acid on the overall 




Area Under Curve For SSA:DOCA Systems 
-1








50667 31553 26748 29779
36003 54188 35579 26409 27920
37880 54790 33504 20530 40072
41036 44848 34686 36158 25773
41220 44093 30407 32485 16076













Table 3.3.42 Area Under Plasma Level Curve Following Oral













For N = 11 “ 2.262 p* = 0.05
N = 12 ^ = 2.228 p* = 0.05tab
Table 3.3.43 Student *t' Test Comparison Between AUC Data For
SSA:DOCA 2:1 and 1:1 Ratio Coprecipitates And Admixtures 
With SSA (75 - 105jim) Alone.
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tion of and half-life data obtained from first order plots 
for individual animals. Following subjective scrutiny of these 
first order plots, data points describing the linear elimination 
phase were submitted to least-squares regression analysis; the 
resultant kgj and th values are given in Tables 3.3.44 and 
3.3.45 for the SSA:DOCA 2:1 and 1:1 systems respectively. First 
order plots of the mean (- SE) plasma salicylate levels for both 
SSA:DOCA ratios are shown in Figs. 3.3.41 and 3.3.42 respectively. 
The latter figure also includes the truncated profiles for the 
1:2 and 1:5 admixtures. The elimination rate constants are 
compared to SSA alone and to each other by a Student 't' test 
the results of which are given in Table 3.3.46.
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Fig. 3.3.42 Plasma Salicylate (Log Scale) vs Time For SSA:DOCA 
Admixtures.
Truncated Due To Termination Of Experiment.
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SSA:DOCA 









For N = 11 
N = 12
tab = 2.262
t. ^ = 2.228 tab
p' = 0.05
Table 3.3.46 Student 't' Test Comparison Between Elimination Data For 
SSA:DOCA 2:1 and 1:1 Coprecipitates And Admixtures With 





Salicylsalicylic acid (SSA) was chosen as a model for this 
investigation for the reasons previously outlined. Firstly it 
seemed likely that its therapeutic efficiency would be limited 
by its poor solubility and secondly, that an improvement in 
the bioavailability of the drug by formulatory manoeuvres 
would provide an analgesic and anti-inflammatory salicylate 
that did not appear to produce extensive gastro-intestinal 
blood loss and was sufficiently prolonged in its action to 
provide alleviation of early morning stiffness. It was further 
hoped that rigorous examination of the physical, chemical and 
dissolution characteristics of this drug would also aid in an 
understanding of the relative importance of the different 
properties of other drugs known to exhibit incomplete 
bioavailability.
The findings of these investigations will be discussed in 
relation to basic pharmacokinetic studies on the drug in 
human volunteers and in rats. However, it is necessary to 
firstly consider some of the physical and chemical properties 
of SSA which, although they are not incorporated into the 
ensuing discussion at every opportunity, are fundamental to a 
full comprehension of the in vitro and in vivo data.
4.1 PHYSICAL CHARACTERISATION OF SSA
The original sample of SSA provided by A. B. Bofors was examined 
for its purity, crystallinity and particle size distribution 
in Sections 2.3.2, 2.3.5 and 2.4 respectively. The absence of 
any salicylic acid and other impurities, as shown by thin layer 
chromatography, suggests that the techniques of SSA separation
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and purification during manufacture had successfully removed 
salicylic acid impurities, and that the material had not 
undergone any detectable hydrolysis prior to use.
The melting points determined in this study were higher than 
those ranging from 135-149° quoted in the literature (See 
Table 2.3.4.1), although there was no evidence of a 
chronological sequence in these values that could be 
associated with continued improvement in production methods.
The differences could result from varying techniques of 
determination although this is improbable since this study 
gave indistinguishable results employing the two methods of 
capillary tube (152°) and the hot bench (152-153°). Melting 
points can, however, be expected to decrease with the 
presence of impurities and the variety in the literature values 
may be attributable to the presence of different amounts of 
salicylic acid and/or other impurities. Subsequent to the 
quality control data provided for SSA (Bofors, 1971) the 
company have stated, in a private communication, that increased 
proficiencies in manufacturing methods since that date have 
improved the quality of the material such that the majority of 
the cited criteria were superceded. Since the bulk material 
supplied was manufactured in 1973 this may account for the 
higher melting point and the absence of salicylic acid.
The particle size of the material provided exhibited a 
logarithmically normal distribution (Fig. 2.4.3) that is 
characteristic of material where particle size reduction has 
been achieved by milling, grinding and other comminutive
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processes (Herdan, 1950), However, the two data points for 
the lower particle size fractions deviated from the linearity 
of the log. normal plot: these two points are those of 30-38
and 38-50 yum and were obtained using micropore sieves that are 
known to have round apertures whereas all other sieve fractions 
were obtained using British Standard wire mesh sieves that have 
square apertures. Since the determination of particle size 
distribution by sieving depends oh the probability of particles 
passing through a sieve of defined shape then the differences 
in the shape of the apertures for the two types of sieve used 
could account for the anomalous results derived using 
micropore sieves.
4.2 CHEMICAL CHARACTERISATION OF SSA
Determinations of SSA solubility in various solvents as a 
function of temperature (See 2.6) did not provide van't Hoff 
plots that were linear and hence amen able to thermodynamic 
examination (See Fig. 2.6.2). However, an interesting feature 
of these results shown in Fig. 2.6.2 is that SSA solubility 
exhibited a greater temperature-related change in 0.IN HCl 
(with or without 1% w/v ethanol) than in distilled water (with 
or without 1% w/v ethanol), since the curves converged at high 
temperatures. A probable explanation for these observations 
may lie in the fact that the ionisation constant (pKa) for 
carboxylic acids is related to temperature in a parabolic 
manner, with a maximum value occurring at 20-25° (Albert and 
Sergeant, 1971) . If the assumption is made that this is also 
true for SSA, then the observed pKa values of 3.45 and 9.83 
(See Table 2.7.2) will decrease over the temperature range at
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which solubility was determined. Thus the relative change in 
the proportions of ionised to unionised SSA as the temperature 
is raised will be more significant in O.lN HCl at pH 1.0 than 
in water where a saturated solution of SSA has a pH very close 
to its pKa.
Another possible factor is that of drug stability since if a 
significant amount of salicylic acid is present it could 
interfere with the specificity of the SSA assay. This is 
unlikely since under conditions of high agitation intensity 
saturation solubility was achieved within 45 minutes whereas 
at pH 3.12 at 70° the t^^^ for SSA hydrolysis is 50 minutes 
(calculated using the rate constant interpolated from the 
Arrhenius plot; Fig. 2.9.4). Therefore, even though hydrolysis 
may have occurred the salicylic acid liberated would not have 
significantly interfe: red with the SSA assay.
The potentiometric determination of the ionisation constants 
of SSA resulted in the production of a titration curve that 
deviated from being truely sigmoid in shape (See Fig. 2.7.1). 
Although the ultraviolet spectrophotometric method provided a 
sensitive technique for pKa measurement, some of the factors 
contributing to the deviation from the sigmoid shape of the 
titration curve warrant discussion.
The potentiometric determination of ionisation constants, 
although capable of being both rapid and accurate is prone to 
errors associated with temperature fluctuations affecting 
electrode response, the presence of carbon dioxide in the
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alkali titre and low drug solubility. The first two criteria 
are readily controlled by the respective use of a constant 
temperature environment and by the preparation and maintenance 
of COg-free potassium or sodium hydroxide. However, drug 
solubility can place severe restrictions on the accuracy of 
this method since it has been suggested that a 0.0IM drug 
concentration is an optimum for accurate pKa values without 
incurring the necessity for activity corrections (Albert and 
Sergeant, 1971). While recommending the use of O.OlM drug 
solutions these authors, based on their own experience, 
indicated that more dilute solutions could be used provided 
the negative logarithm of their molar concentration was not 
less than the expected pKa. Thus, a O.OOOlM solution of SSA
would be unsuitable if the pKa is less than 4. SSA solubility
o - 1at 25 (approximately lOOyuvg.ml. , or 0.0004M; taken from
Fig. 2.6.2) is bordering on the limits of this recommended 
dilution and the accuracy of the value obtained might be 
poor and imprecise since no definite neutralization point 
could be found (See Fig. 2.7.1). The use of a saturated 
solution is in itself another possible cause of error because 
a fall in the temperature of the solution after its 
preparation would result in precipitation of the drug. If this 
occurs prior to the commencement of the titration then any 
precipitated material would redissolve and produce a shallowing 
of, or a shoulder on the potentiometric curve. Even though 
no obvious signs of precipitation were seen the possibility of 
its occurrence and the formation of submicron crystals cannot 
be ruled out.
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A further contributory factor could be that during the 
determination 2 molar equivalents of salicylic acid are formed 
by SSA hydrolysis, these would require a greater volume of 
titre for their neutralization thereby shallowing the poten- 
tiometric curve. This is unlikely since the experiments were 
performed within half an hour whereas the t^^^ at 25° in 
solution at pH 8.15 is 700 minutes (k value interpolated from 
Fig. 2.9.4).
It is probable therefore that the inaccuracy of the poten- 
tiometric method was a consequence of low drug concentration 
and possible precipitation. Furthermore it is unlikely that 
this method would have been able to describe the ionisation 
of the phenolic-hydroxyl group without using a stronger alkali 
titre which would have undoubtedly increased the likelihood 
of significant SSA hydrolysis.
4.3 BIOPHARMACEUTICAL CONSIDERATIONS RELEVANT TO SSA
With drugs where absorption is not permeability-limited it is 
believed that the rate of absorption is dictated by the 
concentration of the drug present in solution at the membrane 
surface in the non-ionised, lipophilic form. The degree of 
ionisation under in vivo conditions (determined by the 
Henderson-Hasselbalch equation(8^ is a function of the 
gastro-intestinal pH and drug pKa. SSA has been shown to 
possess two ionisation constants and to exist as three possible 
chemical species. pK^ and pK^ values of 3.45 and 9.83, 
respectively, have been determined in this study (See 2.7.2). 
Since the environmental pH of any physiological fluid will
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rarely exceed pH 8.0, the bi-ionic species of SSA will not be 
found in vivo to any significant extent. However, under the 
acidic conditions prevailing in the stomach (pH 0.5-2.5) SSA 
would be present predominantly as the non-ionised moiety 
(99.6% at pH 1.0) and, as the intralumenal pH increased through 
the small into the large intestine, then the mono-ionic species 
would become predominant; ie at pH 7.4 SSA would be approximately 
99.9% as the mono-ion.
The octanol/O.lN HCl partition coefficient (See 2.8) showedA
the non-ionised species of SSA to be freely lipid soluble 
at 37°; K = 44.6. It could therefore be anticipated that the 
drug would be readily absorbed from solution in the stomach. 
Furthermore, as the pH increases along the gastro-intestinal 
tract then, according to strict interpretation of the pH- 
partition hypothesis, absorption would be expected to decrease 
due to a reduction in the prevalence of the absorbable moiety. 
This assumes that changes in the surface area of the various 
regions of the gut will not be a determining factor in the 
overall rate and extent of absorption and clearly this will not 
be the case (See 1). It can be expected, therefore, that SSA 
absorption, like that of salicylic acid (Schanker et al, 1957; 
1958), would occur throughout the entire length of the 
alimentary tract provided that some fraction of the drug, 
however small, is present as the non-ionised form. Absorption 
would then only be limited by a slow or delayed dissolution and 
other formulatory influences.
Following characterisation of the dissolution apparatus, studies
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on SSA show that the dissolution rate in O.lN HCl containing 
5x10 w/v polysorbate 80 at 37° is a function of particle 
size, manifested as a linear relationship with BET surface 
area (Fig. 2.11.4). The unexpectedly low dissolution rate of 
the micronized material may be ascribed to a decrease in the 
effective surface area for dissolution resulting from the 
formation of aggregates that were observed to persist for the 
duration of the experiments despite the incorporation of a 
wetting agent into the dissolution medium. Similar effects 
have been observed for the dissolution of griseofulvin and 
glutethamide by Lin et al (1968) who put forward two possible 
explanations for this effect. Firstly,they suggested that 
adsorption op air resulting from jet-mill micronization 
techniques might ultimately increase the hydrophobic nature of 
the powder and, secondly, that an increase in the 
interparticulate binding force might result from an electro­
static charge being imparted to the powder particles. This 
latter effect is the more likely since these same authors 
reported an increase in the electrostatic charge of powders to 
be a consequence of increasing surface area through particle 
size reduction.
It may have been possible, however, to overcome the formation 
of aggregates by increasing the polysorbate 80 concentration 
and/or the agitation intensity within the dissolution vessel, 
although these were not investigated. Any possible 
interference by salicylic acid resulting from SSA hydrolysis 
that occurred during the dissolution studies was negligible 
over the 2-6 hour period employed; as at 50° the t^^^ in
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-7 - 1O.lN HCl is approximately 42 hours, (k = 7x10 sec , obtained 
by interpolation from Fig. 2.9.3) ; therefore after 6 hours at 
50° 2% hydrolysis would have occurred, a value which would be 
reduced at 37°, the temperature used for dissolution rate 
determinations.
4.4 BIOPHARMACEUTICAL STUDIES
Since in all studies SSA Was administered either as a solution, 
suspension or in capsules some comment is required both on the 
stability of the drug in these formulations and in the 
alimentary fluids prior to its absorption.
4.4.1 DEGRADATION OF SSA AND SSA FORMULATIONS
All aqueous dosage forms were administered within 15 minutes 
of their preparation; therefore the extent of hydrolysis 
within that period can be considered to be negligible. The 
stability studies reported in this thesis give no direct 
information regarding the stability of SSA powders over 
extended periods of time, except that in the complete absence 
of water vapour, hydrolysis will not occur. This is a 
difficult situation to attain and it can be assumed that SSA, 
like aspirin, will gradually degrade if stored in the presence 
of water vapour. Hydrolysis on storage has been demonstrated 
by Hanzlik and Presho (1925) who showed a highly significant 
positive reaction with ferric reagent for SSA that had stood 
in the laboratory for two years, whereas a freshly prepared 
sample showed no colour change at all. These results, although 
purely qualitative, are indicative of significant degradation 
and for this reason SSA and all SSA formulations were stored
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in closed jars in a desiccator over phosphorous pentoxide.
4.4.2 DEGRADATION OF SSA IN VIVO
The concentration and time course of salicylate in the blood 
will be dependent upon two interacting factors: the rate
of absorption and the rate of elimination. SSA absorption as 
the unchanged drug may be influenced by the extent of its 
hydrolysis within the gastro-intestinal lumen and the 
bioavailability would be severely reduced if appreciable in
vivo degradation occurs. This has been shown for digoxin 
(Gault^ 1977) and is known to occur for aspirin (Levy and 
Angelino, 1968). However, the relatively slow rate of SSA 
hydrolysis under alimentary conditions cannot be expected to 
be a significant factor in determining the rate or extent of 
the appearance of salicylate in the plasma. Hanzlik and 
Presho (1925) have shown that 1.5% of a solution of SSA is 
hydrolysed after 24 hours at pH 6.0 and 38° and that both 
'pancreatine' and 'fresh beef bile' had a protective effect, 
retarding the liberation of salicylic acid. The conclusions 
of these authors were that the extent of intralumenal hydrolysis 
was negligible and although this is supported by the studies 
in this thesis it does not necessarily imply that the drug 
appearing in the systemic circulation is wholly unchanged since 
enzyme-mediated metabolism may occur during its passage across 
the gastro-intestinal mucosa, through the liver or within the 
vascular fluids of distribution. Transmucosal metabolism has 
been demonstrated for other salicylate esters such as 
Benorylate (Humphreys and Smy, 1975) and aspirin (Levy and 
Angelino, 1968). Similarly transmucosal conjugation of benzoic
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acid with glycine CStrahi and Barr, 1971) and Salicylamide 
conjugation with glucuronic acid (Barr and Riegelman, 1970) 
further imply that metabolism may occur during the passage of 
SSA across the intestinal barriers.
Some drugs, ie aspirin (Harris and Riegelman, 1969) and 
lignocaine (Boyes et al, 1970), although well absorbed from 
the gastro-intestinal tract, exhibit poor systemic availability 
of the unchanged drug due to considerable metabolism occurring 
during passage through the liver. Such first pass effects 
for aspirin have been shown to account for a 32% loss of the 
drug following its oral absorption (Rowland et al, 1972) and, 
together with vascular and extravascular esterase hydrolysis, 
may account for its rapid elimination and the low amount of 
unchanged aspirin (1-2%) found in the urine (Cummings and 
King, 1966). In view of these observations for aspirin, the 
indications are that SSA hepatic clearance, vascular and 
extravascular degradation and elimination are less rapid than 
for aspirin and could provide an explanation for the prolonged 
salicylate levels in the blood and the presence of approximately 
1 0% of unchanged drug in the urine following its oral 
administration (Hanzlik and Presho, 1925; Nordqvist et al,
1965).
4.5 SOLUBILITY AND IN VIVO PRECIPITATION
The initial urinary excretion studies in man demonstrated that 
SSA absorption from solution was rapid, albeit incomplete, and 
that the inter-subject variation in the apparent first order 
elimination rate constants was low (coefficient of variation =
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4.4%). However, when the same dose was given in capsules 
containing 150-180^m particle size material the urinary 
elimination rates for the same group of subjects showed 
greater inter-subject variation (coefficient of variation = 
1 1 .1%) even though the extents of salicylate absorption from 
both formulations were not significantly different * 55-f 1 and 
57^3% dose for the solution and capsule respectively, values 
taken from Table 3.2.6 .
The equal, albeit incomplete, bioavailability of SSA following 
its oral administration in solution and capsules could be due 
to permeability - or dissolution rate-limited absorption. The 
latter may be a consequence of precipitation of the drug from 
solution on the one hand and incomplete dissolution from the 
solid material on the other. Permeability-limited absorption
can be discounted for two reasons. Firstly there is no reported 
evidence of such behaviour for other salicylates, and secondly, 
although rat studies with SSA have shown incomplete absorption 
from solution, 100% bioavailability was observed for the SSAzCA 
1:1 coprecipitate and admixture (See 3.3.17). This latter 
effect cannot be solely associated with bile salt induced 
changes in membrane permeability, since other SSA:CA and 
SSA:DOCA systems did not show similar effects, and was 
attributed to an increased dissolution rate shown to be 
peculiar to the SSA:CA 1:1 molar ratio formulations (See 
2.13.5) .
The proposed argument for incomplete absorption of SSA from 
solution is the occurrence of precipitation of the drug in the
3 19
gastric fluids. Such an argument is based on recrystallization 
studies carried out in vitro (See 2.10), where SSA was observed 
to precipitate from solutions of its sodium salt upon entering 
simulated gastric environments. Precipitates formed in human 
gastric juice and simulated gastric juice were of much smaller 
size than those produced in O.lN HCl under identical conditions 
(See Fig. 2.10.3). These results for SSA and others reported 
in the literature for phenobarbitone sodium (Finholt and 
Solvang, 196^ . suggest that some component of the gastric
fluids may have a mediating effect on crystal growth in vivo. 
The components most likely to fill this role are the colloidal 
mucopolysaccharides and glycoproteins which comprise the mucin 
present in the gastric environment. This inhibitory effect of 
colloids and high molecular weight polymers is commonly used to 
retard and even prevent crystal growth and polymorphic 
transition in suspensions containing crystalline and/or 
amorphous substances (Mullins and Macek, I960; Corrigan and 
Timoney, 1974; Stupak et al, 1974; Migazaki et al, 1976; 
Simonelli et al, 1970). Indeed, the majority of these authors 
have shown PVP to be one of the most effective agents for 
preventing crystal growth and it was therefore investigated 
with respect to its influence on SSA precipitation in the 
in vitro simulated system. Fig. 2.10.3 shows that SSA crystals 
produced in the presence of 0.1 and 2% w/v PVP were much .
feuoer . and angular than those for either the gastric fluid 
or O.lN HCl. These observations for PVP suggest that in vivo 
precipitation of SSA may be prevented by the incorporation of 
PVP into the formulated solution, thereby increasing its 
absorption, although this was not investigated in vivo.
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The low coefficient of variation (4.4%) for the first order 
elimination rate constants obtained from the urinary excretion 
data for the solution may possibly be explained by the fact 
that all subjects were observing a strict experimental protocol, 
under which variations in gastric fluid volume, contents, pH, 
movement etc would be minimal. Thus if precipitation has 
occurred the variation in the extent and time course of 
recrystallizatidn arid subsequent rêdissolutiôn would also be 
minimal, whereas the higher inter-subject variation shown for 
the 150-180yuvm particle size material (coefficient of variation 
1 1 .1 %) is indicative of an erratic rate of absorption and 
probably reflects incomplete and irregular dissolution of the 
larger particles.
Possible polymorphic changes in the in vivo precipitates should 
be considered as a further complicating factor since if formed 
they may have different intrinsic solubilities or dissolution 
rates than the parent material. However, X-ray diffraction 
studies on the SSA precipitates formed in O.lN HCl, human and 
simulated gastric juice and PVP solutions did not show any 
differences in their X-ray diffraction pattern from the 
original material and from each other (See Fig. 2.10.4). This 
suggests that although crystal growth in each system is 
affected by the medium the resultant crystals differ only in 
their habit and not their crystalline structure.
It has previously been proposed that drugs possessing a narrow 
therapeutic index and dissolution rate-limited absorption, eg 
digoxin, will manifest therapeutic inconsistencies associated
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with variable absorption. For compounds, such as the 
salicylates, where the therapeutic index is high, problems of 
toxicity will not be as acute* indeed, for chronic rheumatic 
conditions where prolonged administration is necessary, small 
deviations in bioavailability will induce little change in the 
overall therapeutic efficiency. In spite of this, it is 
desirable that as complete and reproducible an absorption as 
possible should occur for all drugs (except those exerting 
local effects within the gut). The need for this is 
exemplified by the barbiturates which are known to have a 
narrow therapeutic index and which exhibit variable absorption 
that can often instigate the self-administration of a second 
and toxic dose following an initial one ineffective in its 
sedative action due to a delayed absorption.
The possibility of gastro-intestinal precipitation may be of 
further consequence when considering a drug solution as a 
reference for the assessment of oral bioavailability in the 
absence of an intravenous standard. All guide lines for 
measurement of drug availability advocate the oral 
administration of a solution where drug solubility, toxicity 
or ethical factors prohibit its intravenous injection (eg. 
Notari, 1975; Wagner, 1975). The studies with SSA and other 
sparingly soluble drugs have shown that precipitation can occur 
following their oral administration in solution as a soluble 
salt which may result in an unexpectedly low and incomplete 
absorption. It can be anticipated therefore, that other 
compounds may exhibit similar behaviour and that the rate and 
extent of their in vivo precipitation may be greatly influenced
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by the gastro-intestinal environment such that, where 
significant precipitation occurs, a large inter-subject 
variation in absorption can be expected. If this is the case, 
then the oral bioavailability standard may be better served by 
administration of a homogeneous suspension of a known particle 
size distribution. One such case is that for the oral solution 
of reserpine employed by Stupak and Bates (1973) as a standard 
for estimating the bioavailability of reserpine coprecipitates. 
They attributed an unexpectedly low availability of the drug in 
solution to its precipitation in the intestine (reserpine being 
a basic drug). This phenomenon may also provide a further 
interpretation of the variable human absorption rates of 
aspirin from solution, over and above those of physiological 
origin postulated by Rowland et al (1972).
4.6 SALIVA AND PLASMA CORRELATION STUDIES
Studies designed to demonstrate a correlation in salicylate 
concentrations in plasma and saliva produced data that showed 
a time related change in their concentration ratios. (See 
Figs. 3.2.11, 12 and 14). This change was associated with 
the fact that the times of peak salicylate concentration for 
plasma and saliva were not identical and that a stable 
correlation between the two compartments was only achieved 
during the elimination phase, ie. post peak.
A true correlation between salicylate concentrations in the 
saliva and plasma will only be obtained if the concentrations 
measured in each compartment represent the fraction of the 
drug that is freely available to be transferred across the
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glandular epithelium. The protein-bound fraction within the 
plasma is not able to freely pass into the saliva so that any 
displacement of that bound fraction during assay would incur 
an erroneously high and perhaps variable value for transferable 
salicylate. The protein binding of salicylate will be subject 
to alteration for a variety of reasons. The relative proportions 
of unchanged drug and its various metabolites will be altered 
by continuing absorptive, metabolic and excretory processes, 
and, if concentrations permit may exhibit competition for the 
albuniin binding sites since each moiety will have different 
binding characteristics. Furthermore, since the extent of 
partitioning into saliva will be a reflection of the extent 
of protein binding the experimentally measured concentrations 
in saliva and plasma could be in error if, during the assay 
bound material, or a fraction of it, is displaced in such a 
manner that the displacement is preferential for a particular 
salicylate(s) present. It would also seem probable that 
binding of SSA and its metabolites may be dose/concentration- 
related since unbound plasma salicylate has been shown to 
increase with dose (Smith et al, 1946) and urinary elimination 
of salicylate decreases with an increase in plasma protein 
concentration (Hollister and Levy, 1965).
It would therefore, appear that the time related change in the
saliva:plasma concentration ratio could be associated with
alterations in plasma protein binding, particularly, those that
may occur during storage d.f experimentally obtained plasma 
osamples at -15 , their acidification with 4N HCl or during 
the extraction process into ether. In view of this more
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information is needed before saliva can be inferentially 
used to fully describe salicylate disposition following 
administration of SSA. The most obvious answer would be to 
specifically determine the unbound SSA in both physiological 
compartments.
The comparability of salicylate elimination rates, determined 
for the higher dose from saliva and urinary excretion data, has 
been established for SSA (See 3.2.6) and for sodium salicylate 
(Page et al, 1974), and indicates that saliva, while prone to 
contamination from certain food-stuffs and dosage forms etc, 
is capable of providing an adequate description of salicylate 
elimination. Furthermore, providing the complete elucidation 
of the problems associated with plasma assays and protein 
binding behaviour has been achieved, saliva will adequately 
describe drug absorption; bioavailability data could then be 
calculated with some degree of confidence. Regarding this 
last point, AUC data fojc saliva following intravenous drug 
administration would provide an absolute availability standard 
for comparison.
Following oral administration of aspirin to man some subjects 
displayed secondary and even tertiary peaks on the saliva 
salicylate profiles at times where meals had been taken (See 
Fig. 3.2). The phenomenon of changes in drug absorption in 
the presence of food and under fasting conditions is well 
recognised and reviewed elsewhere (Wagner, 1971; Notari, 1975; 
Gibaldi, 1971; among others). Enhancement of drug absorption 
associated with food intake can result from several, often
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interacting, physiological and physicochemical processes. 
Physiological considerations include in gastro­
intestinal motility, fluid secretions, bile flow and mesenteric 
blood flow. Probably the major influences are those of gastric 
emptying, resulting in unabsorbed drug moving into the small 
intestine where an increase in pH will promote dissolution and 
an increase in mesenteric blood flow q,nd absorptive surface 
area will enhance the rate of absorption. Elementary Pavlovian 
reflex mechanisms will raise saliva flow which may promote 
salicylate transfer into the saliva and thereby increase the 
concentration, albeit transiently. However, salicylate transfer 
into the parotid salivary glands of the dog has been shown 
not to be influenced by saliva flow rate (Borzelleca and 
Putney, 1970). Furthermore, such an effect would have been 
observed in all subjects and would have resulted in a much 
greater intra- and inter-subject variation than was observed 
since the salivating ability of each subject varied. Although 
aspirin was given in solution in 300, 600, and 900 mg doses, 
in vivo precipitation cannot be ruled out and since the 
mid-profile peaks were only manifested by Subjects receiving 
the two higher doses they could be attributed to a promoted 
redissolution of any precipitated material by the mechanisms 
previously discussed.
Urinary excretion studies in man presented in this thesis are 
conflicting in that for an oral dose of 60 mg SSA given in 
solutions and in capsules the percentages of the dose excreted 
after 24 hours were 55^1% and 57-̂ 3% respectively whereas, at a 
higher dose of 600 mg, given as micronized material in capsules.
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a mean value of 32+4% was obtained (See 3.2.3 and 3.2.5). 
Although at the lower dose the observed percentage excreted 
agrees with those of 52% and 55-75% quoted in the literature 
for SSA doses of 1-12 g (Hanzlik and Presho, 1925; Bastide,
1955), no explanation, other than a genuine decrease in 
absorption for the encapsulated micronized material at the 
higher dose can be offered. This conclusion is based on the 
observations of Newton and Rowley (1970) who filled different 
particle size ranges of a poorly soluble drug into capsules 
at a known porosity. They measured the dissolution rate of 
the drug and found that at any given porosity the faster 
dissolution rate was obtained with the larger particle size 
material. They attributed this to a reduction in the effective 
surface area of the finer particles available to the dissolution 
medium and associated it with the packing of the capsules. 
Similarly, Aguiar et al. (1967) have studied this phenomenon 
and showed that the greater the compaction inside the capsule 
the poorer the dissolution rate; this problem was more 
significant with poorly soluble drugs. The reduced 
bioavailability of SSA from the 600 mg dose in comparison to 
the 60 mg dose could, therefore, be explained in terms of the 
extent of packing and particle size since the larger dose 
consisted of micronized material firmly packed into two Size 0 
hard gelatin capsules whereas the smaller 60 mg dose of 
150-180jiAm particle size was loosely contained in a single 
Size 0 capsule.
Elimination half lives for total salicylate have been reported 
in the literature for SSA following its oral administration.
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In a study using a single subject urinary excretion data 
represented as a 'Sigma minus' plot gave a t^ of 4.55 hours 
(Bastide, 1955) and a mean elimination half life of 7.8 hours 
(range 6.54-9.63) has been calculated using plasma salicylate 
concentration data from 9 subjects each receiving an oral dose 
of 500 mg SSA (Nordqvist et al, 1965). Both studies suggest 
that the half lives of 4.95 and 5.77 hours for LS and NS 
calculated from plasma data obtained in this work represent 
the trwe elimination rate although this cannot be categorically 
stated since the data points used in their determination were 
not unequivocally shown to completely describe the terminal 
elimination phase.
4.7 RAT STUDIES
Studies in the rat with SSA were carried out initially to 
describe the influences of route of administration, dose and 
oral vehicle on the disposition of salicylate, and subsequently 
to investigate the influence of particle size and coprecipitation 
of SSA with PVP, CA and DOCA on the rate and extent of 
absorption.
The assessment of drug bioavailability was achieved by comparing 
the AUC for the test dosage form with those for either an 
equivalent intravenous or oral standard, to give absolute or 
relative values respectively. Before reviewing the results 
and drawing conclusions from these studies several aspects of 
the experimental protocol and treatment of the data warrant 
discussion.
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4.7.1 THE EXPERIMENTAL PROTOCOL
The number of blood samples taken from each animal over the
course of a single experiment can account for up to a 9 ml
volume. If this was removed as a single entity the haemo-
dynamic condition of the animal would be dramatically affected,
resulting in hypotension, changes in blood distribution and
acute distress. Assuming a 500 g body weight, the total blood
volume can be calculated to be approximately 27 ml (ie.
- 154 ml.kg. : a mean figure taken from Altman, 1961). Therefore 
over a 24 hour period up to one third of the original blood 
volume may have been removed. However, although the 
haematocrit can be expected to decrease the total plasma volume 
and protein concentration may not alter significantly since 
normal physiological control mechanisms will rapidly replace 
body water by increasing fluid intake and, replace protein by 
promotion of the appropriate liver enzyme systems.
Comparing various haematological parameters of blood samples,
obtained by cardiac puncture and from the tail of the rat,
Upton and Morgan (1975) have shown that tail blood gave
consistently higher haematocrit and haemoglobin values. They
further showed that manually-restrained animals gave higher
levels of haemoglobin, plasma protein and haematocrit than
those animals restrained by ether (gaseous), pentobarbitone
- 1sodium (5 mg. 100 g , ip) or fentanyl-droperidol (0.1 ml 
-1100 g , im). The conclusions drawn from this suggest that the 
stress induced by manual restraint reduces plasma water and 
that the site of sampling will influence the haematocrit and 
haemoglobin levels. Unfortunately these authors did not
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investigate the influence of repeated sampling from the tail 
on these parameters, which can be expected to decrease in a 
manner dictated by the frequency and size of sampling and may, 
therefore, induce complicating changes in drug disposition. 
Decreases in blood volume may cause secondary compensatory 
alterations in the distribution of inter- and extra-cellular 
fluids to an extent that pharmacokinetic compartmental volumes 
of distribution may change in a timè-rélàtéd fashion. An 
example of such a change is an increase in the volume of 
distribution of lignocaine in the rhesus monkey induced by 
raising cardiac output with isoprenaline, and a reduction in 
the volume following haemorrhage (Benowitz et al, 1974). From 
these considerations it would be expected that changes in 
salicylate disposition would result from alteration of the 
integrity of the blood. However, a method for repeated blood 
sampling in the conscious rat has been reported (Agrelo and 
Miliozzi, 1974) where replacement of six 1 ml blood samples 
(taken from 100-250 g rats) with whole blood from a donor 
animal or with saline did not produce any significant change in 
the disposition of intravenously-administered quinidine 
sulphate. Both profiles were indistinguishable from each 
other and from a profile composed of single samples, ie, one 
sample per animal only.
Since the same experimental protocol was adopted for each of 
the studies on SSA the changes in blood integrity, if 
significant, can be expected to be similar and will not distract 
from their comparability. There was one study, however, where 
in an attempt to describe the compartmental distribution of
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-1salicylate following a low (2.5 mg.kg. ) intravenous dose,
fifteen blood samples were taken over a five hour period. It
is interesting to note that the apparent first order elimination
rate constants calculated from the data (See Fig. 3.3.4 and
Table 3.3.5) were significantly higher than those for the other
intravenous doses, and may, therefore, be a direct consequence
of changes in salicylate protein binding and compartmental
distribution resulting from an excessive reduction in plasma
protein concentration and body water. Both of these parameters
can be expected to promote the renal clearance of the drug
and could account for the increased K . values.el '
4.7.2 TREATMENT OF PLASMA LEVEL DATA
The two main parameters used to assess the influences of a 
formulatory change on SSA absorption have been the area under 
the curve (AUC) of the plasma level profile and the apparent 
first order elimination rate constant (K^^^. When drug 
disposition can be accurately described by a simple 
compartmental open model where all transfer processes are first 
order then the AUC and values can be calculated using the 
appropriate differential equation(s). In the situation where 
the capacity-limited and first order processes occur in 
conjunction with an inadequately-defined compartmental model 
and, where no suitable computerized analytical method is 
available, then AUC and values for a specific dose can be 
calculated by graphical means. The AUC and data presented 
in this thesis were consequently calculated from the profiles 
for individual animals and are presented with their mean and 
standard errors.
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4.7.3 ELIMINATION RATE CONSTANTS
The number of points that describe the linear terminal phase 
of a plasma salicylate concentration (log scale) time plot 
will automatically determine the accuracy of any derived rate 
constants. In most cases this terminal phase was composed of 
4-7 data points although in some instances there was no 
apparently linear section readily distinguishable. However, 
where values are quoted at least three data points were 
used in their calculation. For some studies the points defining 
a linear section were obvious whereas for the greater proportion 
there was a large subjective element in deciding which points 
to include and which to exclude, particularly at the beginning 
of the terminal phase where the curvature of the zero order 
data on a log scale merges with the first order data or where 
absorption is still occurring.
All elimination rate constants (mean ^  SE) obtained throughout 
these studies are collated in Table 4.1. Most of these values 
are similar and variance ratio analysis carried out for each 
series of studies show that salicylate elimination is not 
significantly influenced by formulation, dose or route of 
administration. Several exceptions do, however, exist (denoted 
by an asterisk in Table 4.1) and will be commented on separately.
- 1-2.5 mg.kg. , iv. A possible explanation for the increased
rate of elimination observed in this study has already been
\
discussed as part of the experimental protocol (See 4.7.1).
-150-180yAm particle size, 20 mg.kg. ^, po. Although the
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Table 4.1 Collated mean (+ SE) Apparent First Order Elimination
Rate Constants (K , ) From All Rat Studies el
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variance ratio analysis data given in Table 3.3.17 for the
values does not show a significant influence due to particle
size, the associated variance is greater than that of animal
origin and the Student 't ' test analysis between particle size
treatments (Table 3.3.15) shows the K , values for theel
150-180y\m material to be significantly less than for all other 
particle sizes. This difference is readily apparent by 
examination of Fig. 3.3.19. The probable explanation for the
lower value is also apparent from closer examination of the 
data points describing the terminal elimination phase for the 
larger particle size study. The terminal linear phase of the 
first order plot is ill-defined since the last samples plotted 
were taken well before the limits of the assay were reached and 
therefore describe salicylate disposition that may not 
necessarily be that for first order elimination. Even though, 
the variance ratio analysis suggested that the larger particle 
influences elimination, and the Student 't' test shows it to 
be significantly different from all other particle sizes, it 
cannot be inferred that the size of the material was directly 
responsible for the anomalous result. It should be pointed 
out, however, that in all the other cases where values are 
given, the first order plots from which they were calculated 
had all reached the limits of the salicylate assay.
-SSA:DOCA 2:1 coprecipitate and 1:1 coprecipitate and 
admixture. Student's 't' test comparison between the SSA:DOCA 
systems and with SSA alone has been given in Table 3.3.46, from 
which the following decreasing rank-order can be defined, 
where the bars show no significant difference in data
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decreasing
SSA SSA:DOCA SSA:DOCA SSA:DOCA SSA:DOCA
alone 2 : 1 1 : 1 2 : 1 1: 1
#- Adm Adm Cop Cop
I------------------------------   1
■i
The influence of a large intestinal presence of bile acids is
known to result in significant decreases in both electrolyte
^ —  —(K , Na , Cl , HCOg ) and water transport across the intestinal
mucosa and it is also known that this effect is more severe 
with deoxycholic than cholic acid (Mekhjian and Phillips,
1970). The difference in effect between the two bile acids 
has been attributed, by the previous authors, to the fact that 
the deoxycholic acid absorption from the colon occurs at twice 
the rate of that for cholic acid. If this is so, then the bile 
acid could be present in toxic concentrations within the 
systemic circulation and changes in electrolyte and water flux 
observed for the intestinal epithelia may then occur in the 
nephron to such an extent that similar decreases in electrolyte 
and water transport ensue; ie, their passage into the urine 
decreases producing a reduction in urine flow and pH, thereby 
retarding salicylate elimination. Deoxycholic acid has been 
demonstrated to reduce the activity of the intestinal mucosal 
sodium- and potassium-ATPase (Gracey et al, 1973); consequently 
the renal activity of this enzyme can be expected to be reduced 
when the bile acid is present in toxic concentrations. Such 
a reduction in ATPase activity would decrease the active
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tubular secretion of salicylate, especially since glycine 
conjugates are excreted via this mechanism (Schachter and 
Manis, 1958).
Another metabolic effect of deoxycholic acid on salicylate 
elimination is the possible competition between salicylate and 
DOCA for enzymatic conjugation with glycine. Salicylate concen­
trations in the urine account for up to.80% of a dose of sodium 
salicylate so that a reduction in the rate of its formation may 
be reflected by a reduction in the overall elimination rate 
constant.
One further feature of interest in Table 4.1 is the lack of 
effect of ethanol (used as a cosolvent for the intravenous 
studies) since it is known to promote drug elimination via its 
diuretic action. The total amount administered in the i.v. 
bolus was obviously insufficient to effect such a change.
4.7.4 AREA UNDER THE CURVE
Precise calculation of the area under the plasma level curve 
Ccin only be achieved by integration (between t^ and to») of the 
appropriate differential equation(s) shown to completely describe 
the disposition of the drug. Previous comment has been made 
regarding the complexities of obtaining and solving this type 
of equation when parallel capacity-limited and first order 
processes occur (See 3.1) and it was therefore necessary to 
resort to using either gravimetric, planimetric or trapezoidal 
techniques for determining the area. The accuracy of these 
methods depends on there being sufficient data points 
to completely define the profile and errors in AUC
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values calculated using these methods can be expected if the 
data points are themselves in error, or if significant sections 
of the profile are ill-defined. This last factor is 
particularly important for the absorptive phase following oral 
administration or the distributive and terminal phases for all 
routes. For precise and accurate values the terminal 
elimination phase should be extrapolated to infinite time 
although in the method employed in these studies the profiles 
were extrapolated to the time where the limits of the assay 
were reached.
The method of comparing AUC for intravenous and oral data to 
gain assessments of % bioavailability assumes that the plasma 
clearance is constant and that the area is a linear function 
of dose. Possible non-linearities in plasma clearance caused 
by excessive blood sampling have been mentioned and can be 
assumed to show little experiment-to-experiment variation since 
the experimental protocol was unaltered throughout. Furthermore, 
even though non-linear sections of the plasma profiles were 
observed after intravenous administration (and used to 
contruct a Lineweaver-Burk plot) their respective AUC values 
were shown to be linearly related to dose following both iv 
and oral administration (See Figs. 3.3.8 and 3.3.14 respectively)
4.8 INFLUENCE OF VEHICLE ON SSA ABSORPTION
SSA has been orally administered to the rat at a dose level of 
-120 mg.kg. in solution and as 75-105yAm particle size material 
suspended in 4% PVA and water. Each of these vehicles produced 
different plasma salicylate profiles (See Figs. 3.3.9 and
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, . . tration
Kgi AUC _ %
(xl0^3min."l (ug.ml. Bioav 
+SE) xmin.) (mean)
Solution 25 (115) 64 (6 6 ) 6.668+0.242 24257 54
4% PVA 100 (390) 54 (58) 5.520+0.505 40532 89
Water 90 (420) 48 (58) 4.280+0.367 37961 84
Table 4.2 Characteristics Of The Plasma Salicylate Profiles
- 1For SSA, 20 mg.kg. PC Given In Solution And 
Suspensions (75-105jxm) in 4% w/v PVA And Water. 
(Figures in parenthesis denote a secondary peak).
One common feature of all three profiles is the appearance of 
a second peak which probably occurs when SSA enters the small 
intestine where the larger absorptive surface area and higher 
intralumenal pH will enhance absorption. The initial peak is 
due to the gastric absorption of SSA present in solution and 
would account for the early peak of higher concentration 
shown when SSA is given wholly in solution. The secondary peak 
for this study could be attributed to in vivo precipitation 
with subsequent incomplete intestinal redissolution as well as 
to physiological changes previously mentioned. A longer time 
gap between the first and second peaks for the suspended
338
formulations would suggest that dissolution was the limiting 
factor rather than gastric emptying since the PVA and aqueous 
vehicles produced similar profiles.
The surprisingly low % bioavailability for the solution could 
not only be a reflection of in vivo precipitation but also an 
elimination rate that is in the upper range of values given in 
Table 4.1 since it could be expected that the buffer salts 
present in the solution would ultimately elevate urinary pH 
thereby promoting salicylate excretion. The presence of the 
potassium cation in the buffer solution may further inhibit 
SSA absorption as has been demonstrated to occur for salicylic 
acid in the everted rat intestine (Mayersohn and Gibaldi, 1970). 
These authors concluded that the reducing effect of (as 
opposed to Na^) was due to an increase in the intestinal tissue 
fluid uptake which ultimately resulted in a decreased drug 
transfer rate. A similar conclusion for salicylate transfer 
has been made by Benet et al. (1971).
4.9 INFLUENCE OF DOSE
The influence of dose on salicylate profiles and AUC following 
intravenous administration has already been described (See 
3.3.9.1).
Following oral administration of SSA, 75-105yu\m particle size, 
at four dosage levels, several features of the resultant 
salicylate profiles (Fig. 3.3.13) other than AUC can be related 
to dose. Plots of the initial peak concentration and time 
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Fig. 4.1 Relationship Between Peak Time (A) And Peak Concentration (B) 
With Dose For Orally Administered SSA, 75-105y4m.
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linearly related suggesting that these parameters can 
justifiably be used to assess changes in the rate of SSA 
absorption in the absence of a suitable mathematical approach. 
The peak times and concentrations were interpolated from 
Fig. 3.3.13, using the first peak if secondary ones were also 
present.
4.10 INFLUENCE OF PARTICLE SIZE
A correlation between the apparent first order dissolution 
rate constant and BET surface area has already been established 
(Fig. 2.11.4) and enforces the concept that SSA would exhibit 
dissolution rate-limited absorption. Such a relationship is 
indeed demonstrated in Fig. 4.2 where the initial peak time 
(log scale) is shown to be linearly related to BET surface area. 
The data used to construct Fig. 4.2 is given in Table 4.3 below.
Particle Size yam) Peak time (mins.) Peak conc. (̂ g.ml. S
Micron 25 (270) 45 (46)
38-53 55 (195) 52 (61)
53-75 70 (220) 51 (51)
75-105 105 (455) 54 (57)
105-150 1 2 0 51
150-180 240 53
Table 4.3 Peak Times And Concentrations For Plasma Salicylate 
Profiles Following Oral Administration Of SSA Of 
Varying Particle Sizes. (Numbers in parenthesis 
denote a second peak).
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BET Surface Area (m^g 10^)
Fig. 4.2 Relationship Between BET Surface Area And Initial Peak Time
(Log Scale) Following Oral Administration Of SSA Of Varying
-1Particle Size Ranges. Dose 20 mg.kg
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The peak salicylate concentration in the plasma does not show 
any obvious dependency on the particle size of the administered 
drug and the AUC data given in Table 3.3.12, although shown by 
the variance ratio test to be influenced by particle size, do 
not lend themselves to any logical explanation since they 
cannot be related to any other feature of their salicylate 
profiles nor to the percentage of the dose excreted determined 
by urinary excretion studies (See 3.3.14).
4.11 SSA BIOAVAILABILITY FROM COPRECIPITATES AND ADMIXTURES WITH 
POLYVINYLPYRROLIDONE (PVP)
Preliminary urinary excretion studies on SSA:PVP coprecipitates 
showed absorption from the 1:5 ratio to be significantly less 
than that for the other SSA:PVP ratios and for SSA alone.
(The 1:10 ratio was not studied) (See 3.3.15). Subsequent 
plasma level studies have further shown the 1:5 SSA:PVP 
coprecipitate, as well as the 1 : 1 0 ratio, to exhibit a lower 
area under the curve in comparison to the pure drug and the 
2:1, 1:1 and 1:2 systems. The bioavailability for each system 
was calculated using the mean AUC value for each in comparison 
to an equivalent intravenous and oral dose and is given in 
Table 4.4.
It is apparent that, even though X-ray diffraction studies 
have shown the SSA:PVP coprecipitates to be amorphous, their 
potential for improving SSA bioavailability was not realized 
in vivo. Ranking of the AUC data shows that for the 2:1 and 
1 : 1 ratios the coprecipitates manifested a larger value than 
their corresponding admixture whereas for the 1:2, 1:5 and
Bioavailability (%)
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AUC vs vsAUC vs
^g.ml. SSA iv SSA po Mg.ml. SSA iv SSA po 
xmin ’ xmin
2:1 38954 85.8 96.1 33159 73.1 81.8
1:1 42139 92.9 103.9 40567 89.4 100.1
1:2 33886 74.7 83.6 40727 89.7 100.5
1:5 28692 63.22 70.8 29761 65.6 73.4
1:10 29406 64.8 72.6 38485 84.8 94.9
-1AUC reference iv 45383 yag.ml. xmin (From Table 3.3.6)
-1AUC reference po 40532^^g.ml. xmin (From Table 3.3.12)
Table 4.4 Bioavailability For SSA:PVP Coprecipitates 
And Admixtures Calculated From Mean AUC 
Data.
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1:10 ratios the order was reversed. (Table 4.5)
SSA:PVP AUC
ratio ranking
2:1 COP ^  ADM
1:1 COP ^  ADM
1: 2 ADM 'y COP
1:5 ADM \  COP
1:10 ADM y  COP
Table 4.5 Ranking Of AUC Data For SSA:PVP Coprecipitates (COP) 
And Admixtures (ADM) For Various Drug:Polymer Ratios
A possible explanation for these results may be obtained by 
consideration of the extensive in vitro studies on sulpha- 
thiazole:PVP coprecipitates reported by Simonelli et al, (1969; 
1976). Based on investigations designed to examine sulpha- 
thiazole and PVP release rates from dissolving coprecipitate 
discs and their transfer using cell diffusion studies, the 
authors came to a general conclusion that, provided drug:PVP 
coprecipitates are amorphous, it can be expected that with an 
increasing drug:PVP ratio the dissolution rate will increase up 
to a critical drug:PVP ratio after which it will fall. Even 
though their studies were performed using compressed discs the 
conclusions may nevertheless be applied to dissolution of 
particulate drug:PVP systems since the mechanisms of dissolution 
will be the same. The plot of AUC vs SSA:PVP ratio, given as
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Fig. 4.3, does show a maximum bioavailability for the 1:1 
coprecipitate with a subsequent decrease for the 1:2, 1:5 and 
1 : 1 0 ratios; this suggests that the in vitro findings for the 
studies on sulphathiazole:PVP systems may provide a valid 
explanation for the results obtained in vivo for SSA:PVP 
coprecipitates. This is further enforced by the observed 
amorphous nature of all the SSA:PVP coprecipitates. Since 
coprecipitation with PVP reduced SSA bioavailability in every 
case, except for the 1 : 1 ratio, a detailed examination of their 
in vitro dissolution and solubility characteristics was not 
performed and may furnish a suggestion for further work.
The amorphous nature of the coprecipitates probably results 
from PVP being in sufficient concentration to form a net-like 
structure around the SSA molecule during solvent evaporation 
thereby preventing nucléation and the formation of a regular 
crystal lattice. This type of behaviour has been assigned to 
the inhibition of sulphathiazole crystal growth in the presence 
of PVP (Simonelli et al, 1970) and is commonly employed to 
stabilize and prevent polymorphic transition with suspensions 
of amorphous substances (Mullins and Macek, 1960). In all cases 
where X-ray diffraction has been employed drug coprecipitates 
with PVP have been shown to be amorphous; this has been 
attributed to be responsible for increased absorption although 
enhanced drug absorption has also been attributed to an increase 
in the surface area of the drug (ie. reduced particle size) 














Fig. 4.3 Relation Between AUC And SSA:PVP Ratio For SSA:PVP 
Coprecipitates And Admixtures
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Examination of the plasma salicylate peak times and 
concentrations (Fig. 4.4) provides a confusing analysis of 
bioavailability from SSA:PVP systems and it can be expected 
that other factors are influential. These factors include the 
effect of vehicle viscosity on drug dissolution, or the 
influence of both viscosity and osmotic pressure within the 
microenvironment of the absorptive membrane and on gastro­
intestinal transit time. For the admixtures there are no 
obvious apparent changes that could be related to with SSA:PVP 
ratio other than the time required to attain the peak 
concentration (Fig. 4.4.B) and this may also be due to changes 
in gastric emptying rate etc, especially for the 1:2, 1:5 and 
1:10 ratios with a proportionately higher PVP content.
The general conclusion from the in vivo absorption studies with 
SSA:PVP systems are that the amorphous nature of the SSA 
within the coprecipitates did not aid its absorption as might 
be expected on theoretical grounds. Coprecipitates and 
admixtures with PVP may, nevertheless, prove beneficial in SSA 
therapy by providing a method for delaying absorption in an 
attempt to prolong its anti-inflammatory/anti-rheumatic action, 
although the potential shown in the rat may not necessarily be 
confirmed in man.
4.12 SSA BIOAVAILABILITY FROM ITS COPRECIPITATES AND ADMIXTURES 
WITH CHOLIC ACID (CA) AND DEOXYCHOLIC ACID (DOCA)
The CA and DOCA systems are discussed as one section since the 
explanation offered for changes in bioavailability are 
applicable to both. Furthermore the gastro-intestinal
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Fig. 4.4 Peak Plasma Salicylate Concentrations (A) And Times (B) 
For SSA:PVP Coprecipitates And Admixtures
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disturbances observed for these bile acids will be contrasted 
and discussed.
Absorption of SSA from both the SSAzCA 1:1 ratio coprecipitate
and admixture was markedly better than that for an equivalent
oral dose of SSA alone and for all other SSA:CA systems.
(Table 3.3.36). The area under the plasma salicylate profile
for each has been given in Tables 3.3.33 and 3.3.34 for the
coprecipitates and admixtures respectively and are further
graphically expressed in Fig. 4.5.A. The AUC values for these
1 : 1 ratios are not significantly different from those for an
equivalent intravenous dose. For 1:1 coprecipitate t^^^ = 1.69;
N = 11; p' = 0.05; t ^ ^  = 2.26: For the 1:1 admixture
t = 1.96; N = 10; p' = 0.05; t. , = 2.31 . The influence of obs ^ tab
SSA:CA formulation on the plasma salicylate peak concentrations 
are shown in Fig. 4.5.B and can be seen to follow the same 
profile as for the respective AUC plot (Fig. 4.5.A). This 
similarity suggests that the enhanced bioavailability results 
from an increase in the dissolution rates of the 1 : 1 systems 
over those for the other SSA:CA systems and SSA alone. This is 
supported by the dissolution behaviour of the SSA:CA systems 
(Fig. 2.13.11) in which both 1:1 formulations show an enhanced 
rate of dissolution over those for the other SSA:CA ratios and 
the pure drug.
Bioavailability for the SSA:CA systems is given in Table 4.6 
where the % available is calculated using AUC data with respect 
to the intravenous standard (Table 3.3.6).
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Fig. 4.5 Relationship Between AUC (A) And Peak Concentration (B) With 




































AUC reference iv 45383^g.ml.”^xmin (From Table 3.3.6)
Table 4.6 Bioavailability For SSAzCA Coprecipitates And 
Admixtures Calculated From Mean AUC Data.
Cholic and deoxycholic acids arç poorly water soluble and it 
can be assumed that in all orally dosed suspensions these bile 
acids were present in excess of their saturation solubility.
Any solubilizing properties will therefore equally occur for 
each formulation ; indeed the saturation solubility of SSA shows 
no difference between any of the SSAzCA ratios whereas each 
bile acid containing system showed a marginal increase in SSA 
solubility over that of the pure drug. (See Table 2.13.6). 
Similarly the wetting properties of cholic acid on the 
permeability of the gastric mucosae, although known to influence 
drug absorption (Bates et al, 1966; Gibaldi and Feldman, 1970;
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among others), will be the same for each system and could not 
account for the increased bioavailability.
The influence of drug coprecipitation with bile acid systems 
on subsequent absorption has been suggested to be mediated 
through an increased surface area of the drug (Malone et al, 
1966; Decato et al, 1969; Stoll et al, 1973): that is to say, 
during the coprecipitation process the bile acid provided a 
large surface area upon which the drug precipitates in a very 
finely-divided form. If during coprecipitation of the 1:1 
ratio SSA and cholic acid combined within the organic solvent 
for from a 1 : 1 molar ratio molecular complex, then on removal 
of the solvent the resultant precipitate may have a differing 
crystal structure than the two original components. Such an 
occurrence, although not substantiated, may account for the 
unique amorphous nature of the SSAzCA 1:1 coprecipitate (Fig. 
2.13.6). This does not, however, account for the improved 
absorption manifested by the 1 : 1 ratio admixture and it must 
therefore be assumed that SSA and cholic acid form a molecular 
complex in solution prior to absorption.
Absorption studies with the SSA:DOCA systems were marred by 
severe gastro-intestinal disturbance; consequently the majority 
of the coprecipitates and admixtures, although prepared and 
characterised, could not be evaluated in vivo. However the 
studies on the 2 : 1 and 1 : 1 systems that were performed show 
that, apart from the 2:1 coprecipitate, all other DOCA- 
containing formulations produced a significant reduction in 
SSA absorption in comparison to SSA alone (See Table 3.3.42 and
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3.3.43). The bioavailability of salicylate from the SSA:DOCA 
formulations is given for each system in Table 4.7; the data 
was calculated with reference to an equivalent intravenous dose 
using AUC values.
Bioavailability (%)











2 : 1 45786 1 0 0 31668 70
1 : 1 28118 62 25963 57
_1AUC reference iv 45383 (pg.ml. xmin) (From Table 3.3.6)
Table 4.7 Bioavailability For SSA:DOCA Coprecipitates And 
Admixtures Calculated From Mean AUC Data.
The poor bioavailability may be a consequence of several 
exacerbating properties of the bile acid, which include the 
solubilization of SSA within a micellar structure, drug:bile 
acid complexation, structural and functional deterioration of 
the gastro-intestinal mucosae and diarrhoea. Gastro-intestinal 
disturbance due to feeding non-physiological amounts of DOCA 
to rats has induced the copious production of liquid light- 
brown stools and ultimately resulted in death. (Shiner, 1969). 
The liquid nature of the stools results from reduced electrolyte
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and water reabsorption from the lower sections of the 
intestine and is more acute following administration of 
deoxycholic than cholic acid (Mekhjian and Phillips, 1970;
Gracey et al, 1973).
The reduced absorption for the SSA:DOCA systems is probably 
due to a combination of increased gastro-intestinal transit 
and impairment of the integrity of the mucosal epithelia 
(especially the villi and microvilli) . Moreover, dissolution 
of nitrofurantoin:deoxycholic acid coprecipitates was faster 
in media at pH 7.4 than at pH 1.0 (Stoll et al, 1973). This 
was attributed to poor DOCA solubility, and could explain the 
lack of an early rise in plasma salicylate levels (before 1 0 0  
minutes) and of secondary peaks since SSA:DOCA coprecipitate 
dissolution in the gastric environment would be small in 
comparison to that in the more alkaline small intestine. This 
would not account for the poor absorption for the SSA:DOCA 
admixtures and it must be assumed that the major influences of 
DOCA on reducing SSA absorption are those of alteration of the 
absorptive properties of the alimentary mucosae, complexation 
and/or increased gut transit associated with diarrhoea. This 
last point is exemplified by the reduced ampicillin absorption 
in subjects suffering with acute shigellosis (Nelson et al, 1972)
It should also be restated that the AUC values calculated for 
the DOCA containing systems may be exaggerated due to reductions 
in the apparent first order elimination rate constant as already 
discussed (See 4.7.2); the changes in AUC will therefore reflect 
the elimination as well as any perturbations in absorption.
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GENERAL CONCLUSIONS AND SUGGESTIONS 
FOR FURTHER WORK
The studies reported in this thesis have shown SSA to be poorly soluble 
and to exhibit dissolution rate-limited absorption. The in vitro 
studies pertaining to physical and chemical characterisation of factors 
influential on its absorption have provided information from which it 
may be concluded that, provided the drug is in solution then its 
absorption will probably occur throughout the entire length of the 
gastro-intestinal tract.
Examination of the bioavailability of SSA from various formulations 
was then performed using the measurement of total salicylate in body 
fluids. The major drawback from such an experimental approach has been 
the inability to describe the compartmental distribution of the drug 
from plasma level data by using the commonly employed techniques of 
'feathering' and subsequent computerised analysis for the elucidation 
of the microconstants associated with absorption, distribution and 
elimination. From a retrospective overview of the in vivo studies it 
is readily apparent that more meaningful information regarding SSA 
bioavailability, absorption rates, etc would have been forthcoming 
had the time been spent in the development of a specific assay for SSA 
and its metabolites in body fluids. The most obvious techniques for 
this are those of gas-liquid chromatography and high pressure liquid 
chromatography. The latter offers the greater potential since it 
would not require the preparation of volatile derivatives, although the 
former would be able to provide a means of identifying metabolites etc 
if linked to a mass spectrometer. Furthermore, the saliva/plasma 
correlation studies would have undoubtedly benefited from a specific
356
assay for SSA, and with such an analytical tool it would have been 
possible to investigate first pass effects on SSA metabolism using 
in situ perfused intestine studies.
The preparation and in vivo evaluation of SSA coprecipitates with 
PVP, CA and DOCA has demonstrated that this type of formulatory 
manoeuvre does not necessarily result in an enhanced absorption and 
that such techniques may show potential for the control of drug 
release over a prolonged time period. The influences of drug coprecip­
itation would be better examined and compared to their physical 
mixtures by in vitro studies designed to monitor the release of both 
components from compressed discs of constant surface area. However, 
in the absence of the necessary apparatus and expertise for this type 
of study it should be put forward as a suggestion for further work, 
that would provide more information on the mechanisms of dissolution 
from experimental formulations than that obtained from studies on 
powders.
The work with PVP leaves open the possibility that other polymers 
may provide greater potential for altering the dissolution rate- 
limited absorption of some drugs since there must be many water soluble 
polymeric systems worthy of investigation.
The use of bile acids as a means of promoting drug bioavailability 
must be equated with the very real hazard of gastro-intestinal 
dyscrasia resulting in diarrhoea. In view of this the potential of 
such systems, although demonstrated in vitro and in vivo for SSA and 
nitrofurantoin (Stoll et al, 1973), must be limited if the drug is to 
be incorporated into formulations that are designed for chronic use.
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Perhaps the use of inert, non-absorbable 'carrier systems', such as 
fumed silica dioxide, as suggested by Monkhouse and Lach (1972a) 





1. LEAST-SQÜARES REGRESSION ANALYSIS
When a linear relationship is assumed to exist between variables 
it is usual to fit a straight line by least-squares regression 
analysis. The simplest statistical model for this assumes that 
the independant variable X is known without error of measurement, 
and that the corresponding measured values of the dependant 
variable Y are scattered normally from their time values. Hence 
each value Yi of the dependant is normally distributed about a 
mean.
The method of least squares obtains estimates of a and b in the 
equation Y = x + bX such that the sum of the squares of the 
deviations of the observations Yi from their mean of oC + jS Xi 
is a minimum.
These values are:-
b = n£xiYi - £  Xi£ Yi n £xi^ - (£,Xi) 2
£  (Xi - X) (Yi - Y) 
£(Xi - X)%
when n is the number of points defining the line,
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l,a Variance of slope (b)
2This is termed Sb and is given by the equation:-
where O  e is the residual sum of variance of the dependant 
variable Y and is obtained from
(n- 2 )
where is the residual sum of squares.
^  T? is obtained from the equation
= ^(Yi - Ÿ)^ - b^ £_(Xi - X)^
The standard error of the slope is given by the square root of 
the variance.
l,b Variance of the Intercept (a)
This is termed Sa^ = £  Xi^ d^e^
n£(Xi - X)2
where (n- 2 )




The correlation coefficient (r) is defined as
f  (Xi - X) (Yi - Ÿ)
(Xi - X)^ (Yi - Ÿ)^
To represent a linear relationship between two variables, X and Y, 
r must be - unity. The calculated value of r is compared with 
the tabulated value at the 5% probability level for n - 2 
degrees of freedom, and, if found to be greater than the 
tabulated value, the observations were considered to be linearly 
related.
2. TO DETERMINE THE EQUALITY OF TWO ESTIMATES OF A PARAMETER
The test is generally known as the Student 't' test. The equality
2 2of estimates P^ and P^ with variances S^ and S^ respectively of a 
parameter P is assessed by means of the following statistic
The value of *t' is compared with tabulated values with n^ + U g - 4 
degrees of freedom where n^ and n^ are the number of observations 
used in the estimation of P^ and P^ respectively. If the 
calculated value of 't ' exceeds the tabulated value at the 5% 
probability level, the parameters are considered to be 
significantly different at that level.
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TO DETERMINE THE EQUALITY OF MORE THAN TWO ESTIMATES OF A 
PARAMETER
This is generally known as the Bartlett Test. When more than one 




/y 2where q  is given by
^  + ....................    .n^s/
"1 + "2 +  "n
where S^ and S^ etc are the standard errors associated with the 
estimates P^, Pg, etc and, n^ and n^ are the number of observa­
tions used in determining the estimates. If the estimates all
come from the same normal distribution, ^(Pi - P)^ will have a
-Y2 3T2distribution with N - 1 degrees of freedom, where N is the
number of estimates.
4. ANALYSIS OF VARIANCE
The contribution to the total variance of a process that is made 
by the variance of each individual component of that process can 
be determined by an Analysis of Variance. Where data can be 
grouped as a series of columns each consisting of a number of 
samples, the analysis of variance enables computation of the 
variance attributable to the differences between columns { ^t?) 
and the variance attributable to the differences within columns
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( £5̂3 ) . This analysis of variance can be calculated as follows, 
and the data tabulated as indicated.
1. Square the individuals and add
2. Obtain the total for each column, square these totals, 
sum these squares and divide the total by the number 
of individuals in each column
3. Obtain the grand total for all individuals, square this 
grand total and divide by the grand total number of 
individuals.
Source of Sum of Degrees of Mean Components
Variance Squares Freedom Square of Variance
Between
Columns 2 - 3 m - 1
2 - 3  
m - 1
Within
Columns 1 - 2 mn — m
1 - 2 
mn - m <^1
Total 1 - 3 mn - 1
Where m is the number of columns
n is the number of individuals in each column
(5 ^̂  is the variance due to differences between columns A
is the variance within columns
To test if the between column variance is significantly greater 
than the within column variance, the ratio (F) of the between 
column mean square of the within column mean square is determined.
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If this value is less than the tabulated value at p' =0.05 with 
m - 1 and mn - m degrees of freedom, then it follows that the 
variance due to differences between columns is not significant.
Analysis of variance was carried out using a computerised system 
that allowed the analysis of data that did not form a complete 
matrix (Nedler, 1973). Missing values were estimated by the 
programme and incorporated into the calculation of the variance. 
All calculations were performed on an ICL system 4 computer at 
the University of Bath, Computer Centre, and the author is most 
grateful to Mr D. G. D. Clark for his considerable assistance.
All tabulated values for the Student 't' test, correlation 
coefficient, ̂  ̂  and analysis of variance were obtained from 
Fisher and Yates ( 1974).
364
APPENDIX II
The determination of ionisation constants by ultra-violet spectro­
photometry depends on the ionic species of the compound exhibiting 
different absorption spectra. If this criterion is satisfied a wave­
length is chosen at which the greatest difference between the 
absorbances of the species is observed. Measurement of absorbance at 
this 'analytical wavelength', at pH values intermediate between those 
at which only one or other of the two species is present, enables the 
ratio of the species to be calculated. Two basic assumptions are made 
in this calculation: firstly, that the total drug concentration
remains constant, and secondly, that both species of the drug obey the 
Beer-Lambert law. Under such conditions the resultant absorbance (A)
will be due to the sum of the absorbances of the ionised (A ) andI
unionised (Â ) species.
i.e. A = A ^ + A  .................................. (50)I u
The absorbance of the unionised species is given by:-
A = Ç  .C.jf .......................................  (51)
U  U
and for the ionised species
Aj. =   (52)
where ^  and are the molar absorbance coefficients for the
unionised and ionised species respectively; C is their concentration 
and J[ the pathlength (taken as 1 cm). Therefore in a mixture of both
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species at a known pH the absorbance at that pH (Apjj) is given by:-
= V u  + V l  .................................  (53)
where f is the fraction unionised or ionised respectively. For the 
ionised species alone the absorbance at the 'analytical wavelength' at 
any measured pH is given by:-
A -  =  (1 -  f;) + 6 1 ^ 1    (54)pH
f'I
= e-u + ((Ei - f:u'
fj. = \ n  " C  u   (55)
Similarly for the unionised alone:-
V  = (1 - V  + f:ufu   (55)
“ é  1 - é  I^u +(6 u^u 
= ^  I + ( è  u -6%)
~ C  I   (57)
6 u
which can be rewritten as?-
5u = 6 1  - » jgH   (58)
- ^ u
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By substitution of the respective fractions for concentrations in the 
Henderson-Hasselbalch equation (8 ) we get;-
pH = pKa + log ^    (59)
fu
and by further substitutions for f^ and f^ and rearrangement
A f—pH = pKa + log pH - ^ u  .........................  (60)
é  I " ^pH
Acceptance of the basic assumptions of constant concentration and the 
adherence of both ionic species to the Beer-Lambert law then:-
é  ^  A and C— o<C Au u ' ^ 1 1
A A
Therefore pH = pKa + log  r—^   (61)
I " pH
A - A
or pKa = pH + log  --- :— ^     (62)
pH “ u
If A „ ' ^ A  equation (62) can be rearranged thuspH / I
A - A
pKa = pH + log — ...     (63)
\
Therefore for a constant concentration the pKa for any ionisation can 
be calculated from the absorbance at a measured pH and knowledge of 
the absorbance for the drug in the totally unionised and ionised forms.
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APPENDIX III
Calculation of the Area Under the Curve (AUC) Using the Trapezoidal 
Rule.
AUC calculations were made using the program given overleaf. The 
program is written in ALGOL and receives raw data from which it 






HEAL AUC,TKI 1 > irC I 2 , SUK FHAP1 
HEAL AKHAY THAP(0 : : 50);
HEAL Ah «AY Y>T/DELTAi<0:;50) j 
START:
HEAD (X)i
IF X=0 THEN GOTO STOP;
HEAD (N);
HEAD (Z);
FOR J:=l STEP 1 UNTIL N DO 
HEAD (T(J),Y(J));




FOH J: = l STEP 1 UNTIL N-l DO 
BEGIN
THAP(J) : = ((Y(J) + Y(J+1) )/2 )*l)ELTAT( J+I ) ;
END;
SUMTRAP:=0. O;
FOH J:=l STEP 1 UNTIL N-l DO 
BEGIN
SUMTHAP : =S'JNTHAP + TRAP ( J ) ;
END;
AUC:=SUMFHAP;
IF X=1 THEN 
BEGIN
WHITE (••CALCULATION OF AREA UNDER PLASMA LEVEL CURVE");
END;
IF X=2 THEN 
BEGIN
V.'H I TE ("CALCULAT ION OF AREA UNDER SALIVA LEVEL CURVE");
END;
IF X=3 THEN 
BEGIN




VJHITEC’ T(J) Y(J) •');
w k It e c ’ ");

















WH ITEON("UN ITS/ML +MIN");
IF Z=7 THEN 
WRITEON("MG *HR");








ABERG, G. and LARSSON, K. S. (1970)
Acta Pharmacol, et Toxicol. £ 8  p.249.
AGKELO, C. E. and MILIOZZI, J. O. (1974)
J. Pharm. Pharmacol. 2^ p.207.
AGUIAR, A. J., KRC, J., KINKEL, A. W. and SAMYN, J. C. (1967)
J. Pharm. Sci. ^  p.847.
ALBERT, A. and SERGEANT, E. P. &971)
In. The Determination of Ionisation Constants............................
A Laboratory Manual.
Chapman and Hall Ltd., London.
ALLEN, T. (1974)
In,Particle Size Measurement.
Chapman and Hall Ltd., London.
ALTMAN, P. L. (1961)
In.Blood and Other Body Fluids p.5.
Compiler. Altman.
Biological Handbooks.
Fed. of Am. Soc. for Experimental Biology, Washington.
ANDERSON, K. W. (1964)
Arch. Int. Pharmacodyn. 147 p.171.
BAILEY, R. W. (1964)
Anal. Chem. 36 p.2021.
BARR, W. H. (1972)
Pharmacology, ^  p.55-101.
BARR, W. H. and RIEGELMAN, S. (1970)
J. Pharm. Sci. 59 p.154
BASTIDE, P. (1955)
Therapie (Paris) JG p.700
BATES, T. R. (1969)
J. Pharm. Pharmacol. 2j_ p.710
BATES, T. R. and GIBALDI, M. (1970)
In, Current Concepts In The Pharmaceutical Sciences; Biopharmaceutics p.57. 
Lea and Febiger, Philadelphia.
BATES, T. R., GIBALDI, M. and KANIG, J. L. (1966)
J. Pharm. Sci 55 p.191
BATES, T. R., LAMBERT, D. A. and JOHNS, W. H. (1969)
J. Pharm. Sci ^  p.1468.
BAYLES, T. B. and TENCKHOFF, H. (1959)
Scientific Exhibit
Am. Acad. G.P. San Francisco, California.
370
BENET, L. Z., ORR, J. M., TURNER, R. H. and WEBB, H. S. (1971)
J. Pharm. Sci ^  p.234.
BENOWITZ, N ., FORSYTH, R . and MELMON, K . (1974)
Clin. Pharmacol. Therap. 16 p.87.
BERGE, S. M., BIGHLEY, L. D. and MONKHOUSE, D. C. (1977)
J. Pharm. Sci ^  p.l.
BERMAN, M., SHAHN, E. and WEISS, M. F. (1962)
Biophys. J. 2  P-275.
BOCHNER, F., HOOPER, W. D., SUTHERLAND, J. M., EADIE, M. J.
and TYER, J. H. (1974)...........
Arch. Neurol. 3j_ p.57.
BOFORS, A.B. (1971)
Internai Report.
BOLHUIS, G. K., LERK, C. F. and ZUURMAN, K. (1973)
Pharm. Weekblad. 108 p.49.
BORZELLECA, J. F. and PUTNEY, J. W. (1970)
J. Pharmacol. Exp. Ther. 174 p.527.
BOXENBAUM, H. G., BERERSKY, I., MATTALIANO, V, and KAPLAN, S . A , (1975) 
J. Pharmacok. Biopharm. 3̂ p.443.
BOYES, R. N., ADAMS, H. J. and DUCE, B. R. (1970)
J. Pharmacol. Exp. Ther. 174 p.l.
B.P. (1973)
British Pharmacopoeia 
H.M. Stationery Office 
Shevnal Press, London.
BRITISH STANDARDS INSTITUTION (1952)
"Methods For The Use Of British Standard Fine Mesh Test Sieves"
British Standard 1796, London.
BRITISH STANDARDS INSTITUTION (1963)
"Specification For Test Sieves"
British Standard 410, London.
BROOKS, P. M., BELL, M. A. and BURNS, H. (1976)
Brit. J. Clin. Pharmacol. 2  p.945.
BUNDGAARD, H. (1974,a)
J. Pharm. Pharmacol. 26 p.18.
BUNDGAARD, H. (1974,b)
J. Pharm. Pharmacol. 26 p.535.
CHIOU, W. L., CHANG, K. and PENG, G. W. (1976)
J. Clin. Pharmacol, p.158.
CHIOU, W. L. and RIEGELMAN, S. (1971 )
J. Pharm. Sci 60 p.1376.
371
COLQUHOUN, J., SCORER, E. C., SANDLER, G. and WILSON, G. M. (1957)
Brit. Med. J. J_p.l451.
CONKLIN, J. D. and HAILEY, F. J. (1969)
Clin. Pharmacol. Therap. p.534.
CORRIGAN, O. I. and TIMONEY, R. F. (1974)
J. Pharm. Pharmacol. 2^ p.838.
CORRIGAN, O. I. and TIMONEY, R. F. (1975)
J. Pharm. Pharmacol. 27 p.759.
CORRIGAN, O. I. and TIMONEY, R. F. (1976)
J. Pharm. Pharmacol. 2^ p.703.
CROUTHAMEL, W. G., DIAMOND, L., DITTERT, L. W. and DOLUISIO, J. T. (1975) 
J. Pharm. Sci. 64, p.664.
CUMMINGS, A. J. and KING, M. L. (1966)
Nature 209 p.620.
DECATO, L., MALONE, M. H., STOLL, R. G. and NIEFORTH, K. A. (1969)
J. Pharm. Sci. ^  p.273.
DEXTER, M. B. (1975)
J. Pharm. Pharmacol. 22 Suppl. 58P.
DICTIONARY OF ORGANIC COMPOUNDS (1965)
4th Ed. Vol. 5 p.2885 
Eyre and Spottiswoode, London.
DOCUMENTA GEIGY (1962)
Scientific Tables 
6 th Ed. Ed. Diem, K.
Geigy Pharmaceutical Co. Ltd., Manchester.
EDMAR, D. (1970)
Acta Radiol. Diagn., 11 p.57.
EDMONDSON, I. C. (1967)
Adv. In Pharm. Sci. 2  P*95.
EL-GORAB, M. I., UNDERWOOD, B. A. and LOERCH, J. D. (1975)
Biochim. Biophys. Acta 401 p.265.
ENEY, R. D. and GOLDSTEIN, E. O. (1975)
J. Allergy Clin. Immun. 22 P'95.
FALOON, W. W., PAES, I. C., WOOLFOLK, D., NANKIN, H., WALLACE, K. 
and HARO, E. N. (1966)
Ann. N.Y. Acad. Sci. 132 p.879.
FELDMAN, S., REINHARD, M. and WILLSON, C. (1973)
J. Pharm. Sci. 62 p.1961.
FINCHER, J. H., ADAMS, J. G. and BEAL, H. M. (1965)
J. Pharm. Sci. 54 p.704.
372
FINHOLT, P. and SOLVANG, S. (1968)
J. Pharm. Sci. 57 p.1322.
FISHER, R. A. and YATES, F. (1974)
Statistical Tables, For Biological, Agricultural and Medical Research 
6 th Edition 
Longman, Edinburgh.
FLORENCE, A. T. and SALOLE, E. G. (1976)
J. Pharm. Pharmacol. 28 p.637.
FUREZ, S. (1958)
Antibiot. Chemother. N.Y. 2  p.448.
GARRETT, E. R. (1964)
Antibiot. et Chemother. Adv. 12 p.227.
GARRETT, E. R. and ALWAY, C. D. (1964)
Proc. 3rd Int. Congr. Chemother. S3 p.1666.
GAULT, M. H., CHARLES, J. D., SUGDEN, D. L. and KEPKAY, D. C. (1977)
J. Pharm. Pharmacol. 22 p.27.
GIBALDI, M. (1971)
Introduction to Biopharmaceutics p.16 
Lea and Febiger, Philadelphia.
GIBALDI, M. and FELDMAN, S. (1970)
J. Pharm. Sci. 59 p.579.
GIBALDI, M. and PERRIER, D. (1975)
Pharmacokinetics 
Marcel Dekker Inc., N.Y.
van GINNEKEN, C. A. M., van ROSSUM, J. M. and FLEUREN, H. L. J. M. (1974) 
J. Pharmacok. Biopharm. 2  p.395.
GLYNN, J. P. and BASTAIN, W. (1973)
J. Pharm. Pharmacol. 22 P*420.
GOLDBERG, A. H., GIBALDI, M. and KANIG, J. L. (1965)
J. Pharm. Sci 54 p.1145.
GOLDBERG, A. H., GIBALDI, M. and KANIG, J. L. (1966,a)
J. Pharm. Sci 22 P-482.
GOLDBERG, A. H., GIBALDI, M., KANIG, J. L. and MAYERSOHN, M. (1966,b).
J. Pharm. Sci 55 p.581.
GOLDBERG, A. H., GIBALDI, M. and KANIG, J. L. (1966,c)
J. Pharm. Sci 22 P«487.
GRACEY, M., PAPADIMITRIOU, J., BURKE, V., THOMAS, J. and BOWER, G. (1970) 
Gut 2i p.519.
GRAHAM, G. and ROWLAND, M. (1972)
J. Pharm. Sci 61 p.1219.
373
GREENE, E. C. (1935)
Anatomy of the Rat.
In Transactions of the American Philosophical Society. 
Volume 27.
GROTH, U., PRELLWITZ, W. and JAHNCHEN, E. (1974)
Clin. Pharmacol. Therap. p.490.
GUNNING, S. R., FREEMAN, M. and STEAD, J. A. (1976)
J. Pharm. Pharmacol. 22 p.758.
HANZLIK, P. J. and PRESHO, N. E. (1925)
J. Pharmacol. Exp. Ther. 26 p.61.
HANSCH, C. and DUNN, W. J. (1972)
J. Pharm. Sci 21 P-1*
HARRIS, P. A. and RIEGELMAN, S. (1969)
J. Pharm. Sci 58 p.71.
HERDAN, G. (1960)
In, Small Particle Statistics p.81 
Butte rworths, London.
HIGUCHI, T., HAVINGA, A. and BUSSE, L. W. (1950)
J. Am. Pharm. Assoc. (Sci.Ed.) 39 p.405.
HIGUCHI, W. I. (1967)
J. Pharm. Sci 52 p.315.
HIGUCHI, W. I. and HAMLIN, W. E. (1963)
J. Pharm. Sci 21 P-575.
HILL, S. A., JONES, K. H., SEAGER, H. and TASKIS, C. B. (1975)
J. Pharm. Pharmacol. 2J_ p.594.
HOGBEN, C. A. M. (1971)
In Concepts In Biochemical Pharmacology XXVIII p.l 
Springer-Verlag, New York.
HOGBEN, C. A. M., SCHANKER, L. S., TOCCO, D. J. and BRODIE, B. B. (1957)
J. Pharmacol. Exp. Ther. 120 p.540.
HOGBEN, C. A. M., TOCCO, D. J., BRODIE, B. B. and SCHANKER, L. S. (1958)
J. Pharmacol. Exp. Ther. 125 p.275.
HOLLISTER, L. and LEVY, G. (1965)
J. Pharm. Sci 54 p.1126.
HUMPHREYS, K. J. and SMY, J. R. (1975)
J. Pharm. Pharmacol. 2Z p.964.
IRWIN, G. M., KOSTENBAUDER, H. B., DITTERT, L. W., STAPLES, R.,
MISHER, A. and SWINTOSKY, J. V. (1969)
J. Pharm. Sci. 58 p.313.
374
JOUBERT, P. H. , MULLER, P\ O. and AUCAMP, B. N. (.1976)
Brit. J. Clin. Pharmacol. 2  P-673.
JOUNDA, A. J. and SOTHMANI, A. (1973)
Lancet 2 P - 202.
JUSKO, W. J. and LEWIS, G. P. (1973)
J. Pharm. Sci. 62 p.69.
KABASAKALIAN, P., KATZ, M., ROSENKRANTZ, B. and TOWNLEY, E. (1970) 
J. Pharm. Sci 59 p.596.
KALLNER, A. (1975)
Lancet I p . 338. ...................................................
KANENIWA, N. and WATARI, N. (1974)
Chem. Pharm. Bull. 22 p.1699.
KELLY, C. A. (1970)
J. Pharm. Sci 59 p.1053.
KHALAFALLAH, N., KHALIL, S. A. and MOUSTAFFA, M. A. (1974)
J. Pharm. Sci 63 p.861.
KIMURA, T., SEZAKA, H. and KAKEMI, K. (1972)
Chem. Pharm. Bull. 20 p.1656.
KO%SOOKO, R., ELLIS, E. F. and LEVY, G. (1974)
Clin. Pharmacol. Therap. JL_5 p.454.
KRAKOWKA, P., IZDEBSKA-MAKOSA, Z. and WARESKA, W. (1966)
Pol. Med. J. 2  p.895.
KUHNERT-BRANDSTATTER, M. (1965)
J. Pure Appl. Chem. p.133.
KUHNERT-BRANDSTATTER (1971)
In, International Series of Monographs in Analytical Chemistry. Vol.45 
Eds. Belcher and Freiser 
Pergamon Press.
von LEHMANN, B., WAN, S. H., RIEGELMAN, S. and BECKER, C. (1973)
J. Pharm. Sci 62 p.1483.
LEONARDS, J. R. (1962)
Proc. Soc. Exp. Biol. Med. 110 p.304.
LEONARDS, J. R. (1969)
J. Lab. Clin. Med. 74 p.911.
LEVINE, R. R., BLAIR, M. R. and CLARK, B. B. (1955)
J. Pharmacol. Exp. Ther. 114 p.78.
LEVINE, R. R. and PELIKAN, E. W. (1961)
J. Pharmacol. Exp. Ther. 131 p.319.
LEVY, G. (1963)
J. Pharm. Sci 52 p.1039.
375
LEVY, G. (1965)
J. Pharm. Sci 54 p.959.
LEVY, G., AMSEL, L. P. and ELLIOT, H. W. (1969) 
J. Pharm. Sci 2® p.827.
LEVY, G. and ANGELINO, N. J. (1968)
J. Pharm. Sci 2 2  P«1449.
LEVY, G., ELLIS, E. F. and KOYSOOKO, R. (1974) 
Paediatrics 22 P-873.
LEVY, G. and HAYES, B. A. (1960)
New Engl. Med. j.. 252 p.1053..................
LEVY, G. and JUSKO, W. J. (1965)
J. Pharm. Sci. 22 P-219.
LEVY, G. and PROCKNAL, J. A. (1962)
J. Pharm. Sci. 22 P*294.
LEVY, G., TSUCHIYA, T. and AMSEL, L. P. (1972)
Clin. Pharmacol. Ther. 22 P*258.
LEVY, G. and YACOBI, A. (1975)
J. Clin. Pharmacol. 12 P-525.
LIN, S-L, MENIG, J. and LACHMAN, L. (1968)
J. Pharm. Sci. 22 P.2143.
LOO, J. C. K., FOLTZ, E. L., WALLICK, H. et al (1974)
Clin. Pharmacol. Ther. 16 p.35.
LOO, J. C. K. and RIEGELMAN, S. (1968)
J. Pharm. Sci. 22 P*818.
LOWENTHAL, D. T., BRIGGS, W. A. and LEVY, G. (1974)
J. Clin. Invest. 54 p.1221.
MACDONALD, H., PISANO, F., BURGER, J., DORNBUSH, A. and PELCAK, E. (1969) 
Drug Inform. Bull. 2  P« 76.
MACDONALD, M. (1973)
Internal Report
Pharmaceutics Group, University of Bath.
MACLEOD, C., RABIN, H., OGILVIE, R., RUEDY, J., CARON, M., ZAROWNEY, D. 
and DAVIES, R. O. (1974).
Can. Med. Assoc. J. Ill p.341.
MAHFOUZ, M. (1949)
Brit. J. Pharmacol. 2  p.295.
MALONE, M. H., HOCHMAN, H. I. and NIEFORTH, K. A. (1966)
J. Pharm. Sci. 22 P-972.
MARRIOT, C. and KELLAWAY, I. W. (1976)
J. Pharm. Pharmacol. 28 p.620.
376
MARTIN, A. N., SWARBRICK, J. and CAMMARATA, A. (1970)
In, Physical Pharmacy 2nd Ed.
Lea and Febiger, Philadelphia.
MARTIN, B. K. (1967)
Brit. J. Pharmac. Chemother. 29 p.181.
MARTIN, B. K. (1971)
Adv. In Pharm. Sci. 2  107.
MARTIS, L. and LEVY, R. H. (1973)
J. Pharmacok. Biopharm. 2 p.283
MATINy S.. B. , WAN, S. H. and KARAM, J.. H. (197.4)
Clin. Pharmacol. Therap. 22 p.1052.
MAYERSOHN, M. and GIBALDI, M. (1966)
J. Pharm. Sci. 55 p.1323.
MAYERSOHN, M. and GIBALDI, M. (1971)
Am. J. Pharm. Educ. 35 p.19.
MCGLASHAN (1971)
In, Manual Of Symbols And Terminology For Physicochemical Quantities 
and Units p.33 
Butterworths, London.
MEKHJIAN, H. S. and PHILLIPS, S. F. (1970)
Gastroenterology 59 p.120.
METZLER, C. M. (1969)
Clin. Pharmacol. Therap. 22 p.737.
MIYAZAKI, S. , ARITA, T. , HORI, R. and ITO, K. (1974)
Chem. Pharm. Bull. 22̂  p.638.
MIYAZAKI, S., NAKANO, M. and ARITA, T. (1975)
Chem. Pharm. Bull. 23 p.552.
MIYAZAKI, S., NAKANO, M. and ARITA, T. (1976)
Chem. Pharm. Bull. £4 p.2094.
MONKHOUSE, D. C. and LACH, J. L. (1972,a)
J. Pharm. Sci. 61 p.1430.
MONKHOUSE, D. C. and LACH, J. L. (1972,b)
J. Pharm. Sci., 61 p.1435.
MULLINS, J. D. and MACEK, T. J. (1960)
J. Am. Pharm. Assoc. (Sci. Ed.) 49. P-245.
NEDLER, J. A. (1973)
Genstat Reference Manual
Compiled At Statistics Department, Rothampstead Experimental Station, 
Harpenden, Herts.
(Edinburgh University Cat. No. 15.042.715).
377
NELSON, E. (1957)
J. Ara. Pharm. Assoc. (Sci. Ed.) 47. p.297.
NELSON, E. (1958)
J. Am. Pharm. Assoc. (Sci. Ed.) 47 p.297.
NELSON, E., HANANO, M. and LEVY, G. (1966)
J. Pharmacol. Exp. Ther. 156 p.285.
NELSON, J. D., SHELDON, S., KUSMIESZ, H. T. and HALTALIN, K. C. (1972) 
Clin. Pharmacol. Therap. J_3 p.879.
NEUVONEN, P. J. PENTIKAINEN, P. J. and ELFVING, S. M. (1977)
Int. J. Clin. Pharmacol. Biopharm. P.84.
NEWTON, J. M. and ROWLEY, P. (1970)
J. Pharm. Pharmacol. 22 p.1635.
NIGHTINGALE, C. H., AXELSON, J. and GIBALDI, M. (1971)
J. Pharm. Sci. 60 p.145.
NIGHTINGALE, C. H. and MOURAVIEFF, M. (1973)
J. Pharm. Sci. 62 p.860.
NORDQVIST, P., HARTHON, J. G. L. and KARLSSON, R. (1965)
Nordisk Med. 74 p.1074.
NOTARI, R. E. (1975)
In, Biopharmaceutics and Pharmacokinetics. An Introduction.
2nd Ed.
Marcel Dekker Inc., N.Y.
NOYES, A. A. and WHITNEY, W. R. (1897)
J. Am. Chem. Soc. 22 p.930.
OCHSENFAHRT, H. and WINNE, D. (1968)
Life Sci. 2  p.493.
O'REILLY, R. A., NELSON, E. and LEVY, G. (1966)
J. Pharm. Sci. _55 p.435.
PAGE, M. A., ANDERSON, R. A., BROWN, K. F. and ROBERTS, M. S. (1974) 
Austr. J. Pharm. Sci. NS3 p.95
PARROTT, E. L. (1975)
J. Pharm. Sci. (64 p.878.
PATEL, S., PERRIN, J. H. and WINDHEUSSAR, J. J. (1972)
J. Pharm. Sci. 61 p.1794.
PENTIKAINEN, P. J., WAN, S. H. and ARZANOFF, D. L. (1974)
J. Pharm. Sci. 63 p.1431.
PHARM. HELV. (1934)
Pharmacopoeia Helvetica 
5th Ed. 1st Suppl.
378
PICCOLO, J. and TAWASHI, R. (1971)
J. Pharm. Sci. 60 p.59.
PINDELL, M. H., CULL, K. M., DORAN, K. M. and DICKISON, H. L. (1959)
J. Pharmacol. Exp. Ther. 125 p.287.
PLAKOGIANNIS, F. M., LIEN, E. J., HARRIS, C. and BILES, J. A. (1970)
J. Pharm. Sci. 59̂  p. 197.
POOLE, J. W., OWEN, G., SILVERO, J., FREYHOF, J. N. and ROSENMAN, S. B. 
(1968)
Curr. Ther. Res. 10 p.292.
PRESCOTT, L. F. (1975)...................................................
In, Handbook of Experimental Pharmacology 28 (3)
Concepts In Biochemical Pharmacology p.234 
Eds. Gillette and Mitchell 
Springer-Verlag, N.Y.
RHODES, J., BARNADO, D. E., PHILLIPS, S. F., ROVELSTAD, R. A. and 
HOFMANN, A. F. (1969)
Gastroenterology 57 p.241.
RIEGELMAN, S., KOO, J. C. K. and ROWLAND, M. (1968)
J. Pharm. Sci. 2Z P-H7.
ROWLAND, M. (1973)
In, Current Concepts In The Pharmaceutical Sciences 
Dosage Form Design And Bioavailability p.181 
Lea and Febiger, Philadelphia.
ROWLAND, M., RIEGELMAN, S., HARRIS, P. A. and SCHOLKOFF, P. (1972)
J. Pharm. Sci. 62 p.379.
RUBIN, H. S. (1964)
Am. J. Med. Sci. 248 p.31.
SCHACHTER, D. and MANIS, J. G. (1958)
J. Clin. Invest. 22 P'800«
SCHANKER, L. S. (1959)
J. Pharmacol. Exp. Ther. 126 p.283.
SCHANKER, L. S. (1960)
J. Med. Pharm. Chem. 2  p.343.
SCHANKER, L. S. (1971)
In, Concepts In Biochemical Pharmacology XXVIII p.21 
Springer-Verlag, New York.
SCHANKER, L. S., SHORE, P. A., BRODIE, B. B. and HOGBEN, C. A. M. (1957) 
J. Pharmacol. Exp. Ther. 120 p.528.
SCHANKER, L. S., TOCCO, D. J., BRODIE, B. B, and HOGBEN, C. A. M. (1958) 
J. Pharmacol. Exp. Ther. 123 p.81.
379
SCHERRER, R. A. (1974)
In Medicinal Chemistry p.45 
A Series of Monographs 13 (1)
Ed. Scherrer and Whithouse 
Academic Press, N.Y.
SCHNEIERSON, S. S. and AMSTERDAM, D. (1958)
Nature 182 p.56.
SCHWARTZ, M. A. and BUCKWALTER, F. U. (1962)
J. Pharm. Sci. 51 p.1119.
SEDMAN, A. J. and WAGNER, J. G. (1974)
AUTOAN. A Decision-Making Pharmacokinetic Computer Program 
Publication Distribution Service 
615 East University Avenue 
Ann Arbor, Mich.
SEDMAN, A. J. and WAGNER, J. G. (1972)
In. Abstracts of Symposia and Contributory Papers
Presented To The A. Ph. A. Acad. Pharm. Sci. 119th Annual Meeting 
Vol. 2  (1) Abstr. 16 p.61.
SEMPLE, P. F. and RUSSELL, R. I. (1975)
Gastroenterology 6 8  p.67.
SHELL, j. W. (1963) ,
J. Pharm. Sci. 52 p.24.
SHINER, M. (1969)
In. Bile Salt Metabolism p.41 
Eds. Schiff, Carey and Dietschy
C. T. Thomas, Springfield, 111.
SHORE, P. A., BRODIE, B. B. and HOGBEN, C. A. M. (1957)
J. Pharmacol. Exp. Ther. 119 p.361.
SIMONELLI, A. P., MEHTA, S. C. and HIGUCHI, W. I. (1969)
J. Pharm. Sci. _5§. p.538.
SIMONELLI, A. P., MEHTA, S. C. and HIGUCHI, W. I. (1976)
J. Pharm. Sci. 65 p.355.
SKELLY, N. E. (1966)
Anal. Chem. 3£ p.934.
SMITH, P. K., GLEESON, H. L., STOLL, R. G. and ORGOVZALEK, S. (1946) 
J. Pharmacol. Exp. Ther. 82 P.237.
SOLVANG, S. and FINHOLT, P. (1970)
J. Pharm. Sci. 22 p.49.
STEEL, M., GOERNER, A. and HALEY, F. L. (1931)
J. Lab. Clin. Med. 17 p.139.
STEVENS, L. A. (1973)
Bachelor of Science Project Report 
Department of Pharmacology 
University of Leeds.
380
STEVENS, L. A. and PADFIELD, J. M. (1976)
J. Pharm. Pharmacol. 28 Suppl. IP.
STOLL, R. G., BATES, T. R., NIEFORTH, K. A. and SWARBRICK, J. (1969) 
J. Pharm. Sci. 58 p.1457.
STOLL, R. G., BATES, T. R. and SWARBRICK, J. (1973)
J. Pharm. Sci. 62 p.65.
STRAHL, N. and BARR, W. H. (1971)
J. Pharm. Sci. 60 p.278.
STUPAK, E. I. and BATES, T. R. (1973)
J. Pharm. Sci.. 62. p.l806............................................
STUPAK, E. I., ROSENBERG, H. A. and BATES, T. R. (1974)
J. Pharmacok. Biopharm. 2  p.511.
SVOBODA, G. H., SWEENEY, M. J. and WALKLING, W. D. (1971) 
J. Pharm. Sci. 60 p.333.
SWARBRICK, J. (1971)
In, Current Concepts In The Pharmaceutical Sciences p.265 
Biopharmaceutics.
Lea and Febiger, Philadelphia.
TACHIBANA, T. and NAKAMURA, A. (1965)
Kolloid-Z 221 P'130.
TOMLINSON, E. and DAVIS, S. S. (1976)
J. Pharm. Pharmacol. 21 Suppl. 75P.
UNDERWOOD, F. L. and CADWALADER, D. E. (1976)
J. Pharm. Sci. 65 p.697.
UPTON, P. K. and MORGAN, D. J. (1975)
Lab. Animals 2 p.85.
U.S.P. (1975)
United States Pharmacopoeia 
19th Ed.
Mack Publishing Co., Pa.
f(< ( S-e-Ç IC15+
WAGNER, J. G. (1969)
J. Pharm. Sci. 58 p.1253.
WAOJER, J. G. (1971)
Biopharmaceutics and Relevant Pharmacokinetics 
1st Edition
Drug Intelligence Publications 
Hamilton, 111.
WAGNER, J. G. (1973a)
J. Pharmacok. Biopharm. 2  p.103.
WAGNER, J. G. (1973b)
J. Pharmacok. Biopharm. 1 p.363.
381
WAGNER, J. G. (1974)
J. Pharmacok- Biopharm. 2  P-469.
WAGNER, J. G. (1975)
Fundamentals of Clinical Pharmacokinetics 
Drug Intelligence Duplications 
Hamilton, 111.
WAGNER, J. G. (1975a)
J. Pharmacok. Biopharm. 2 P»51.
WAGNER, J. G. and NELSON, E. (1963)
J. Pharm. Sci. 52 p.610.
WAN, S. H. and RIEGELMAN, S. (1972)
J. Pharm. Sci. 61 p.1284.
WHITEHOUSE, M. W. (1965)
Prog. Drug. Res. 2 p.321.
WHITWORTH, C. W. and JUN, H. W. (1973) 
J. Pharm. Sci. 62 p.1890.
WINNE, D. and REMISCHOVSKY, J. (1970) 
J. Pharm. Pharmacol. 22 p.640.
WOOD, J. (1967)
Pharm. Acta Helv. 42 p.129.
WURSTER, D. E. and TAYLOR, P. W. (1965)
J. Pharm. Sci. _54 p. 169.
ZUIRBLIS, P., SOCHOLITSKY, I. and KONDRITZER, A. A. (1956) 
J. Am. Pharm. Assoc. (Sci. Ed.) 45 p.450.
UTERMARK and SCHICKE (1963)
In. Melting Point Tables of Organic Compounds
Eds. Utermark and Schicke
Interscience
John Wiley and Sons, N.Y.
